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Tau protein has been discovered in 1975 from brain tissues and its main function 
in neurons is to bind and stabilize microtubules. This observation was followed by 
the identification of Tau as one of the main actors able to induce neuronal toxicity 
in a group of neurodegenerative disorders named tauopathies. From these 
discoveries, the scientific community has invested great efforts to elucidate the 
mechanisms involving Tau and to find a way to prevent its pathological effects. 
Tau toxicity is due to its displacement from microtubules, progressive aggregation 
of the protein and spreading in several brain areas causing neuronal dysfunction 
and death. These are considered the central events leading to 
neurodegeneration. However, recently it has been demonstrated that Tau is 
located not only on microtubules or in the cytoplasmic aggregates but also in 
other subcellular regions, in particular in dendrites and in the nuclear 
compartment where it exerts functions related to synaptic transmission and 
genome protection, respectively. 
In order to investigate the dynamics of Tau from physiological conditions to 
destabilization and aggregation, we developed a FRET-based biosensor, the 
Conformational Sensitive Tau (CST), able to determine the conformational 
changes of Tau during the progression of the pathology. We showed that in 
physiological conditions, in living cells, Tau binds microtubules with a paperclip 
conformation. After drug treatments or tauopathy-related mutations, the 
conformation of Tau opens indicating an impairment of Tau binding to tubulin. 
Finally, by treating cells with different kinds of Alzheimer’s aggregates, the CST 
displaced from microtubules and formed FRET-positive intracellular inclusions 
demonstrating that it is a powerful tool to study also aggregation. The CST 
employment allowed the characterization of a particular mutation associated to 
Pick’s disease, Q336H. Remarkably, we found that this mutation induces a closer 
conformation of Tau and a higher affinity to tubulin, an effect that is opposite to 
previously discovered mutations. 
We applied the CST to develop a cell-based aggregation assay to screen 
compounds impairing Tau pathology. A first screening identified the ERK kinase 
inhibitor PD-901 as a compound reducing Tau aggregation. Moreover, to test the 
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efficacy of therapeutic compounds in vivo, a transgenic zebrafish expressing the 
CST is under development to establish a zebrafish-based aggregation platform. 
The signal of the CST is detectable not only in the cytoplasm but also in the 
nucleus, however, the FRET analysis in this compartment revealed that nuclear 
Tau conformation is probably more open and relaxed.  
We investigated the nuclear function of Tau and we found that the increase in the 
soluble pool of Tau enhances its translocation into the nucleus and, 
concomitantly, the nuclear Tau alters the expression of VGluT1, a disease-
relevant gene, indicating that Tau has a role in gene expression modulation. We 
observed that the increase in VGluT1 expression mediated by Tau causes 
neuronal hyperexcitability in hippocampal primary neurons, an event typical of the 
first stages of AD. We found that this Tau function is impaired by the P301L 
mutation and by pathological aggregation.  
To identify other possible genes modulated by Tau we performed an RNAseq 
experiment and we found a global gene expression alteration that strongly 
resembles the late mild cognitive impairment. The investigation of molecular 
mechanisms involving nuclear Tau indicates that it competes with HDAC1 for the 
binding with TRIM28, a nuclear protein involved in heterochromatin formation. 
This competition causes the delocalization of HDAC1 from the nucleus modifying 
the chromatin structure and leading to VGluT1 increased levels, suggesting that 
Tau modulates the gene expression by altering the chromatin condensation. 
In conclusion, the CST developed in this study allows to follow in real time the 
pathological process depicting the early and the late stages of aggregation; thus, 
it is now at the bases of two screening platforms for the drug discovery and 
validation in reporter cells and in a transgenic model. In addition, this study 
demonstrated for the first time that Tau in the nuclear compartment modulates 
the expression of genes probably by altering the chromatin structure and this role 
seems to be strongly related to mild cognitive impairment stages when Tau is 
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Chapter 1  
Introduction 
1.1 Dementia 
Dementia is a general term referring to several different neurodegenerative 
diseases characterized by mental dysfunctions. The urgency of resolving these 
pathologies is deeply felt since these diseases have a big impact on our society, 
with more than 50 million people affected worldwide (Prince et al., 2015). Among 
the most common dementias, tauopathies represent a conspicuous part. 
Tauopathies group multifactorial diseases which often differ for development and 
symptoms, but all of them are characterized by the alteration in structure and 
function of Tau protein.  
1.2 Tau 
Tau is a microtubule associated protein (MAP) discovered in 1975, when it was 
isolated from porcine brain and identified as a factor able to induce tubulin 
polymerization in vitro (Weingarten et al., 1975). Tau is mainly expressed in the 
central nervous system (CNS) but recently it was found also in other regions of 
the organism, heart, kidney, lung, testis, pancreas and in fibroblasts (Gu et al., 
1996; Ingelson et al., 1996; Sergeant et al., 2005; Vanier et al., 1998). It was also 
discovered to be expressed in some cancers as breast cancer (Bonneau et al., 
2015). Even if Tau can be found in different tissues and conditions, currently it is 
mainly studied because of its involvement in tauopathies since, in these 






Figure 1.1: MAPT gene and splicing isoforms. Adapted from Luna-Munoz et al., 2013. 
Tau protein is encoded by the microtubule associated protein Tau (MAPT) gene 
located on chromosome 17q21. MAPT contains 16 exons whose alternative 
splicing yields to six isoforms of the protein. Upstream of exon 1 there are 
consensus binding sites for transcription factors like AP2 and SP1 (Andreadis et 
al., 1992; Sadot et al., 1996). The alternative splicing involves exons E2, E3 and 
E10 leading to isoforms ranging from 352 to 441 aminoacids (Figure 1.1). 
Splicing of exons E2 or E3 generates isoforms carrying 2, 1 or none particular 
sequences at the N-terminal end of the protein, while the splicing of E10 
determines the presence of a repeated aminoacidic sequence at the C-terminal 
end (Goedert and Jakes, 1990; Goedert et al., 1989b, 1989a). The expression of 
different Tau isoforms is specific of brain development. The shortest Tau isoform 
of 352aa, often referred as foetal Tau 0N3R (splicing of E2, E3 and E10), is 
characteristic of embryonal brain and is progressively lost during brain 
development. All the other isoforms are expressed in the adult brain but an 
additional isoform including E4a was also found to be specific of the peripheral 




Tau protein is a hydrophilic polypeptide which appears as a random coiled 
protein (Cleveland et al., 1977; Hirokawa et al., 1988). It shows very small 
content in secondary structures (Mukrasch et al., 2009). When bound to 
microtubules (MTs) Tau shows a preference to assume a loop-like conformation 
in which the N- and the C-terminal ends are close (Jeganathan et al., 2006; Di 
Primio et al., 2017). Moreover, in pathological conditions, Tau assumes a β-sheet 
secondary structure which leads to formation of amyloidogenic aggregates 
(Daebel et al., 2012).  
 
Figure 1.2: Tau protein domains. Adapted from Wang and Mandelkow, 2016. 
Tau protein can be divided in two large domains: the projection domain and the 
microtubule binding domain. The projection domain contains the amino-terminal 
region (NTD) with high proportion of acidic residues and the proline-rich region 
(PRD); the microtubule-binding domain is subdivided into a basic true tubulin 
binding domain with three or four repeats (MTBD) and the acidic carboxy-terminal 
region (CTD) (Figure 1.2). The six Tau isoforms differ from each other for the 
presence of three or four microtubule-binding repeats of 31 or 32 residues 
(isoform 3R or 4R) and for the presence or absence of one or two inserts (29-
amino acids) at the N-terminal portion of the protein (Avila et al., 2004; Binder et 
al., 1985). The projection domain plays several roles such as the determination of 
space between axonal microtubules, the interaction with other proteins and cation 
binding (Chen et al., 1992; Hirokawa et al., 1988). Motifs identified in this region 
include the KKKK sequence involved in heparin binding and the PPXXP/PXXP 
motifs in the proline-rich region for the binding of Tau with proteins containing 
SH3 domains such as the tyrosine kinase Fyn (Ittner et al., 2010; Lau et al., 
2016; Mondragón-Rodríguez et al., 2012). The repeats of the microtubule-binding 
domain can be divided in two parts, one composed of 18 residues containing the 
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minimal region with microtubule binding capacity, while the second region 
composed of 13/14 residues is known as the inter repeat (Avila et al., 2004). Tau 
isoforms bind MTs by the MTBD with different affinity depending on the number 
of repeats: higher for Tau 4R isoforms, lower Tau 3R (Lu and Kosik, 2001). 
1.3 Tau function and localization 
 
Figure 1.3: Tau subcellular localization and function. Adapted from Wang and Mandelkow, 
2016. 
Tau was originally found associated to MTs as a protein factor able to induce and 
stabilize the tubulin polymerization (Weingarten et al., 1975), however, in recent 
years other functions of Tau have been identified in several subcellular 
compartments (Figure 1.3). Tau is mostly located in axons, where it interacts with 
MTs stabilizing them and promoting their assembly (Weingarten et al., 1975). 
MTBD binds specific pockets in β-tubulin at the inner surface of the MTs while the 
proline-rich regions, positively charged, are bound to the negatively charged MT-
surface; the acidic N-terminal domain branches away from the MT-surface 
probably because of electrostatic repulsion. Moreover, the β-tubulin pockets of 
adjacent filaments may be occupied by different repeats of the same MT-binding 
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domain causing crosslinking of three or four dimers (Amos, 2004; Kar et al., 
2003). The projection domain determines spacing between MTs in the axon and 
may increase the axonal diameter. It interacts with other cytoskeletal components 
like spectrin and actin filaments allowing Tau-stabilized MTs to interconnect with 
neurofilaments restricting the flexibility of MTs lattices (Kolarova et al., 2012). 
Besides regulating MT assembly and stabilization, several evidences associate 
Tau with the regulation of axonal transport. Tau was seen to detach the cargoes 
from kinesin without influencing the speed of movement along MTs (Trinczek et 
al., 1999). In vitro, Tau is able to interfere with the dynamics of motor proteins 
and knock-down of Tau protein is able to increase transport velocity in iPSC-
derived dopaminergic neurons (Beevers et al., 2017; Dixit et al., 2008). Moreover, 
in SHSY5Y cells, Tau is also able to bind p150 subunit of dynactin and to 
stabilize its binding to MTs, thereby promoting dynein transport (Dixit et al., 2008; 
Magnani et al., 2007). 
Tau protein also localizes in dendrites (Figure 1.3). It has been proposed that it 
can be found in spines since in brain tissues Tau co-immunoprecipitates with 
PSD-95 (Ittner et al., 2010). Moreover, upon synaptic activation, Tau moves from 
the dendritic shaft to spines in cultured neurons and hippocampal slices  
(Frandemiche et al., 2014). At the synapse, Tau also interacts with Fyn, a 
tyrosine kinase from the Src-family involved in protein trafficking, by the proline-
rich domain which binds SH3 domains of several proteins. Tau is necessary for 
Fyn localization at the post-synaptic compartment. There, Fyn phosphorylates 
NMDA subunit NR2B thereby stabilizing its interaction with PSD-95 (Ittner et al., 
2010; Lau et al., 2016; Mondragón-Rodríguez et al., 2012). In addition, Tau has a 
role in signal transmission and synaptic plasticity. Tau reduction results in 
resistance to pathological network hyperexcitability in a variety of models (DeVos 
et al., 2013; Holth et al., 2013). It has also been demonstrated that Tau KO 
shows impaired LTP (Ahmed et al., 2014), but this finding is still debated. Tau is 
also localized at the axon terminal upon stimulation with NGF (Yu and Rasenick, 
2006). Tau is able to potentiate NGF and EGF signalling thus increasing 
activation of the downstream pathway and influencing neurites extension 
(Leugers and Lee, 2010). Tau has also been described to have a role in other 
signalling pathways such as PLC pathway in vitro (Hwang et al., 1996). Post-
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translational modifications seem to alter Tau distribution, for example 
phosphorylation in the proline-rich region localizes Tau protein mainly in the 
somatodendritic compartment, whereas, if the proline-rich region is 
dephosphorylated or if the phosphorylation occurs in the C-terminal domain, Tau 
localizes in the distal axonal region (Dotti et al., 1987; Mandell and Banker, 
1996). 
It has been recently discovered that Tau  is involved in miRNA activity. As a 
matter of fact, Tau interacts with the DEAD box RNA helicase DDX6 involved in 
translation repression and mRNA decay as well as in the miRNA pathway. 
Tau/DDX6 interaction increases the silencing activity of the miRNA let-7a, miR-21 
and miR-124 affecting the expression of their targets (Chauderlier et al., 2018). 
Tau has also been localized in many organelles where it can exert non-canonical 
functions such as ribosomes, mitochondria and endoplasmic reticulum (Tang et 
al., 2015). Moreover, Tau has been found in the nucleus where it is involved in 
several functions (Loomis et al., 1990). 
1.3.1 Tau nuclear function 
In 1990 Tau protein was identified in the nucleus of neuroblastoma cells and in 
1995 its nuclear localization was confirmed in human brains. At the beginning, 
nuclear Tau was detected by immunofluorescence experiments which showed 
Tau labelling in the nucleus and nucleolus. This evidence was confirmed by 
subcellular fractionation of chromatin nuclear fraction (Loomis et al., 1990; Rady 
et al., 1995). The interaction between Tau and chromatin has been further 
investigated in vitro and in vivo. In vitro experiments demonstrated that the 
binding of Tau to DNA is mediated by the second half of the proline-rich domain 
and the R2 of the MTBD (Hua and He, 2003; Qi et al., 2015). Moreover, while 
hyperphosphorylation of Tau reduces the affinity to DNA, the hypophosphorylated 
Tau has a higher affinity (Qi et al., 2015). 
Other studies clarified that Tau has higher affinity to specific DNA sequences 
determining also its preferential localization when bound to chromatin. 
Biophysical studies identified GC-rich sequences as more affine to Tau and 
demonstrated that the interaction stabilizes the DNA structure when altered by 
physical agents as high temperature (Vasudevaraju et al., 2012). Fluorescence in 
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situ hybridization (immune-FISH) in non-neuronal cells revealed that nuclear Tau 
binds AT-rich α-satellites and colocalizes with nucleolin, supporting the fact that 
nuclear Tau is localized in the internal periphery of nucleoli (Sjöberg et al., 2006). 
In addition, by a ChIP-on-chip experiment on primary neurons, it was recently 
demonstrated that Tau is highly enriched in intergenic chromatin regions even if it 
is also bound to promoter regions, with a high specificity for the GAGA motifs 
(Benhelli-Mokrani et al., 2018).  
An open question in nuclear Tau field regards possible different functions of Tau 
isoforms and the effect of post-translational modifications in the nuclear 
compartment. In adult mice brains 1N Tau isoform is overrepresented in soluble 
nuclear fraction, while 2N Tau isoform is overrepresented in chromatin-bound 
fraction (Liu and Götz, 2013). Tau can be found either in a phosphorylated and 
non-phosphorylated state in the nucleus, probably depending on the sub-nuclear 
localization. In fact, nucleolar Tau appears to be mainly non-phosphorylated, 
while in the rest of the nucleoplasm, it can also be phosphorylated (Loomis et al., 
1990; Sultan et al., 2011). Moreover, nuclear Tau phosphorylation at specific 
residues, such as the AT100 epitope, increases with aging, with higher affinity to 
heterochromatin, suggesting an epigenetic role for Tau (Gil et al., 2017). 
One of the first evidence about the function of nuclear Tau was on DNA 
protection and stability. First in vitro experiments showed that Tau is able to 
increase the dsDNA melting temperature stabilizing its structure and protects 
DNA from oxidative stress induced by hydroxyl radicals (Hua and He, 2003). This 
result was further supported by Wei et al. demonstrating that Tau binds the minor 
groove of the double helix preventing damage by peroxidation (Wei et al., 2008). 
Recently in vivo results reported that non-phosphorylated nuclear Tau levels 
increase in neurons after oxidative stress and hyperthermic conditions which 
should induce the formation of ROS. By Comet and TUNEL assays and ɣH2AX 
immunofluorescence detection in these conditions, it has been observed that Tau 
protects the genome of cortical and hippocampal neurons from damage. 
Moreover, it seems that Tau also protects RNA molecules in cytoplasmic and 
nuclear compartments (Sultan et al., 2011; Violet et al., 2014). Intriguingly 
expression of mutated Tau in residues related to tauopathies is strongly 
associated to chromosome aberrant recombination and aneuploidy in mouse and 
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human samples, supporting the key role of nuclear Tau in genome stability (Rossi 
et al., 2008, 2013, 2014). 
Tau is also involved in chromatin remodelling and gene expression regulation 
even if the mechanisms are still unclear. A first observation in Tau knock-out 
mouse models revealed the altered expression of several genes, intriguingly 
some of them regulates themselves (Gómez de Barreda et al., 2010; Oyama et 
al., 2004). Increase in nuclear Tau levels is able to induce global chromatin 
relaxation in Tau overexpressing drosophila and mice, indicating Tau as a factor 
responsible for the loss of heterochromatin in AD human brains. These 
alterations result in an increased transcription of genes that are 
heterochromatically silenced in controls. This observation was shown to be 
disease relevant since heterochromatin restoration in Drosophila is able to 
recover the locomotor impairments shown in Tau overexpressing individuals 
(Frost et al., 2014). More recently, it has been demonstrated that increased Tau 
levels induce transcription of transposable elements in Drosophila brains and in 
human AD and PSP brains. Dysregulation of transposable elements is due to 
both the loss of heterochromatin and the reduction in piwi elements which 
prevents transposon expression and genomic integration (Guo et al., 2018; Sun 
et al., 2018). Moreover, it has been demonstrated that Tau not only reduces 
heterochromatin but it has also a repressive role. As a matter of fact, Tau 
interacts with TIP5, a transcriptional repressor of rDNA, in the nucleolus and Tau 
depletion results in an increase of 45S-prerRNA synthesis, suggesting that Tau 
might be involved in rDNA silencing (Maina et al., 2018). In addition, by ChIP-on-
chip experiments, a transcriptional repressive function has been observed 
towards promoters bound directly by Tau (Benhelli-Mokrani et al., 2018). Other 
studies support the possible role of Tau in chromatin remodelling. A recent work 
demonstrated that Tau interacts with the nuclear protein TRIM28 which is able to 
shuttle it to the nucleus. This was shown tracking the Tau-TRIM28 complex 
exploiting bimolecular fluorescence complementation and was confirmed 
observing that TRIM28 overexpression was able to boost Tau shuttling to the 
nucleus (Rousseaux et al., 2016). Tripartite motif-containing 28 (TRIM28), also 
known as transcriptional intermediary factor 1b (TIF1b) and KAP1 (KRAB-
associated protein-1), is a nuclear protein mainly involved in transcriptional 
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regulation and chromatin remodelling. TRIM28 acts as a co-repressor of KRAB 
zinc finger proteins, moreover it interacts with histone deacetylase complexes 
and methyl transferases (Iyengar and Farnham, 2011). Since Tau is strongly 
associated to chromatin remodelling and it interacts with TRIM28, it would be 
interesting to further investigate the nature of this interaction to find out whether 
TRIM28 or one of its interactors could mediate nuclear Tau functions. 
1.4 Tau pathology 
 
Figure 1.4: Tau pathological changes in subcellular compartments. Adapted from Wang and 
Mandelkow, 2016. 
As stated above, Tau protein is a key player in a group of neurodegenerative 
diseases named tauopathies and among these Alzheimer’s disease is one of the 
most common and studied. Tauopathies can differ for the progression and 
symptoms, but all these diseases show a common hallmark that is the 
pathological destabilization and aggregation of Tau protein. Tauopathies include 
Alzheimer’s disease (AD), Frontotemporal dementia with parkinsonism-17 
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(FTDP-17), Pick disease (PiD), progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD), agyrophilic grain disease (AGD) and 
Huntington disease (HD), and most of them show both familiar and sporadic 
forms (Lee et al., 2001). In the first steps of these pathologies, whose 
mechanisms are still not clear, MTs-bound Tau is post-translationally modified. 
These modifications lead to Tau displacement from MTs with its increase in the 
cytoplasmic pool. Post-translational modifications change Tau molecular 
properties and structure causing the association of Tau monomers into oligomers 
and then in amyloidogenic aggregates. The molecular mechanisms inducing the 
toxic effect of Tau aggregation are still debated even if it is strongly supported 
that the aggregation causes cellular stress and damage to neuronal and non-
neuronal cells. 
1.4.1 Tau mutations 
 
Figure 1.5: Localization of the main MAPT mutations. Adapted from Wang and Mandelkow, 
2016 
The processes involved in the pathogenesis of tauopathies are still unclear. 
These diseases can be sporadic or familial and genetic analyses of Tau in 
patients with familial tauopathies demonstrated that specific mutations are 
associated to the insurgency of Tau destabilization and Tau failure. Familial 
tauopathies like FTDP-17 can be caused by several intronic and exonic 
mutations in MAPT gene such as Δ280K, P301L, P301S and E10+3 (Figure 1.5) 
(Bugiani et al., 1999; Hutton et al., 1998; Rizzu et al., 1999; Spillantini et al., 
1998a). Several studies show that these mutations can induce Tau alterations, 
making it more prone to destabilization and aggregation. Exonic missense or 
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deletion mutations destabilize Tau binding to MTs and decrease the ability to 
induce MT assembly (Goedert et al., 1999). Intronic mutations can affect 
alternative splicing of E10 thus increasing 4R Tau as observed in patients’ brains 
(Spillantini et al., 1998a). The discovery of mutations altering MAPT splicing 
suggests that disruption of 3R:4R ratio is sufficient to cause neurodegeneration 
and dementia, conversely maintaining the physiological 3R:4R ratio appears to 
be crucial for normal brain functions. The mechanisms around the dementia 
caused by isoform imbalance is still obscure, but it is hypothesized that it could 
somehow interfere with Tau binding to MTs thus increasing Tau soluble pool (Liu 
and Gong, 2008). 
An inversion polymorphism arising about 3 million years ago of approximately 
900kb on chromosome 17q21 generated two haplotypes, H1 and H2 
encompassing MAPT locus (Stefansson et al., 2005). Genome association 
analyses showed that H1 haplotype is associated with increased risk for PSP and 
CBD (Baker et al., 1999; Di Maria et al., 2000). In time, variations of each 
haplotype generated sub-haplotypes which differentially influence the insurgency 
of tauopathies. For example, the H1c sub-haplotype has been associated with 
increased risk for PSP and AD (Baker et al., 1999; Myers et al., 2005). In order to 
explain the pathogenic mechanisms of these haplotypes it has been 
hypothesized that they can affect Tau expression or Tau splicing. As a matter of 
fact, reporter genes under H2 promoter show a reduction in transcriptional activity 
compared to the H1 promoter (Kwok et al., 2004). Moreover, H1/H2 
heterozygous neuroblastoma cell line models and human brains indicate that the 
H1 chromosome induce a significantly higher expression of transcripts including 
E10 (Caffrey et al., 2006). 
Since Tau mutations are strongly associated to Tau pathological behaviour, they 
are experimentally employed to induce, both in a cellular context and in vivo, Tau 
destabilization and aggregation since wild-type Tau is not able to aggregate 
spontaneously. In particular, mouse models expressing mutated Tau are largely 
used to clarify the neurotoxic mechanisms mediated by Tau aggregation and to 
simulate the progression of tauopathies even if a “perfect” model able to 
represent all the characteristics of a specific tauopathy is not available yet 
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(Bondulich et al., 2016; Eckermann et al., 2007; Kremer et al., 2011; Lewis et al., 
2000; Schindowski et al., 2006; Yoshiyama et al., 2007). 
Intriguingly, mutations in Tau protein seem not only to affect Tau interaction with 
tubulin leading to aggregation as canonically described (Goedert et al., 1999). 
Recent studies showed that pathological mutations, along with genomic instability 
and neuronal damage, cause also an increased probability of tumorigenesis 
suggesting a role for Tau also in other tissues of the organism (Rossi et al., 2008, 
2013, 2014, 2018). Moreover, the P301S mutation associated to FTDP and PiD 
affects the interaction with DDX6, resulting in an impairment of miRNAs silencing 
activity (Chauderlier et al., 2018). 
1.4.2 Tau post-translational modifications  
As described above, Tau protein is exposed to several post-translational 
modifications that influence both its physiological and pathological behaviour. In 
particular, it is commonly assumed that Tau modifications, above all 
hyperphosphorylation and cleavage, are the first events leading to aggregation 
(Pevalova et al., 2006; Wang and Mandelkow, 2016). 
Phosphorylation: 
 
Figure 1.6: Relevant Tau phosphorylation residues. Adapted from Wang and Mandelkow, 
2016. 
Phosphorylation is the most characterized post-translational modification of Tau. 
79 putative serine and threonine phosphorylation sites have been identified. 
During embryonic development it has been demonstrated that Tau protein is 
much more phosphorylated than in post-natal period. Tau physiological 
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phosphorylation seems to control MT dynamics during normal neurite growth and 
maturation. In tauopathies Tau becomes hyperphosphorylated leading to the 
formation of amyloidogenic aggregates. Moreover, in recent years, changes in 
body temperature have been demonstrated to be environmental factors able to 
alter Tau phosphorylation leading to a predisposition in developing tauopathies 
(Bretteville et al., 2012; Planel et al., 2004; Tournissac et al., 2019; Vandal et al., 
2016; Whittington et al., 2013). By mass spectrometry and antibody detection 
experiments all six Tau isoforms have been identified in aggregates and have 
been demonstrated to be phosphorylated at 40 different residues (Avila et al., 
2004; Pevalova et al., 2006).  
Among critical sites involved in Tau aberrant activity implicated in AD and in other 
tauopathies, AT8 epitope (Ser199/Ser202/Thr205) has an important role. The 
phosphorylation of these three residues is sufficient to cause MTs remodelling 
and instability, diminished mitochondrial transport, cell death and 
neurodegeneration (Shahpasand et al., 2012). A similar effect is observed by 
phosphorylation of residues Thr212/Thr231/Ser262 (Alonso et al., 2010). In vitro 
kinetic studies of the binding of unphosphorylated and hyperphosphorylated Tau 
to tubulin suggest that Ser199/Ser202/Thr205, Thr212, Thr231/Ser235, 
Ser262/Ser356, and Ser422 are among the critical phosphorylation sites that 
convert Tau to pathological molecule that sequesters normal microtubule-
associated proteins from MTs (Figure 1.6) (Abraha et al., 2000; Alonso et al., 
2004; Gong et al., 2005; Haase et al., 2004; Sengupta et al., 1998). The 
phosphorylation of these residues depends on the activity of both kinases and 
phosphatases, whose equilibrium plays a key role in Tau pathology. 
Kinases: 
GSK3β 
Glycogen synthase kinase-3 (GSK3β) is expressed ubiquitously but it can be 
found at high levels in the brain where it localizes predominantly in neurons. It 
belongs to the PDPK class (proline directed protein kinases), and is a 
serine/threonine-specific kinase. GSK3β influences Tau behaviour both in 
physiological and pathological conditions (Pei et al., 1997; Pevalova et al., 2006). 
Brains of AD patients show a higher immunoreactivity against GSK3β than 
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control brains, with the kinase predominantly colocalizing with NFTs (Pei et al., 
1997). Among the residues phosphorylated by GSK3β, Thr231 has been 
observed to be strongly related to the beginning of AD. This epitope is an 
example of primed phosphorylation because it occurs after Ser235 
phosphorylation. The modification of Thr231 causes a conformational change in 
Tau affecting its stability and affinity to MTs (Cho and Johnson, 2003; Daly et al., 
2000). Preclinical studies employing GSK3β inhibitors revealed that the block of 
kinase activity decreases aggregation and protects against axonal degeneration 
in TauP301L mice (Noble et al., 2005). 
Cdk5 
Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase of the PDPK 
class. It contributes to phosphorylation of human Tau on Ser202, Ser205, 
Thr212, Thr217, Ser235, Ser396 and Ser404, epitopes phosphorylated in AD 
brains. Cdk5 interacts with p35 to exacerbate its function. It has been seen that 
the conversion of p35 in p25 due to pathological conditions causes prolonged 
activation and mislocalization of Cdk5 and hyperphosphorylation of Tau (Cruz et 
al., 2003; Lee et al., 2000; Maccioni et al., 2001; Tsai et al., 2004). The 
knockdown of Cdk5 in AD mouse models strongly decreases the number of 
neurofibrillary tangles in the hippocampus (Piedrahita et al., 2010). 
ERK1/2  
Extracellular signal-regulated kinases isoforms 1 and 2 (ERK1/2) belong to the 
PDPK class of kinases. Analysis on post-mortem AD brains showed that they 
predominantly colocalize with NFTs (Perry et al., 1999). Consistently, the 
administration of an ERK2 inhibitor was able to reduce the levels of abnormally 
phosphorylated Tau and to rescue motor deficits in a mouse model of tauopathy 
(Le Corre et al., 2006). 
JNK  
C-Jun amino-terminal kinase (JNK) belongs to the PDPK group of kinases. JNK 
is able to hyperphosphorylate Tau, moreover immunohistochemical analysis of 
phopho-JNK showed increased activation of the kinase in the hippocampi of AD 




Other kinases have an important role in the pathogenesis of tauopathies. PKA is 
a ubiquitous serine/threonine kinase activated by cAMP. It phosphorylates Tau at 
Ser214, Ser217, Ser262, Ser396/404 and at Ser416 (Andorfer and Davies, 2000; 
Carlyle et al., 2014; Zheng-Fischhöfer et al., 1998). CaMKII too seems an 
important factor inducing Tau aberrant hyperphosphorlation.  The function of this 
kinase is to regulate important neuronal functions including neurotransmitter 
synthesis and release, modulation of ion channel activity, synaptic plasticity and 
gene expression. The kinase phosphorylates Tau at Ser262, Ser356, Ser409 and 
Ser416 that are phosphorylated in brains of AD patients. The phosphorylation of 
all these residues by PKA and CamKII is strongly associated to Tau pathology 
since this mechanism influences Tau binding on MTs, cleavage and aggregation 
(Andorfer and Davies, 2000; Carlyle et al., 2014; Singh et al., 1996; Steiner et al., 
1990; Zheng-Fischhöfer et al., 1998). 
Phosphatases 
Several studies have shown that three major protein phosphatases, PP5, PP2B 
and PP2A, can dephosphorylate Tau protein. PP2B influences the dynamics of 
MTs and microfilaments. PP5 is associated with MTs and dephosphorylates Tau 
in the neuronal cytoplasm. PP2A is localized on MTs and can dephosphorylate 
Tau by direct interaction or indirectly, regulating the activity of several Tau 
kinases (Liu et al., 2005; Pevalova et al., 2006). The inhibition or the absence of 
these phosphatases in cells cause the hyperphosphorylation of Tau suggesting a 
possible role of these proteins during tauopathy development. Remarkably, in AD 
brains the impaired activity of PP2A has been observed (Gong et al., 1993). 
Other Tau post-translational modifications 
Tau undergoes several other post-translational modifications which could 
influence its functions such as   acetylation, glycation, glycosylation and 
truncation. 
As to post-translational modifications, studies on the composition of aggregates 
revealed that Tau is cleaved at different sites. Tau truncation is characterized by 
a progressive cleavage of the protein in specific residues which leads to smaller 
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and smaller fragments prone to aggregation (Gamblin et al., 2003; Guillozet-
Bongaarts et al., 2005; Novak et al., 1993; Rissman et al., 2004). Several 
enzymes have been identified as able to cleave Tau such as caspases but also 
calpains, thrombin, cathepsins and the aminopeptidase PSA. In particular, in 
tauopathies, these enzymes are deregulated and target Tau protein inducing and 
enhancing its destabilization and aggregation (Arai et al., 2006; Cataldo et al., 
1997; Nakanishi et al., 1997; Rao et al., 2008; Saito et al., 1993). The study of 
the progressive Tau cleavage revealed that some residues are cut in early stages 
of tauopathies and other in late stages. A caspase-cleaved Tau species, cleaved 
at Asp421, was identified in NFTs (Gamblin et al., 2003). Tau conformational 
studies suggest that this cleavage is an early event in the pathogenesis of AD 
(Guillozet-Bongaarts et al., 2005; Rissman et al., 2004). Intriguingly, caspase 
cleavage at Asp421 can be inhibited by phosphorylation at Ser422 suggesting 
that some phosphorylations are protective (Guillozet-Bongaarts et al., 2006). 
Truncated Tau at Glu391 is found in NFTs in tauopathy brains and it is 
associated to a late stage of the disease. In Tau aggregates a 12KDa fragment 
from His268 to Glu391containing the MTBD has been identified, and it is referred 
to as the PHF-core (Novak et al., 1993). Further experiments showed that 
phosphorylation and truncation work synergically and together they influence Tau 
aggregation. As a matter of fact, in cells with or without GSK3β, transfected Tau 
fragment aggregates only in presence of the kinase (Cho and Johnson, 2004). 
Another post-translational modification whose importance is becoming relevant is 
lysine acetylation, which has been revealed to affect Tau properties. This 
modification neutralizes charges in the MT-binding domain interfering with Tau 
binding to MTs. Moreover, acetylation of Lys280 increases cytosolic Tau fraction 
and it’s correlated with Tau hyperphosphorylation. It is present mostly in 
intracellular NFTs rather than in pre-tangles or extracellular aggregates and it 
precedes Tau truncation (Cohen et al., 2011; Irwin et al., 2012). 
Glycosylation is the covalent bonding of sugars to the side chain of a polypeptide 
which can occur at the amine group of an asparagine (N-glycosylation) or at the 
hydroxyl radical of serine or threonine (O-glycosylation). These modifications 
seem to have opposite effect, as O-glycosylation is decreased in AD brain, while 
N-glycosylation is increased (Wang et al., 1996). Phosphorylation and O-
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glycosylation target the same residues, suggesting a mutually exclusive 
competition. As a matter of fact, in AD patients, a negative correlation has been 
reported between O-glycosylation level and Tau phosphorylation (Liu et al., 
2009). However, it has been reported  that the biological effect at each 
phosphorylation site is different (Gong et al., 2005). Moreover, deglycosylation of 
PHFs converts them in bundles of straight filaments and successive 
dephosphorylation results in the release of Tau monomers (Wang et al., 1996). 
Oxidation too seems to increase aggregation of monomeric Tau protein because 
it produces disulphide cross-linking between cysteine residues. Isoforms of Tau 
containing three repeats (3R) have only one cysteine residue in the MTs binding 
domain with respect to 4R isoforms which have two cysteines. For this reason, 
3R Tau is more prone to aggregate rather than 4R isoform which may form 
intramolecular disulphide bonds (Barghorn and Mandelkow, 2002). 
Other modifications are still under investigation, even if they seem to be related to 
late stages of Tau pathology. In PHFs and NFTs Tau is also ubiquitinated with 
the covalent bonding of the 76aa protein ubiquitin. Also glycation, the non-
enzymatic linkage between a reducing sugar and the amino side chain of 
polypeptide, can be identified in PHFs isolated from AD brains while it’s not 
present in normal Tau (Münch et al., 2002; Yan et al., 1995). 
1.4.3 Tau aggregation  
 
Figure 1.8: Tau aggregation process from monomers to neurofibrillary tangles.  
Tau molecule has long stretches of positively and negatively charged regions 
which don’t allow intermolecular hydrophobic association. The β-structure, typical 
of amyloidogenic proteins, is present in repeated regions, in particular in R2 and 
R3, which can assemble by their own in filaments (von Bergen et al., 2000). Self-
aggregation is inhibited by the presence of intact N- and C-terminal domains but 
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when Tau undergoes post-translational modifications, the conformational 
structure changes exposing the sticky repeat regions which lead to formation of 
aggregates (Alonso et al., 2001). Even if Tau aggregation is a common event of 
all tauopathies, fibrils isoform composition differs between tauopathies. In AD 
tangles include both 3R and 4R Tau (Sergeant et al., 1997), in PiD they are 
mainly made up of 3R (Delacourte et al., 1996) and in PSP, CBD, AGD and 
FTDP-17 they predominately comprise 4R Tau (Arai et al., 2001; Buée-Scherrer 
et al., 1996; Togo et al., 2002). 
 
Figure 1.7: PHFs and SFs ultrastructure level. Adapted from Fitzpatrick et al., 2017. 
The aggregation process seems to involve several steps. At the beginning, small 
Tau inclusions with low content in β-sheet structures are formed in a process 
called nucleation; after that other Tau molecules associate to this core to form 
paired helical filaments (PHFs) and straight filaments (SFs). Finally, PHFs further 
self-assemble to form neurofibrillary tangles (NFTs). The formation of Tau fibrils 
can be experimentally induced by the addition of preformed aggregates which 
mimic the nucleation step in a process named seeding. It has been demonstrated 
that the administration of small Tau assemblies in the extracellular medium can 
induce prion-like homotypic-seeding both in vivo and in vitro (Clavaguera et al., 
2009; Frost et al., 2009). The smallest assembly having these seeding properties 
is Tau trimer (Mirbaha et al., 2015). Remarkably, in recent papers it has been 
demonstrated that Tau monomers isolated from tauopathy brains are able to 
induce Tau aggregation that is specific for the tauopathy the monomer is 
obtained from. This result opens to new insights suggesting that the monomer 
possesses peculiar pathological characteristics specific for each tauopathy 
independently from the oligomerization (Mirbaha et al., 2018; Sharma et al., 
2018).  It is thought that this occurs because nucleation is the limiting step in Tau 
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aggregation and if preformed aggregates are administrated, this step can be 
skipped. Electron-microscopy experiments showed that NFTs consists mainly of 
10 – 20 nm PHF (KIDD, 1963) and of 15 – 18 nm straight filaments (SF) 
(Yagishita et al., 1981). PHFs and SFs also differ at ultrastructure level as both of 
them consist in two protofilaments with C-shaped subunits but with different 
symmetry. The N- and C-terminal ends protrude from the core of the aggregate 
forming the fuzzy coat (Fitzpatrick et al., 2017). 
It has been demonstrated that in patients the number of NFTs correlates with the 
level of cognitive impairment. For this reason, it has been hypothesized that 
NFTs are toxic for the cell (Arriagada et al., 1992). In tauopathies, Tau is 
ineffective to keep the cytoskeleton organized in axonal processes because its 
affinity to tubulin is reduced. This loss of function is due to conformational 
changes and misfolding which lead to aberrant aggregation in fibrillary toxic 
structures inside neurons. Tau is redistributed in the somato-dendritic 
compartment and in isolated processes of affected neurons (Kolarova et al., 
2012). The destabilization of MTs affects axonal trafficking in particular the plus-
end-directed transport by kinesin (Ebneth et al., 1998). Inhibition of transport 
slows down exocytosis and the localization of organelles; the absence of these 
mechanisms causes a decrease in glucose and lipid metabolism, ATP synthesis 
and a loss of Ca2+ homeostasis which lead to a distal degeneration process 
(Futerman and Banker, 1996; Trojanowski and Lee, 1995). It has been seen that 
aberrant Tau not only can create aggregates sequestering normal Tau but it can 
also remove from MTs the two other major neuronal MAPs, MAP1 and 2 (Alonso 
et al., 1997).  
1.4.4 Other mechanisms of cellular toxicity mediated by Tau 
Increasing evidences show that NFTs are not the only toxic Tau species in 
tauopathies, in fact, in AD brains neuronal loss may exceed Tau aggregation 
(Gómez-Isla et al., 1997). Other pathological mechanisms can be involved in the 
neurotoxicity mediated by Tau. Dendritic Tau seems to mediate Aβ-induced 
neurotoxicity in AD since, in absence of Tau protein, Aβ-mediated LTP 
impairment is prevented (Shipton et al., 2011). Moreover, as already described, 
dendritic Tau is necessary for Fyn localization and scaffolding at the post-
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synaptic compartment. There, Fyn phosphorylates NMDA subunit NR2B thereby 
stabilizing its interaction with PSD95. Under disease conditions, redistribution of 
Tau from the axon into the somatodendritic compartment is thought to increase 
Tau-dependent sorting of Fyn to dendrites, leading to toxic hyperexcitability 
caused by NMDA receptors. Indeed, the loss of Tau can prevent postsynaptic 
targeting of Fyn, and as a consequence NMDA-dependent excitotoxicity and 
memory impairment (Ittner et al., 2010; Lau et al., 2016; Mondragón-Rodríguez et 
al., 2012). Therefore, Fyn is important to potentiate glutamatergic signalling and it 
could mediate excitotoxicity in tauopathies. As described above, in vivo studies 
showed that the increase of Tau in the nucleus is associated to global chromatin 
relaxation resulting in alteration of gene expression. Intriguingly, chromatin 
relaxation has been shown to be neurotoxic (Frost et al., 2014). Moreover, Tau 
loss of function induced by mRNA knock down results in an increase of 45S-pre-
rRNA synthesis in SHSY5Y (Maina et al., 2018). Other evidences suggested that 
oligomeric nuclear Tau has a more efficient repressive role than monomeric Tau 
in mouse models, supporting a global gene expression alteration that can affect 
neuronal homeostasis (Benhelli-Mokrani et al., 2018). Aberrant Tau influences 
also miRNA activity, as a matter of fact mutated Tau is less efficient in modulating 
the activity of miRNA let-7a (Chauderlier et al., 2018). All these evidences 
strongly support that in tauopathies, Tau is able to induce cellular toxicity since it 
alters several mechanisms crucial for the correct functioning of the cell.  
1.4.5 Tau secretion and spreading 
In pathological conditions, Tau aggregation starts in specific areas of the brain 
and during the pathology progression, Tau inclusions can be found also in other 
regions indicating a diffusion of amyloidogenic Tau. Its spreading occurs with a 
standard pattern with close or connected brain areas being affected one after the 
other (Braak et al., 2006). The mechanisms behind Tau spreading are still under 
investigation. Tau aggregates were found first intracellularly and the protein 
detected in the extracellular space was considered as a release from dead cells. 
On the contrary, further studies reported that Tau is secreted by different 
neuronal and non-neuronal cell types, associated to exosomes or other 
membrane vesicles (Kim et al., 2010; Medina and Avila, 2014; Shi et al., 2012). It 
was also observed that pathological post-translational Tau modifications enhance 
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its secretion suggesting that the release mechanism is linked to the progression 
of Tau pathology (Plouffe et al., 2012). Several mechanisms for the uptake have 
been proposed such as internalization of soluble Tau via receptor-mediated 
endocytosis, dynamin-driven endocytosis of soluble Tau aggregates or even 
proteoglycan-mediated macropynocytosis (Medina and Avila, 2014). Spreading 
could also occur trans-synaptically or via diffusion (Wang and Mandelkow, 2016). 
1.5 Molecular tools to investigate Tau by imaging  
Due to the key role of Tau in several neurodegenerative diseases, it is crucial to 
develop molecular tools providing a clear and simple interpretation of the state of 
Tau protein. These tools can be extremely useful for diagnosis or to screen 
molecules targeting pathological Tau. 
The main approaches to study Tau aggregation rely on biosensors and amyloid 
binding dyes. Tau biosensors are chimeric proteins containing fluorophores that 
provide information about the molecular state of Tau. The advantage of 
fluorophores is that they can be genetically controlled (Kaláb and Soderholm, 
2010). An intermolecular sensor that relies on bimolecular fluorescence 
complementation (BiFC) has been developed. Tau proteins are fused to non-
fluorescent N- or C-terminal fragments of V-YFP and when two Tau molecules 
interact, the fluorophore is reconstituted and the protein fluoresces providing an 
output for Tau aggregation (Tak et al., 2013). An intermolecular FRET biosensor 
developed by Kfoury et al. is commonly used in laboratories that investigate Tau 
aggregation. Tau fragments, prone to aggregate, are fused to either YFP or CFP 
and when two Tau molecules interact, a FRET positive signal is observed. The 
strong advantage of this biosensor is that it detects Tau aggregation by 
fluorescence imaging but it is also optimized for FRET cytofluorimetry (Kfoury et 
al., 2012). Finally, in our laboratory we developed an intramolecular FRET 
biosensor that will be described later (Di Primio et al., 2017). 
Another method to visualize Tau aggregation is the employment of dyes such as 
Thioflavin T, Thiazin Red and K114. These compounds have high affinity to β-
sheet structures typical of amyloidogenic aggregates and can be used in cellular 
cultures or tissues with the limitation that they need to be fixed by fixation 
methods. Amyloid binding dyes emits a fluorescence signal when bound to Tau 
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aggregates which allows to study aggregation dynamics by imaging techniques 
(Crystal et al., 2003; Luna-Muñoz et al., 2008; Santa-María et al., 2006). 
A novel approach is the employment in pre-clinical and clinical studies of 
molecules for PET imaging. The interest for PET compounds is due to the 
possibility to accurately and specifically target Tau deposits in vivo in patients’ 
brains. The advances of molecular imaging in recent years provided promising 
Tau-specific tracers such as THK5317, THK5351, AV-1451, and PBB3. The 
employment of these tracers guarantees the investigation in real-time of Tau 
deposition patterns in vivo for different pathologies, discriminating between 
neurodegenerative diseases, including different tauopathies, and monitoring 
disease progression. In AD, the topographical distribution of tracers  follows the 
known distribution of NTFs and is closely associated with neurodegeneration 
(Okamura et al., 2018; Saint-Aubert et al., 2017). 
1.6 Tauopathy animal models 
In order to investigate the behaviour of Tau in physiology and, above all, in 
pathology, several animal models based on the expression of human Tau have 
been generated. The main model employed for Tau studies is mouse but also D. 
rerio and Drosophila are commonly used. The advantage of using animals is 
obviously that the biological context is complex and closer to human, 
guaranteeing a higher reliability compared to the in vitro conditions. However, the 
main counterpart is that these models does not develop tauopathies and they 
need to be genetically modified with Tau molecules prone to pathological 
aggregation. 
Several mouse models have been developed in the last 20 years and most of 
them are transgenic mice expressing mutated human Tau. The employment of 
Tau isoforms mutated in specific residues enhances the pathological behaviour of 
Tau, indeed, in these models Tau is unstable on MTs and forms toxic aggregates 
spontaneously. Each mouse usually expresses a specific mutation such as 
TauP301L, TauP301S or TauΔK280 and all of them lead to aggregation of Tau even if 
there are differences in the progression and spreading (Allen et al., 2002; 
Eckermann et al., 2007; Lewis et al., 2000; Terwel et al., 2005; Yoshiyama et al., 
2007). Mouse models for Tau pathology can be divided into two groups: the first 
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resembles pure tauopathies expressing mutated Tau or Tau fragments, the 
second combines the Tau pathology with the Aβ pathology, a condition 
resembling Alzheimer’s disease. However, tauopathy models share common 
aspects of pathology development. The expression of mutated Tau causes a 
progressive neurodegeneration with formation of neurofibrillary tangles around 
the 6th month (Allen et al., 2002; Lewis et al., 2000; Terwel et al., 2005; 
Yoshiyama et al., 2007) but there are cases of late aggregation as for TauΔK280 
model which shows mature tangles only after 24 months (Eckermann et al., 
2007). Other models are based on the expression of a Tau fragment which is 
prone to form intracellular inclusions. In these animals spontaneous aggregation 
occurs at 9-10 months and progresses with age (Bondulich et al., 2016; Filipcik et 
al., 2012). All these models show strong neuronal damage worsening with the 
progression of Tau toxic aggregation. As a matter of fact, common features are 
the synaptic loss, neuronal death and cognitive deficits which become more 
severe with aggregation. In some cases also gliosis can be detected suggesting 
that the neurodegeneration gives rise to an inflammatory process. The main brain 
areas affected by aggregation and neuronal loss are the spinal cord, cortical 
areas, amygdala, hippocampus with a spreading which increases with the 
development of the tauopathy (Allen et al., 2002; Boekhoorn et al., 2006; 
Bondulich et al., 2016; Filipcik et al., 2012; Van der Jeugd et al., 2011; Kremer et 
al., 2011; Lewis et al., 2000; Terwel et al., 2005; Yoshiyama et al., 2007). 
Mutated Tau is also employed for the development of AD mouse models 
expressing human APPSWE as well. Remarkably, in these animals the presence of 
both toxic proteins causes a severe Tau and Aβ aggregation suggesting that 
there is a cooperative effect in the formation of toxic aggregates. Moreover, 
neuronal and synaptic loss are present and coupled with gliosis. Intriguingly, the 
brain areas first involved in these processes are slightly different.  Indeed, the 
hippocampus and cortical areas show pathological aggregation followed by 
spreading in other regions (Lewis et al., 2001; Oddo et al., 2003; Schindowski et 
al., 2006). Even if a lot of models have been developed and characterized, there 
is still the lack of a “perfect” model mimicking all the aspects of tauopathies. 
However, the employment of these animals has been valuable to study 
pathological mechanisms with cognitive readouts and to test treatments impairing 
or enhancing Tau toxicity. 
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Even if the mammalian animal model is the most employed, the long 
experimental time required to develop the disease, the difficulties in handling and 
the failure of therapies efficient in human patients induced the scientific 
community to explore alternative models for specific applications.  
During the last decade, Drosophila gained attention as a model system for 
common human neurodegenerative brain disorders. Most basic molecular and 
cellular mechanisms are highly conserved between humans 
and Drosophila and ~70% of all human disease genes have an evolutionary 
conserved fly homolog, providing a reliable model (Bier, 2005; Bilen and Bonini, 
2005). Many Drosophila models have been generated using human Tau. Some 
are based on wild-type Tau isoforms whereas others express mutated forms such 
as TauR406W, TauV337M, and TauP301L. To explore specific mechanisms of Tau 
toxicity or dysfunction, transgenes with targeted mutations and truncations were 
also generated, with constructs which abolish or mimic Tau phosphorylation or 
proteolytic cleavage. Together, these models explore the great diversity of 
tauopathies (Gistelinck et al., 2012). Expression of Tau protein in flies results in 
neurotoxicity which can be evaluated by morphological readouts of the animal. 
Roughening of the eye is the most commonly used external phenotype to 
evaluate toxicity of Tau in Drosophila (Gistelinck et al., 2012). Moreover, 
Drosophila notum harbours around 200 bristles, which are sensory organs 
connected at the base with the dendrite of a sensory neuron. Tau toxicity can be 
quantified by simply counting bristles and overexpression of different variants of 
Tau leads to bristle loss (Yeh et al., 2010). Other common readouts are the 
lifespan and pupal lethality, as a matter of fact flies overexpressing Tau show a 
reduced lifespan and increased death of larvae (Talmat-Amar et al., 2011). All 
these readouts can be used to easily evaluate the toxic effect of Tau and also to  
screen genes or drugs altering the toxicity of the protein. Moreover, neuronal cell 
death can be detected by TUNEL or immunostaining of activated cleaved 
caspase-3 which indicate increased apoptosis in brains of Tau-expressing flies 
(Ali et al., 2012; Colodner and Feany, 2010; Talmat-Amar et al., 2011). Neuronal 
degeneration in Drosophila can also be observed by the presence of vacuoles in 
brain tissues and can be used as a quantitative readout (Ali et al., 2012; Mershin, 
2004; Talmat-Amar et al., 2011). Alterations in axonal transport has also been 
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observed in flies expressing Tau bearing pathological mutations and PTMs and 
this causes locomotor defects and altered release of neurotransmitters and 
neurohormones (Gistelinck et al., 2012). Finally this model can be applied for 
behavioural tests, in particular olfactory learning and memory in Tau-expressing 
flies is strongly impaired and almost a complete loss of mushroom bodies is 
observed suggesting a relevant toxic effect of Tau (Kosmidis et al., 2010; 
Mershin, 2004). The significant damage caused by Tau in Drosophila and the 
easy readouts led to a relevant use of this model for the identification of Tau 
mechanisms and interactors related to transport and transmission and for genetic 
screenings (Gistelinck et al., 2012). 
Another animal model which has been considered to study Tau pathological 
mechanisms is Danio rerio (zebrafish). This animal offers several distinct 
advantages over other vertebrate models: the easy maintenance in laboratory 
due to its simple habitat conditions, the large clutch size with hundreds of eggs, 
the transparency of embryos allowing an easy imaging analyses, the feasibility of 
the genetic manipulation, the vertebrate neural structural organisation and the 
presence of several orthologue genes similar to humans. Moreover, the small 
size of larvae allows the high-throughput screenings of neuroactive compounds 
(Saleem and Kannan, 2018). The zebrafish model has been employed for the 
study of tauopathies by expressing wild-type or mutated forms of Tau. 
Interestingly, the pathological features develop much earlier in zebrafish as 
compared with other available rodent models. Tau expression in zebrafish shows 
early pathological hallmarks like hyperphosphorylation and conformational 
changes within the first 2 days of embryonic development. After few days, the 
larvae develops substantial neurodegeneration displaying pathological features 
including neurofibrillary tangles by 5 weeks of development (Paquet et al., 2009). 
Tau aggregation can be observed after Tau overexpression in neurons and these 
cellular inclusions are positive for pathological phosphorylations in residues 
related to Tau aggregation and for structural antibodies and dyes (Bai and 
Burton, 2011; Bai et al., 2007; Paquet et al., 2009, 2010). Moreover, Tau 
expression in neurons disrupts the cellular cytoskeletal structure (Tomasiewicz et 
al., 2002). The stereotypic escape response, a behavioural test employed to 
observe the motility and the response to an external stimuli, has been also 
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evaluated and at 48 hpf the escape is highly reduced or absent in Tau-expressing 
larvae (Paquet et al., 2009). Due to the peculiar characteristics of the model and 
to the effect of Tau overexpression which spontaneously leads to 
neurodegeneration, zebrafish is considered a promising model to study 
pathological mechanisms and to develop screenings to impair Tau mediated 
toxicity. 
1.7 Therapeutic approaches against Tau pathologies 
Tauopathies are complex multifactorial diseases and the development of 
therapies has been slow and often inconclusive. Current approaches do not rely 
on disease modifying drugs, but rather on symptomatic ones and aim to manage 
behavioural symptoms. Several symptomatic drugs for AD treatment are 
approved by the Food and Drug Administration and they mainly rely on 
cholinesterase inhibitors, to prevent the breakdown of acetylcholine described in 
the brain of AD patients (Birks, 2006) and, at late stages, on NMDA antagonists, 
to prevent excitotoxicity (Wang and Reddy, 2017). However, these treatments 
can be unsatisfactory as they cannot halt the progress of the pathology. For 
these reasons, many efforts have been spent to study the two main lesions in 
AD, i.e. amyloid plaques (APs) and NFTs in order to come up with a disease 
modifying treatment. However, all the attempts targeting APs failed  in blocking or 
curing the disease (Makin, 2018; Wischik et al., 2014). Consequently, an 
increasing interest toward the role of Tau in the etiology of tauopathies has 
arisen. Recently active or passive immunization showed great potentialities in 
preventing Tau aggregation, leading to promising clinical trials that are still in 
progress. As to the passive immunization, the injection of selected antibodies 
against pathological Tau has been considered and several approaches have 
been exploited leading to clinical trials (Novak et al., 2018a; West et al., 2017). 
Recent evidences showed that the reduction of total Tau in adult brains doesn’t 
affect physiological functions and prevents toxicity caused by Tau aggregation. 
This study opened to a new approach employing ASOs molecules to target Tau 
expression and reduce the aggregation in patient’s brains (Devos et al., 2017; 
DeVos et al., 2018). Actually the most promising therapeutic intervention is the 
active immunization by the AAD1vac, a vaccine against pathological Tau. 
Preclinical studies on mice models revealed that this vaccine specifically reduces 
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Tau pathological aggregates in the brain and currently it is employed in a clinical 
trial for AD. The phase II for the evaluation of side effects in patients has recently 
concluded and further investigations are in progress to determine the therapeutic 
effect (Kontsekova et al., 2014; Novak et al., 2018c, 2018b, 2018a). 
Another possibility to treat Tau pathology is to target hyperphosphorylation since 
Tau phosphorylation is a key event in the pathology. Many kinase inhibitors have 
been approved for the treatment of cancer and other diseases, opening to the 
possibility of a therapeutic application of existing drugs also for 
neurodegenerative diseases. Among these molecules, PD-901 is a potent 
inhibitor of ERK pathway whose effect on Tau pathology was previously 
described. It is currently in clinical trial for the treatment of lung cancer and sold 
tumors (ClinicalTrials.gov Identifier: NCT02022982; NCT02039336; 
NCT03905148). Another interesting kinase inhibitor is D-JNKI-1, a cell-
penetrating peptide that inhibits JNK pathway which is currently in clinical trial for 
the treatment of acute hearing loss (ClinicalTrials.gov Identifier: NCT02809118; 
NCT02561091). 
1.8 Förster Resonance Energy Transfer 
Förster or fluorescence resonance energy transfer (FRET), is a mechanism of 
energy transfer between two light-sensitive molecules described in 1948 by 
Theodor Förster (Förster, 1948). Generally, an excited fluorophore can lose its 
exceeding energy by emitting a photon or by non-radiative dissipation. In the 
FRET mechanism, if two fluorophores are sufficiently close each other, one can 
transmit its energy to the other. The excited fluorophore, the donor, can return to 
its ground state by non-radiative transfer of energy from its excited dipole to the 
dipole of the acceptor one. The acceptor fluorophore in turn can return to its 
ground state by different mechanisms including photon emission, non-radiative 
dissipation or again energy transfer to another acceptor molecule. No light 
photons are transferred to the acceptor and no acceptor fluorescence is required 
for resonance energy transfer to occur. In order for FRET to happen some 
conditions must be considered. The donor emission spectrum must overlap the 
acceptor excitation spectrum. Moreover, FRET efficiency is influenced by the 
distance (R) of the molecules involved. The efficiency decreases at the 6th power 
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of R and increases with R0, the distance at which the probability of the energy 
transfer between the donor and the acceptor is 50% (Förster distance): E = 𝑅06 / 𝑅06 +  𝑅6. The orientation of the dipoles also influences FRET efficiency infact 
no FRET occurs when the dipoles are perpendicular while it’s maximal for parallel 
dipoles (Kaláb and Soderholm, 2010; Shrestha et al., 2015). However, it has 
been demonstrated that in a biological context, the impact of dipoles orientation is 
less significant than the parameters described above since both donor and 
acceptor fluorophores can acquire all possible random orientations during the 
donor’s lifetime (Shrestha et al., 2015). The choice of the fluorophores is 
fundamental for an analysis based on FRET technique. The most commonly 
used donor-acceptor pairs in biology are synthetic organic dyes and fluorophores. 
However, also other molecules have been introduced such as synthetic 
nanoparticles, non-natural autofluorescent aminoacids, genetically encoded 
protein tags targeted by synthetic dyes and bioluminescent donors. Synthetic 
organic dyes are small molecules with favourable photochemical and spectral 
properties respect fluorophores. The advantage of fluorophores is that they can 
be genetically controlled outweighing the fact that are large molecules (Kaláb and 
Soderholm, 2010). FRET is a useful technique to study protein interactions and 
conformational changes in the same molecule and it has also been applied in 
several Alzheimer’s disease studies. Takahashi et al exploited FRET strategy to 
construct a sensor detecting Aβ oligomers using CFP and YFP respectively as 
donor and acceptor fluorophores (Takahashi and Mihara, 2012). Kinoshita et al 
used FRET to visualize the interaction between APP and β-secretase from the 
surface of cells to the endosomal compartment (Kinoshita et al., 2003). In another 
study the method has been employed for the detection of Tau aggregation by the 
expression of Tau repeat domains fused to CFP and YFP (Holmes et al., 2014). 
Other studies employs FRET to study localization of Tau protein on MTs (Nouar 
et al., 2013). These examples are indicative of the different applications in which 
FRET can be used in a biological context, to study the interaction between 
proteins or to detect conformational changes inside the protein. 
1.9 Aim of the thesis 
This work is focused on the study of molecular mechanisms involved in Tau 
pathology. First, a Tau intramolecular biosensor named Conformational Sensitive 
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Tau (CST) has been developed and characterized to study Tau conformational 
changes. CST revealed the 3D conformations of Tau in physiological and 
pathological conditions. In particular, we demonstrated that Tau assumes a loop-
like conformation when bound to MTs while soluble cytoplasmic Tau shows a 
more relaxed conformation. Moreover, destabilizing conditions related to 
tauopathies, such as Tau mutations, induce a conformational change towards a 
more open structure and a higher solubility of Tau protein. Finally, CST is also 
sensitive to Tau aggregation, with the formation of FRET positive aggregates. 
The CST allowed to characterize a peculiar Tau mutation associated to Pick’s 
disease, TauG336H, which shows a higher stability and a closer loop-conformation 
on MTs, determining an opposite effect with respect to previous characterized 
mutations. 
The CST has been applied for the development of in vitro and in vivo aggregation 
screening platforms. As to the in vitro platform, CST reporter cells displaying 
aggregates were treated with several kinase inhibitors in order to screen potential 
therapeutic molecules. Among these molecules, we identified a ERK pathway 
inhibitor actually used in oncological clinical trials, PD-901, as a drug able to 
reduce Tau pathological aggregation. An in vivo screening platform with CST 
expressed in a zebrafish model has been developed with the aim to obtain a 
more complex but easy-to-use model for high-throughput screenings of potential 
therapeutic compounds. 
The CST analysed in the nuclear compartment revealed that 3D conformation of 
nuclear Tau is different from Tau bound to tubulin. The role of nuclear Tau has 
been investigated in non-neuronal and in neuronal cell lines. We demonstrated 
that Tau is able to induce a significant increase of mRNA and protein levels of the 
Vesicular Glutamate Transporter 1 (VGluT1), a disease-relevant gene, in all the 
considered cell lines. The modulation of VGluT1 is due to the increase in the 
nuclear amount of Tau protein. Intriguingly, pathological mutation P301L or Tau 
aggregation lead to a loss of nuclear Tau function, preventing VGluT1 
expression. To determine the global effect on gene expression mediated by Tau, 
a transcriptome experiments on differentiated SHSY5Y showed an alteration of 
all the glutamate release pathway. A comparison with microarray data on 
hippocampi of patients affected with AD at different stages revealed that cellular 
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system overexpressing Tau mimics the first steps of AD. Finally, experiments to 
clarify the nuclear mechanisms mediated by Tau suggested that Tau in involved 
in epigenetic mechanisms. In particular, it interacts with the nuclear protein 
TRIM28 thus competing with HDAC1 which is delocalized from the nucleus to the 
cytoplasm. This mechanism seems to modulate VGluT1 expression revealing 




Chapter 2  
Materials and methods  
2.1 Chimeric constructs cloning 
The Conformational Sensitive Tau (CST) has been generated by cloning the 
cDNA encoding the Tau isoform D (383aa) into the BspEI site of the plasmid 
pECFP-EYFP already available in the lab (EYFP cloned in frame with ECFP into 
pECFP-C1 from Clontech at the BspeI site). Both the forward and reverse cloning 
primers contain the RSIVT linker sequence between the BspEI site and the Tau 
sequence (forward primer: 5'- GTC GTT TCC GGA AGA TCT ATT GTC ACT 
ATG GCT GAG -3'; reverse primer: 5'- AAC GAC TCC GGA AGT GAC AAT AGA 
TCT CAA ACC CTG -3'). The monolabeled constructs pECFP-Tau and pTau-
EYFP have been generated by subcloning the Tau cDNA into the BspEI site of 
plasmid pECFP-C1 and pEYFP-N1 (Clontech Laboratories, Inc., Saint-Germain-
en-Laye, France)(FWD-BspEI-TAU: 5'- AAT TAT TCC GGA ATG GCT GAG CCC 
CGC CAG-3' ; REV-BspEI-TAU: 5'- ACT TGA TCC GGA CAA ACC CTG CTT 
GGC CAG -3'; FWD-BspEI-RSIVT-TAU: 5'- AAT TAT TCC GGA AGA TCT ATT 
GTC ACT ATG GCT GAG CCC CGC CAG-3'; REV-BspEI-RSIVT-TAU: 5'- ACT 
TGA TCC GGA AGT GAC AAT AGA TCT CAA ACC CTG CTT GGC CAG -3'). 
The cDNA encoding human Tau isoform htau23 (352aa) was derived from 
pET28-his-3C_Tau352 (Addgene). To obtain a mammalian expression vector, 
htau23 was digested at XbaI/XhoI site and cloned in pEGFP-C1 by substituting 
GFP sequence in NheI/XhoI cloning site. Tau-NLS has been generated by 
digestion and cloning of the 3xNLS (pDonor-tBFP-NLS-Neo was a gift from 
Kazuhisa Nakayama Addgene plasmid # 80766; RRID: Addgene_80766) in the 
XhoI/BamHI site. Tau-NES has been obtained by PCR amplification of NES 
(pmTurquoise2-NES was a gift from Dorus Gadella; Addgene plasmid # 36206; 
RRID: Addgene_36206) and cloning in EcoRI/BamHI site. Mutagenesis 
experiments were performed on CST and Tau sequences by employing Site-
Directed Mutagenesis Kit Q5 (New England BioLabs). The primers for Tau 
mutagenesis are: S199A/S202A/T205A (AT8mut) Fwd 5’-CCC AGG CGC ACC 
CGG CAG CCG CTC CCG C -3’; Rev 5’- GCG CCG GGG GCG CTG TAG CCG 
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CTG CGA TCC CC -3’; P301L Fwd 5’-AAACACGTCCTGGGAGGCGGC-3’; Rev 
5’-GATATTATCCTTTGAGCCACACTTGGACTG-3’; ΔK280 Fwd 5’-
AAGCTGGATCTTAGCAAC-3’; Rev 5’-ATTAATTATCTGCACCTTCC-3’; P301S 
5’-AAACACGTCTCGGGAGGCGGC-3’; Rev 5’-
GATATTATCCTTTGAGCCACACTTGGACTG-3’; Q336H Fwd 5'- AGG AGG 
TGG CCA CGT GGA AGT -3'; Rev 5'-GGT TTA TGA TGG ATG TTG CC -3'. For 
bacterial expression of TauP301S, mutated Tau was digested at NdeI/BamHI sites 
and cloned in pET11a plasmid already available in the lab. The plasmid pEZX-
VG::Gfp was generated by GeneCopoeia. The pTagRFP-tubulin plasmid was 
purchased from Evrogen (FP145).  
2.2 Cell Culture, transfections and treatments 
HeLa cells and immortalized hippocampal neurons HT22 were maintained in 
Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10% 
FBS. SH-SY5Y (ATCC® CRL-2266TM) cells were maintained in DMEM/F12 
(GIBCO) supplemented with 10% FBS. SH-SY5Y were differentiated with 10 μM 
retinoic acid (Sigma-Aldrich) for 5 days followed by 50ng/ml BDNF (Alomone) in 
DMEM/F-12 medium not supplemented with FCS for three days. The day before 
the experiment cells were seeded at 105 cells in six-well plates or in Willco dishes 
(Willcowells). Lipofection was carried out with Effectene (QIAGEN) or 
Lipofectamine2000 (Thermo-Fisher) according to manufacturer’s instructions. 
Primary hippocampal neurons were obtained from postnatal day (P)0 B6/129 
mice. Hippocampi were dissected and triturated in cold calcium-free Hank's 
balanced salt solution with 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 
digested in 0.1% trypsin, followed by inactivation in 10% FBS DMEM (GIBCO) 
with 100 U/ml DNase. Neurons were seeded on poly-D-lysine-coated glass 
coverslips. For initial plating, neurons were maintained in Neurobasal-A medium 
(Invitrogen) supplemented with 4.5 g/l D-glucose, 10% FBS, 2% B27 (Invitrogen), 
1% Glutamax (Invitrogen), 1 mM pyruvate, 4 μM reduced glutathione, and 
12.5 μM glutamate. From the following day on, neurons were grown in 
Neurobasal-A medium (Invitrogen) supplemented with 2% B27 (Invitrogen), 1% 
Glutamax (Invitrogen), and 1 μg/ml gentamicin. For IF experiments, neurons at 
day in vitro (DIV) 18 have been used. Cells were treated with: PTX (Sigma) 1µM 
for 10 min; Noc (Sigma) 1µM for 30 min; Colchicine (Sigma) 1µM for 24 hours; 
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Staurosporin (Sigma) 10µM for 45min/4h; Epothilone D (Santa Cruz 
Biotechnology) 1µM for 30 min; TSA (Sigma) 800 nM for 16 h. For cellular 
aggregation induction, cells were plated in glass bottom dishes and 1.2 µg of Tau 
fibrils were delivered to cells with µl of Lipofectamine 2000 transfection reagent 
diluted in 300 ml of Opti-MEM Reduced Serum Medium (Gibco). Cells were 
treated for 2h, then DMEM/F-12 was added back to cells. The day after Tau 
seeding, cells have been treated with 1 µM PD-901 or 6 µM D-JNKI-1 for 48h in 
the presence of fibrils, while 10 µM Staurosporine (STS) or 200 nM okadaic acid 
(OA) were administered 72h after Tau seeding for 45 min. AD brain lysates have 
been provided by Abcam (ab29969, ab29971) and cells have been treated with 
10µg for 48h. AβOs have been collected from 7PA2 cells conditioned medium as 
described by 46, and 500µl of AβOs have been added to 1 ml of complete 
medium for 96h. Microtubules labeling in live cells has been obtained by SiR-
tubulin Kit (excitation wavelength l = 633 nm) (SPIROCHROME) in FRET 
experiments to avoid interference in FRET signal. 
2.3 Transgenic zebrafish 
Danio rerio was raised and bred at a temperature of 28 °C with a photoperiod of 
14h light/10h dark. Animal care was performed in strict accordance with protocols 
approved by the Italian Ministry of Public Health and the University of Pisa Ethical 
Committee, in compliance with EU legislation (Directive 2010/63/EU). Zebrafish 
embryos were obtained by natural spawning, staged according to the hours post 
fertilization and raised at 28 °C in 1× E3 medium (NaCl 5.0 mM, KCl 0.17 mM, 
CaCl2 0.33 mM, MgSO4 0.33mM, 0.1% methylene blue) in Petri dishes. For the 
generation of the CST transgenesis vector, CST sequence has been cloned 
under the HuC promoter in the Tol2-elavl3-GCaMP6s plasmid (Tol2-elavl3-
GCaMP6s was a gift from Misha Ahrens Addgene plasmid # 59531; RRID: 
Addgene_59531) at AgeI site which removes the GCaMP6 sequence. Eggs were 
harvested and injected at zygote stage. For microinjection borosilicate 
microcapillaries were used. Capillaries were pulled with a micropipette puller 
(P97, Sutter Instrument). For transient CST mRNA injection, capped CST mRNA 
was prepared by employing the mMESSAGE mMACHINE SP6 transcription kit 
(Invitrogen). The needles were filled with 2 μl of water solution containing 
100ng/µl of CST mRNA, 0.4 M KCl and 1% phenol red. For the generation of 
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transgenic zebrafishes, the needles were filled with 2 μl of water solution 
containing 20–30 ng/μl of plasmid DNA, 20–30 ng/μl of Tol2 transposase mRNA, 
0.4 M KCl, and 1% phenol red as visual control of successful injections. Embryos 
were injected with approximately 2 nl of mix solution and the drop volume was 
estimated under a microscope using a calibrated slide. Injections were performed 
under the Nikon C-PS stereoscope. F0 fishes were screened under fluorescence 
microscope at 24 hpf for zebrafish larvae. Six different founders were selected for 
line establishment. 
2.4 Silencing mediated by lentiviral shRNAs 
MISSION® TRC shRNA bacterial glycerol stocks containing Tau shRNAs (MAPT 
MISSION shRNA SHCLNG-NM_010838) were purchased from SIGMA. A 
lentiviral vector containing scramble shRNA was used as control. For the 
generation of viral vector stocks, HEK 293T cells were transfected with 10μg of 
the packaging plasmid pCMVΔR8.91, 5μg of VSV-G and 20μg of the gene 
transfer plasmid. The cell culture supernatant was collected twice, at 48h and 72h 
after transfection and filtered through a 0.45μM pore size filter. Viral vectors were 
titered by quantification of p24 antigen in cell culture supernatants with an 
enzyme-linked immunoabsorbent assay (Innogenetics, Gent, Belgium). 
Differentiated SHSY5Y cells were transduced with lentiviral particles 
supplemented by 10µg/ml polybrene (Millipore) for six hours. Cells were collected 
and analysed 72 hours after transduction. 
2.5 Tau Purification and Aggregation 
BL21 bacterial cells were transformed with pET11a-P301S-hTau plasmid. Cells 
were lysed according to direct boiling method described in (KrishnaKumar and 
Gupta, 2017) in 50mM MES pH 6.25 buffer. The lysate was purified using a 
cation-exchange chromatography. Column was equilibrated with MEF buffer 
supplemented with 0.5mM DTT. Tau was eluted with MES buffer with 1M NaCl. 
Heparin-assembled P301S Tau fibrils were prepared as described in (McEwan et 




2.6 Cell Survival 
For cells survival analysis, SHSY5Y cells were plated on in 24-well plates. Cells 
were treated with 0.5, 1 and 2 mM PD-901 or 3, 6 and 12mM D-JNKI-1 for 48 h, 
while 5, 10 and 20mM Staurosporine (STS) or 100, 200 and 400nM okadaic acid 
(OA) were administered 45 min. Then cells were harvested using trypsin and 
alive cells count was performed using the Scepter Cell Counter (Millipore). 
2.7 Coimmunoprecipitation 
Total cell extracts were prepared in ice-cold RIPA buffer (150 mM NaCl RIPA) 
supplemented with protease and phosphatase inhibitors (Roche). The lysate was 
quantified using Bradford assay (Thermo Fisher Scientific) and 2mg of protein 
were incubated with 2µg of primary antibody overnight at 4°C. 20µl of agarose 
resin conjugated protein G (Santa Cruz) or magnetic beads conjugated protein G 
(BioRad) were incubated for 2h at 4°C. Samples were washed in ice-cold RIPA. 
Finally, samples were analysed by Western blot. 
2.8 Western Blot 
Total protein extracts were prepared in lysis buffer supplemented with protease 
and phosphatase inhibitors. To guarantee the maximum reproducibility and the 
minimal contamination in the fractionation experiments, the Subcellular Protein 
Fractionation Kit for Cultured Cells (Thermo-Fisher) was used according to 
manufacturer’s instructions. Briefly, the protocol enables segregation and 
enrichment of proteins from five different cellular compartments. The first kit 
reagent, when added to the cell pellet, causes selective membrane 
permeabilization, releasing the soluble cytoplasmic contents named Cytoplasmic 
Fraction (CF). The second reagent dissolves plasma, mitochondria and ER-Golgi 
membranes. After recovering intact nuclei by centrifugation, a third reagent yields 
the soluble nuclear extract named SNF. An additional nuclear extraction with 
micrococcal nuclease is performed to release chromatin-bound nuclear fraction 
named CBF. The last reagent extracts the cytoskeletal proteins. For preparation 
of Triton-X insoluble fraction, cells were lysed in Triton-X lysis buffer (1% Triton-X 
100 in PBS with protease and phosphatase inhibitors) and the extract was 
centrifuged at 16000g for 15min. The supernatant was designated as Triton X-
100 soluble fraction. The pellet was dissolved in Triton-X lysis buffer 
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supplemented with 1% SDS, sonicated and boiled. This fraction was designated 
to be Triton X-100 insoluble fraction. Proteins were quantified by BCA (Thermo-
Fisher). For each sample 10-20-30µg were loaded. Proteins were separated by 
SDS-PAGE and electro-blotted onto Hybond-C-Extra (Amersham Biosciences) 
nitrocellulose membranes. Membranes were blocked with 5% skimmed milk 
powder in TBS, 0.1% Tween 20. Primary antibodies for WB: mouse anti-Tau 
(Tau5) 1:1000 ab80579 (AbCam); rabbit anti-actin 1:10000 (A300-485A BETHYL 
LABORATORIES); goat anti-Hsp70 1:1000 (sc-1060 Santa Cruz); rabbit anti-
histone H2b 1:2000 (Santa Cruz); mouse anti Tau-C3 1:500 (Abcam), mouse anti 
Tau13 1:1000 (Santa Cruz), rabbit anti GFP 1:1000 (Abcam); mouse anti-
GAPDH 1:15000 (Fitzgerald); rabbit anti-VGluT1 ab77822 1:500 (AbCam); rabbit 
anti-HDAC1 1:500 (Santa Cruz); rabbit anti-TRIM28 1:1000 (Abcam); rabbit anti-
pTau (Ser202, Thr205) 1:500 (Thermo Fisher Scientific); rabbit anti-pTau 
(Ser356) 1:500 (Thermo Fisher Scientific); anti anti-pTau (Thr231) 1:500 (Thermo 
Fisher Scientific). Secondary antibodies for Western blot analysis were HRP-
conjugated anti-mouse, anti-rabbit, or anti-goat purchased from Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA. Western blot quantification has been 
performed using ImageJ software. 
2.9 Immunofluorescence and immunohistochemistry 
Cells were seeded on chamber slides (LabTek) and after transfection and/or drug 
treatment were fixed with cold methanol for 4 min. Soon after fixation cells were 
permeabilized with 0.1% Triton X-100 and blocked for 30 min with the blocking 
solution (PBS+Tween 0,1% + BSA 1% fresh). Primary antibody incubation has 
been done in blocking solution for 1h or O/N. Zebrafish embryos were manually 
dechorionated, fixed in 4% paraformaldehyde at the desired developmental 
stages and stored in methanol at −20°C. Permeabilization has been performed in 
ice cold acetone / PBS and then in PBS+ triton 1%. Embryos were blocked for 1h 
in blocking solution (PBS 1% Triton + 10% FCS) at room temperature followed by 
incubation with peroxidase blocking solution (0.1% H2O2 diluted in blocking 
buffer) O/N at 4°C. Primary antibody incubation has been done in blocking 
solution O/N. After secondary antibody incubation, DAB substrate was added 3h 
at room temperature followed by DAB+H2O2. Primary antibody used are: mouse 
anti α-tubulin 1:1000 (Sigma-Aldrich); mouse anti-tau (Tau-13) 1:500 (Santa 
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Cruz); rabbit anti-VGluT1 ab77822 1:250 (AbCam); DAPI 1:15000 (Sigma); rabbit 
anti-pAT8 1:100 (Abcam); rabbit anti-VGluT1 ab77822 1:250 (AbCam); rabbit 
anti-HDAC1 1:200 (Santa Cruz); rabbit anti-TRIM28 1:200 (Abcam); rabbit anti-
pTau (Ser202, Thr205) 1:50 (Thermo Fisher Scientific); anti anti-pTau (Thr231) 
1:50 (Thermo Fisher Scientific). Excess antibody was eliminated by several 
washes with PBS 1X and secondary antibody incubation was performed in 
blocking solution for 1h. Secondary antibodies for IF: Alexa Fluor 633; Alexa 
Fluor 488 (Life Technologies). Chamber slides were mounted by using 
Vectashield mounting media (Vector Laboratories). For Tau aggregates staining, 
samples were incubated with 1 mM K114 (Sigma-Aldrich) for 10 min. 
2.10 Real-time PCR 
Total RNA was extracted by Nucleospin (Macherey-Nagel) and retro-transcribed 
by Reverse Transcriptase Core kit (Eurogentec) according to manufacturer’s 
instructions. Real-time PCR was performed using the iTaqTM Universal SYBR® 
Green Supermix (BioRad), and performed for 40 cycles of amplification with 
denaturation at 95°C for 15s, annealing at 60°C for 25s, extension at 72°C for 
20s. The primers employed were: Actin: fwd 5'-
TCCATCCTGGCCTCACTGTCCAC-3', rev 5'-
GAGGGGCCGGACTCATCGTACT-3'; Tau: fwd 5’-
GTGACCTCCAAGTGTGGCTCATT-3’, rev 5’-CTTCGACTGGACTCTGTCCTTG-
3’; VGluT1: fwd 5’-GAGGAGTGGCAGTACGTGTTCC-3’, rev 5’- 
TCTCCAGAAGCAAAGACCCC-3’. 
2.11 RNA sequencing 
Sequencing procedure was performed in Ctrl and Tau-overexpressing 
differentiated SHSY5Y cells using Illumina methodology (Bentley et al., 2008). 
Around 2.5 µg of total RNA was used for library preparation (Illumina, TruSeq™ 
RNA Sample Prep Kit v2) using the manufacturer’s description. Libraries were 
sequenced using a HiSeq2000 (Illumina) running in 50bp single-read mode using 
sequencing chemistry v2. This resulted in around 29-54 million reads per sample 
with 50bp length. Reads were extracted in FASTQ format using CASAVA v.1.8 
(Illumina). FASTQ formatted reads were used for following analysis. Read 
mapping was performed using Bowtie (Langmead et al., 2009). On average, 50% 
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of all reads could be mapped uniquely and were used for counting afterwards. All 
transcripts were used for further analysis. The read counts were normalized with 
respect to the size of the individual transcript contigs and to the total amount of 
mappable reads obtained for the particular sample, resulting in reads per 
kilobase and million mapped reads (RPKM) values (Mortazavi et al., 2008) for 
each transcript contig. 
2.12 Transcriptome analysis 
Differentially expressed genes (DEGs) were identified by applying the statistical 
tests of the edgeR, DESeq and baySeq packages (Anders and Huber, 2010; 
Hardcastle and Kelly, 2010; Robinson et al., 2010), while DEGs were selected 
according a FDR < 0.05 by all three tests. The RPKM counts were clustered in 
order to identify common expression profiles. DEGs were used for Gene 
Ontology analysis with ClueGO plug-in (Bindea et al., 2009). The attribute used 
to import the network in the tool was “name” and the comparison was made with 
Homo sapiens identifiers. As statistical test “Enrichment (Right-sided 
hypergeometric test)” was used, with correction for multiple testing and a p-value 
threshold of 0.05. Moreover, the options “Use GO Term Fusion” and “Use GO 
Term Grouping” were selected. DEGs clustering was performed by considering 
three different databases: KEGG, GO and Interactome. In order to characterize 
the cellular system, a transcriptome meta-analysis was performed employing a 
public transcriptomics dataset sourced from the Gene Expression Omnibus 
(GEO) platform hosted on NCBI (https://www.ncbi.nlm.nih.gov/geo/). The gene 
dataset considered is GSE84422 which includes 1053 post-mortem brain 
samples across 19 brain regions from a total of 125 patients dying at different AD 
stages, with 50-60 subjects per brain region. Patients are clustered by AD 
severity into 4 groups according to clinical dementia rating (CDR), Braak NFT 
score, sum of NFT density across different brain regions, average neuritic plaque 
density and average CERAD. Gene expression profiling has been done on the 
Affymetrix Human Genome U133A Array (GPL96), Affymetrix Human Genome 
U133B Array (GPL97), Affymetrix Human Genome U133 Plus2.0 Array (GPL570) 
(Wang et al., 2016). In order to import datasets and create subsets by diagnosis 
and brain region R packages “GEOquery”, “Rcpp” and “tidyselect” were used. To 
compare different platforms, platform-specific IDs were converted into Entrex 
47 
 
Gene IDs using the corresponding R annotation databases from Bioconductor, 
available via bioMart (version 3.8). Multiple platform IDs matching the same gene 
were summarized in a single entry with gene expression as the mean of probe 
expression. Probes mapping on the same gene with discordant logarithmic fold 
change (logFC) were excluded from the analysis. The patients included in the 
GSE84422 dataset were classified by Alzheimer disease stage into early mild 
cognitive impairment (E-MCI), late MCI (L-MCI) and Alzheimer’s disease (AD) 
and each subset was compared to our SHSY5Y data. For an overview of the 
global transcriptome profile, we considered all the genes with at least a small 
mean fold change (log2 fold change > 0.1) and p-value < 0.05 in our dataset. We 
compared the differentially expressed genes in our dataset (FDR < 0.1) to all the 
genes in the hippocampal dataset. Finally, we assessed the correlation of the 
most significant genes in both datasets. In-built R “plot” function was used to 
draw scatterplots comparing gene expression in the different conditions. 
Enrichment of GO terms in SHSY5Y transcriptome compared to hippocampal L-
MCI dataset was assessed by overrepresentation analysis (ORA) as described 
above. The direction and magnitude of the fold change of genes in the most 
differentially represented pathways was compared to that of patients with L-MCI 
in dataset GSE84422. 
2.13 Image Acquisition and Analysis 
For FRET experiments images were acquired with the TCS SP2 laser-scanning 
confocal microscope (Leica Microsystems, Milan, Italy) equipped with 
galvanometric stage using a 63/1.4 NA HCX PL APO oil immersion objective. A 
heated and humidified chamber mounted on the stage of the microscope was 
used for live imaging experiments in order to maintain a controlled temperature 
(37°C) and CO2 (5%) during image acquisition. An Argon laser was used for 
ECFP (l = 458 nm) and EYFP (l = 514 nm), a Gre-Ne laser for RFP (l = 543 nm) 
and a He-Ne laser for l = 633 nm. For the quantification of morphological 
parameters such as the total filament length and the number of crossover points 
the filament tracer option of the IMARIS Bitplane software has been exploited. In 
detail, these two parameters are deduced by a software plugin that, based on 
connectivity and fluorescence intensity, automatically detects and segments 
filamentous structures revealing information about the topology of filaments as 
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the sum of the lengths of all lines and the number of crossover points within the 
filament. For IF experiments a Leica TCS SP8 confocal laser-scanning 
microscope (Leica Microsystems, Mannheim, Germany) equipped with Leica 
Application Suite (LAS) X software was used. All frames were captured by means 
of HC PL APO CS2 40X/1.30 (*) oil objective, a format size of 2048 x 2048 pixel 
and a sequential scan procedure. All confocal frames were taken by a suitable 
scanning power and speed along with gain level to achieve the greater signal 
definition and avoid any background noise. (*) N.A.=1.30. For colocalization 
experiments, K114 was excited at 380 nm and its fluorescence emission was 
collected between 530 and 600 nm. ECFP was excited at 458 nm and its 
fluorescence emission was collected between 470 nm and 500 nm. The two 
channels were excited sequentially in order to minimize the bleed-through. 
Images underwent background subtraction and were analysed using Costes 
approximation method (Costes et al., 2004) in the ImageJ plugin “Coloc2”. 
Threshold regression was set to Costes and Costes’ significance test was 
performed. Point spread function was set to 2.0. Costes randomisations were set 
to 100. 
2.14 FRET and FRAP Experiments 
For sensitized emission FRET experiments, each image was recorded in a 
spectral mode, by selecting specific regions of the emission spectrum. The donor 
ECFP was excited at 458 nm and its fluorescence emission was collected 
between 470 nm and 500 nm (donor channel) and between 530 nm and 600 nm 
(FRET channel). The acceptor EYFP was excited at 514 nm and its fluorescence 
emission was collected between 530 nm and 600 nm (acceptor channel). The 
donor and acceptor fluorophores were excited sequentially. The ImageJ software 
was used for images analysis and FRET quantification. Briefly, FRET images 
were corrected from cross-talk between donor and acceptor channel using 
Youvan’s method: Findex = IFRET – A x ID – B x IA, where IFRET, ID and IA are the 
images of the sample in the FRET, donor and acceptor channel, respectively, 
after background subtraction and A and B are the fraction of the donor and 
acceptor leak-through into the FRET channel, respectively. I determined the A 
parameter in cells expressing only the donor (pECFP plasmid) by acquiring 
images in donor and FRET channels. A plot of the intensity of each pixel of the 
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FRET channel image as a function of the intensity of the same pixel in the donor 
channel image (regression graph) was automatically generated by the ImageJ 
plugin (FRET and colocalization Analyzer) and then fitted with a linear equation 
from which A parameter was derived. Images displaying saturated pixel has been 
discarded. For the evaluation of the B parameter cells transiently expressing only 
the acceptor (pEYFP plasmid) have been acquired in FRET and acceptor 
channel and then subjected to same process of A in the ImageJ plugin. Typical 
values in our experimental conditions are A = 0.1 and B = 0.25, respectively. 
Normalized FRET (NFRET) was performed with the ImageJ software plugin 
‘‘pixFRET’’ (Feige et al., 2005) by using: NFRET = Findex/√(ID x IA) (Xia and Liu, 
2001). Mathematically, NFRET values should range between 0–1; the plugin 
automatically multiplies these values 100; NFRET intensities images were 
represented in false-colour obtained by using the ‘‘fire’’ lookup table option in 
ImageJ software. Due to the mathematical subtractions in Findex calculation, 
NFRET negative values in some pixels are considered as zero. In FRET 
experiments investigating intramolecular and intermolecular FRET, to obtain a 
comparable amount of Tau I transfected cells with 300 ng of CST or 150 ng 
ECFP-Tau + 150 ng EYFP-Tau (ML/2); to obtain a comparable amount of 
fluorophores I transfected cells with 300 ng ECFP-Tau+ 300 ng EYFP-Tau (ML). 
Since in a transient transfection the expression of the transgene varies from cell 
to cell, to perform a reliable NFRET quantification in ML samples I selected cells 
that express comparable amount of fluorescence intensity in the donor and 
acceptor channel with respect of CST; to perform the NFRET quantification in 
ML/2 samples I selected cells that express about half the amount of fluorescence 
intensity in the donor and acceptor channel with respect of CST. I measured the 
level of expression by fluorescence intensity in individual cells, under the 
microscope. FRAP experiments were performed by using the FRAP module 
coupled to the confocal microscope and consists of three different phases: (1) a 
pre-bleach phase, in which 10 frames of 512x512 pixel images at 1000 Hz have 
been recorded in order to define the initial level of fluorescence intensity; (2) a 
photobleaching phase, in which a selected circular ROI with a radius of 2 mm in 
the cytoplasm of the cell was excited at higher laser power (50% for EYFP) for 
five frames at 1000 Hz; (3) a post-bleaching phase, in which 120 images have 
been recorded in order to follow the recovery of the fluorescence intensity in the 
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selected ROI. Fluorescence recovery was extracted from images of the bleached 
ROI and subjected to the following manipulation steps: (1) background 
subtraction; (2) first normalization to the initial pre-bleach value of fluorescence 
intensity; (3) correction for the fluorescence loss: in particular, I evaluated the 
fluorescence of the whole cell for each time point, before and after the 
photobleaching phase; then I multiplied every element of the data of the bleached 
ROI by (Fpre-wholecell/Fpost-wholecell), where Fpre-wholecell means prebleach intensity 
within the whole cell, Fpost-wholecell stands for postbleach intensity at any given time 
point. In any case, I set up the experimental parameters of acquisition in order to 
avoid strong photobleaching (5%–10%); (4) additional normalization to set the 
first post-bleach point to zero. At least 30 separate FRAP experiments for each 
sample has been performed. FRAP recovery curves have been fitted by a two 
phase exponential association function.  
2.15 Patch-clamp recordings and electrophysiological data analysis  
Recordings were performed on primary neuronal cultures, by adapting the 
procedure described in Piacentini et al. (Piacentini et al., 2017). Cells were 
continuously bathed using Tyrode’s solution containing: NaCl 150 mM, KCl 4 
mM, MgCl2 1 mM, CaCl2 4 mM, Glucose 10 mM, HEPES 10 mM, pH 7.4 with 
NaOH. Borosilicate glass pipettes were pulled with a P-97 puller (Sutter, CA) to a 
resistance of 5-6 MΩ when filled with an internal solution containing: K-Gluconate 
145 mM, MgCl2 2 mM, HEPES 10 mM, EGTA 0.1 mM, Mg-ATP 2.5 mM, Na-GTP 
0.25 mM, phosphocreatine 5 mM, pH 7.35 with KOH. Miniature Excitatory 
Postsynaptic Currents (mEPSCs) were recorded while holding the neuron at a 
command potential of -70 mV. Data were acquired using a MultiClamp 700A 
amplifier, connected to a Digidata 1322A digitizer (Molecular Devices, CA). Data 
were analyzed using Clampfit 10.7 (Molecular Devices) as described in Mainardi 
et al. (Mainardi et al., 2017). An event template was constructed and used to 
detect mEPSCs; stringency of detection was ensured by setting the “template 
match threshold” to 4. After event detection, the cumulative distributions for 




2.16 Statistical analysis  
For Western Blot and quantitative real-time PCR, statistical significance was 
assessed by non-parametric Kruskal-Wallis test followed by pairwise Mann-
Whitney test. For imaging experiments statistical significance was assessed by 
Student’s t-test or one-way ANOVA followed by Tukey multiple comparisons test. 
For qPCR, gene expression was calculated with Pfaffl method (Pfaffl, 2001). 
Each sample was run in triplicate and at least three biological replicates were 
performed for each experiment. All results are shown as mean ± SEM from at 
least three independent experiments. Significance is indicated as * for p<0.05, ** 
for p<0.01, *** for p<0.001 and **** for p<0.0001. For patch-clamp recordings, 






3.1 Tau conformations in live cells by the CST biosensor 
 
Figure 3.1. Conformational Sensitive Tau sensor (CST) construct colocalizes with tubulin 
in cells. A. Schematic representation of chimeric constructs. B. Imaging of HeLa and HT22 cells 
co-transfected with CST and Tubulin-RFP plasmids; donor channel (blue), acceptor channel 
(yellow), Tubulin (red). White scale bar = 10 µm. 
As described above, Tau is an intrinsically disordered protein whose structure in 
normal conditions is still unclear since it is not possible to analyse it by current 
molecular approaches. If Tau structure is difficult to elucidate, the conformation of 
the protein is a simpler target of investigation. In vitro studies suggested that Tau 
assumes a conformation in which its ends are close to each other (Jeganathan et 
al., 2006; Sabbagh and Dickey, 2016). However, these experiments have been 
performed in conditions which does not take into account the complexity of a 
cellular system. In order to investigate the conformation that Tau assumes in 
physiological and pathological conditions, we generated a conformational 
biosensor called Conformational Sensitive Tau (CST). The CST is a chimeric 
protein made of a Tau-D isoform (0N4R) fused at the N-terminal end with a ECFP 
and at the C-term with a EYFP (Figure 3.1A). The presence of these fluorophores 
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assumes in different conditions. Due to the peculiar architecture of the chimeric 
protein, it is expected that, depending on the conformation of Tau, a FRET signal 
could be generated by the decreased distance between the N- and C-termini of 
Tau molecules, thus realizing a context-dependent Conformational-Sensitive Tau 
sensor. First, we demonstrated that the CST expressed in HeLa cells, that do not 
express endogenous Tau, and in immortalized hippocampal HT22 cells 
colocalizes with tubulin-RFP, indicating that the CST maintains Tau physiological 




Figure 3.2. The CST displays a positive intramolecular FRET signal on MTs. A. NFRET 
analysis of positive and negative controls in HeLa cells. B. NFRET signal localization along MTs. 
Donor (blue), acceptor (yellow), NFRET (false color) and tubulin labeled with Sir-tubulin 
(magenta). C. FRET measurements in Hela cells expressing CST, ECFP-Tau and Tau-EYFP at 
comparable Tau levels to CST (ML/2) or ECFP-Tau and Tau-EYFP at comparable fluorophore 
levels to CST (ML). Donor (grey), acceptor (grey) and Normalized FRET (NFRET) images (false 
color). White scale bar = 10 mm. D. Magnification of the outlined box in C and Fluorescence 
intensity profile (F.I.) along the white line (black graph) and NFRET intensity profile along the 
white line (red graph). E. Box plot of NFRET values calculated on MTs network in CST (40 cells), 
ML/2 (50 cells) and ML (60 cells). Box spans the standard error of the mean (black square) while 
whiskers indicates the standard deviation (**p < 0.01 ANOVA one-way test). 
To exploit the CST as a conformational probe, the quantitative sensitized 
emission FRET microscopy for the detection of protein conformational changes 
has been used. FRET parameters have been optimized in cells expressing the 
donor and the acceptor fused into a chimeric construct (ECFP-EYFP) (See 
Materials and Methods), as a FRET positive control, and in cells expressing 
both the donor and the acceptor from separate plasmids (pECFP and pEYFP), as 
a FRET negative control (Figure 3.2A). Imaging analysis in HeLa expressing the 
CST showed a positive FRET signal which colocalized with tubulin, suggesting 
that N- and C-terminal ends of Tau protein are close each other on MTs (Figure 
3.2B). In order to determine if this FRET signal is due to an intermolecular or 
intramolecular interaction between Tau terminal ends, cells co-expressing 
monolabeled Tau constructs (ECFP-Tau and Tau-EYFP) have been compared 
with cells expressing the CST. Since each CST molecule contains two 
fluorophores, we considered either cells expressing the same levels of 
monolabeled Tau, with respect to CST cells (half amounts of fluorophores, ML/2) 
or cells expressing double levels of monolabeled Tau, with respect to CST cells 
(hence same amount of fluorophores, ML) (Figure 3.2C). Along selected lines at 
the intersection with MTs, the CST displayed NFRET values in the range of 15–
30 (Figure 3.2D). In cells expressing monolabelled Tau, in both conditions the 
NFRET signal was significant lower than cells expressing the CST (Figure 3.2E). 
This result demonstrated that the FRET signal was mainly due to an 
intramolecular interaction between the N- and C-termini in the same protein, 





Figure 3.3. Loss of NFRET signal in cells treated with MT interfering drugs. A. Western blot 
of the cytoplasmic fraction in reporter cells untreated (UT) or treated with Nocodazole (Noc) or 
Paclitaxel (PTX). B. FRAP relative recovery curves of CST in untreated cells (black square), 
treated with Nocodazole (empty circle) or Paclitaxel (empty triangle). C. Donor (blue), acceptor 
(yellow) and NFRET images (false color) in CST reporter cells untreated (UT, upper panels) or 
treated with Nocodazole (Noc, lower panels). White scale bar = 10 µm. D. Box plot of NFRET 
values in untreated cells (40 cells) along MTs and in Nocodazole treated cells (20 cells) in random 
points in the cytoplasm. Box spans the standard error of the mean (black square) while whiskers 
indicates the standard deviation (**p < 0.01 ANOVA one-way test). E. Real-time FRET analysis of 
Nocodazole treated reporting cells. NFRET is displayed in false color. F. NFRET quantification of 
E at different time points. G. Donor (blue), acceptor (yellow) and NFRET images (false color) in 
CST reporter cells untreated (UT, upper panels) or treated with Paclitaxel (PTX, lower panels). 
White scale bar = 10 µm. H. NFRET quantification of G along MTs in untreated cells or in random 
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points in PTX treated cells. Box spans the standard error of the mean (black square) while 
whiskers indicates the standard deviation (**p < 0.01 ANOVA one-way test).  
To analyse the conformation of Tau monomers soluble in the cytoplasm and not 
bound to MTs, CST reporter cells were treated with Nocodazole (Noc), a MTs 
disrupting drug. Treated cells were first analysed by subcellular fractionation, to 
isolate the cytoplasmic fraction (CF) of CST reporter cells. The CF contains the 
pool of proteins soluble in the cytosol and it allows to quantify the unbound Tau 
fraction in response to treatments. As shown in figure 3.3A, the treatment with 
Noc induced an increase in the soluble pool of the CST after MTs destabilization, 
in fact the signal of Tau in the CF was higher than untreated cells. This evidence 
has been confirmed by FRAP experiments. FRAP technique distinguishes the 
freely diffusing pool of proteins, compared to the pool bound to other structures 
(Azoury et al., 2008; Himmel et al., 2009). The rate of fluorescence recovery 
indicates how fast fluorescent molecules fill the bleached area and the protein 
mobility is determined by both diffusion and binding interactions (Breuzard et al., 
2013). The recovery curve showed a significant increase of the CST mobile 
fraction in nocodazole-treated cells (CST: 76±3%; Noc: 91±4%), indicating a 
higher amount of unbound CST in the cytosol (Figure 3.3B). In these treated cells 
the NFRET signal was strongly reduced (CST: 14.43±0.73SE; Noc: 
4.87±0.64SE), supporting the fact that soluble Tau assumes a different 
conformation with respect to molecules bound to MTs (Figure 3.3C-D). In 
particular, the low NFRET indicates a relaxed conformation in which the terminal 
ends are distant. A time course analysis of the FRET signal in cells treated with 
nocodazole showed that the loss of NFRET parallels the MTs disruption, and just 
10 min after addition of nocodazole the NFRET drops by almost 50% (Figure 
3.3E-F). This result demonstrated that CST can be used to monitor the state of 
association of Tau to cellular MTs. 
To determine whether the loss of FRET signal is a consequence of MTs 
disruption or only of the detachment of Tau from MTs into a soluble pool, CST 
reporter cells were treated with the MTs stabilizing drug Paclitaxel (PTX), which 
induces the stabilization of MTs and competes with Tau for its binding to MTs 
(Hernández et al., 2013; Kar et al., 2003; Makrides et al., 2004). As shown by 
Western blot and FRAP experiments, PTX treatment induced an increased signal 
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in the CF compared to untreated cells and a shift of the recovery curve 
(CST:76±3%; PTX: 93±3%), meaning that the competitive effect of PTX with Tau 
caused the CST delocalization from the MTs to the cytosol (Figure 3.3A-B). 
FRET analysis showed a loss of NFRET signal in soluble Tau similar to the one 
observed with nocodazole treatment (PTX: 5.14±0.61SE), supporting the fact that 
Tau assumes a relaxed conformation in the cytoplasm in a way independent from 
the integrity of the MT network. In conclusion, these results demonstrated that, in 
the cell, Tau molecule bound to MTs assumes a structured hairpin folding 




3.2 Pathological point mutations alter Tau mobility and conformation 
 
Figure 3.4. Point mutations alter Tau conformation and mobility. A. FRAP relative recovery 






 and related mobility analysis. B. Phospho-AT8 
epitope detection by western blot of cells expressing CST or CST
AT8mut
. C. Example of network 
analysis by confocal imaging of reporter cells (Acceptor channel, yellow) expressing CST and 
CST-P301L. White boxes are image magnifications. D. Morphological analysis of fluorescent 
network density in reporter cells expressing CST (n = 10), CST
P301L
 (n = 10) and CST
AT8mut
 
(N=10). Data shown are mean and SEM. E. NFRET images (false colour), donor (Blue), acceptor 
(yellow) of reporter cells. White scale bar = 10 µm. F. NFRET quantification along MTs of cells 
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expressing CST (n = 40), CST
P301L
 (n = 35), CST
DK280
 (n = 20) and CST
AT8mut
 (n = 20). Box spans 
the standard error of the mean (black square) while whiskers indicates the standard deviation (**p 
< 0.01 ANOVA one-way test). 
In order to characterize the effect of mutations related to tauopathies on Tau 
conformation, we mutated the CST with the destabilizing P301L or ΔK280 point 
mutations (Dayanandan et al., 1999; Hasegawa et al., 1998a; Hutton, 2006; 
Momeni et al., 2009; Spillantini et al., 1998b). Moreover, we investigated the 
effect of the mutation at the AT8 epitope (AT8mut) by substituting the 
unphosphorylatable aminoacid Ala to Ser199, Ser202 and Thr205 commonly 
phosphorylated in pathological conditions (Bertrand et al., 2010; Bibow et al., 
2011; Braak et al., 1994). Reporter cells expressing the different Tau mutants 
were analysed by FRAP experiments, to analyse the effect on Tau motility. 
Recovery curves revealed that CSTP301L and CSTΔK280 displayed an overall 
higher mobile fraction with respect to CSTWT indicating that the destabilizing 
mutations increase Tau mobility. Remarkably, the rapid diffusion phase doubled, 
highlighting that these mutations have an impact on the balance between 
diffusive and binding phases. The time constants of both diffusing and bound 
phases were not altered, indicating that the CST integrity was maintained (Figure 
3.4A). As seen by Western blot experiments, the CST was partially 
phosphorylated at the AT8 epitope (Figure 3.4B). Phospho-AT8 is associated to a 
reduced affinity of Tau with tubulin, MTs destabilization and Tau aggregation 
(Bertrand et al., 2010; Bibow et al., 2011; Braak et al., 1994). In order to impede 
the destabilization induced by this modification, we mutated the AT8 epitope with 
alanine to prevent the phosphorylation and then we analysed the effect on the 
CST (Figure 3.4B). FRAP measurements on this mutant revealed that the 
CSTAT8mut FRAP recovery curve was slower than that of CSTWT (CSTWT: 76±3; 
CSTAT8mut: 54±1), thus indicating a lower mobile fraction (Figure 3.4A). This result 
suggested that the prevention of AT8 phosphorylation increases the stability of 
Tau on MTs. Furthermore, to investigate the impact of different mutations on MTs 
organization, a network analysis was performed by exploiting the IMARIS 
software. The total filament length and the number of branching points of the MT 
network were considered. Reporter cells expressing the destabilizing mutation 
CSTP301L showed a significant reduction of both parameters compared to CSTWT, 
resulting in a reduced MT network complexity. On the contrary, CSTAT8mut, which 
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increases the stability of Tau on MTs, resulted in a network with a higher 
complexity then cells expressing CSTWT, as indicated by the significant increase 
in filament length and branching points (Figure 3.4C-D). These results confirmed 
that Tau mutations can alter the affinity of Tau to MTs thus influencing the MT 
network complexity. In order to investigate whether the different affinities for MTs 
could correspond to different Tau conformations we performed a FRET analysis. 
We observed a significant reduction of NFRET signal on MTs for CSTP301L and 
CSTΔK280 compared to CSTWT (CSTP301L: 8.21±0.41SE; CSTΔK280: 7.44±0.29SE) 
indicating that the destabilizing mutations P301L and ΔK280 not only affect Tau 
binding with tubulin but also alter Tau conformation on MTs (Figure 3.4E-F). This 
result indicates that Tau pathological mutants, even when associated to MTs, 
have a conformation that disadvantages FRET events. On the contrary, the 
stabilizing mutation AT8mut led to a significant increase of the NFRET signal 
(CSTAT8mut: 28.84±1.54SE) indicating that the terminal ends of CSTAT8mut bound 
to MTs are closer than CSTWT (Figure 3.4E-F). Overall these results demonstrate 
that the pathological mutations P301L and ΔK280 consistently alter both the 
protein conformation and the interaction of Tau with MTs, conferring it an 
increased mobility. On the other hand, the mutant CSTAT8mut assumes a 
conformation where N- and C-termini interaction is favoured and which is also 
associated to a slower mobility and a higher stability of Tau on MTs. 
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3.3 The pathological mutation Q336H increases the stability of Tau on MTs 
 
Figure 3.5. The pathological mutation Q336H promotes a closer loop conformation of Tau 
and a more complex network. A.  Imaging of HeLa cells expressing CST or CST
Q336H
 and signal 
localization along MTs. Donor (blue), acceptor (yellow), tubulin (red). B. NFRET images (false 
color), donor (Blue), acceptor (yellow) of reporter cells. C. NFRET quantification of cells 
expressing CST (n = 20) and CST
Q336H
 (n = 20). Box spans the standard error of the mean (black 
square) while whiskers indicates the standard deviation (***p < 0.001 t-student test). D. 
Morphological analysis of fluorescent network density in reporter cells expressing CST (n = 10) 
and CST
Q336H
 (N=10). Data shown are mean and SEM. 
The CST demonstrated to be a very sensitive and reliable tool in detecting the 
stability and conformation of Tau, thus it is possible to exploit it to clarify the effect 
of pathological mutations still not properly characterized. With this purpose, we 
selected a Tau mutation, discovered in a patient affected with Pick’s disease, 
whose effect on Tau behaviour has not been investigated, the missense Q336H 
mutation. In vitro experiments revealed that TauQ336H promotes tubulin 
polymerization more than TauWT, an uncommon behaviour for Tau pathological 
mutations previously described (Tacik et al., 2015). Colocalization experiments 
on HeLa cells expressing CSTQ336H showed that the mutated protein is localized 
on MTs (Figure 3.5A). FRET analysis indicated that the CSTQ336H displayed a 
significant higher NFRET compared to cells expressing CSTWT suggesting that 
this mutation induced a folding with a reduced distance between the terminal 
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ends of Tau (Figure 3.5B-C). To further evaluate the impact of this mutation on 
MT network, we performed a network analysis on total filament length and on the 
number of branching points, in cells expressing CSTWT or CSTQ336H. Remarkably, 
CSTQ336H-cells showed a significant increase in both filament length and 
branching points, indicating that this mutation is clearly associated to a higher 
complexity of the MT network (Figure 3.5D), an opposite result compared to the 
effect of the P301L or DK280 mutations previously described. In conclusion, the 
exploitation of CST for the characterization of the Q336H mutation revealed that 
this mutation related to Pick’s disease, leads to a closer conformation of Tau 
molecule and to a higher MT complexity suggesting a stabilizing effect that is 
quite uncommon for Tau pathological mutations. 
3.4 CST is sensitive to Tau aggregation 
 
Figure 3.6. CST is sensitive to pathological aggregation in cells treated with homotypic or 
heterotypic seeds. A. Imaging of CST expressing cells untreated (UT) or treated with AD human 
brains, Tau seeds or AβOs. CST reporter cells have been treated for 48h with Tau seeds 200nM, 
for 96h with 10µg of AD human brain lysate or with AβOs. Tubulin is represented in red B. 
Western blot of Sarkosyl soluble (SF) and insoluble fractions (IF) of reporter cells treated with Tau 
seeds or AβOs. C. Immunofluorescence of Tau expressing cells treated with Tau seeds (middle 
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panel) and AβOs (lower panel). Cells expressing unlabeled Tau are stained with anti Tau13 
antibody (green). D. Western blot of Sarkosyl soluble (SF) and insoluble fractions (IF) of cells 
expressing unlabeled Tau and treated with Tau seeds or AβOs. E. FRET images of untreated and 
treated reporter cells. 
Several studies demonstrated that misfolded Tau drives its aggregation and 
spreading in tauopathy disease progression. We exploited the CST sensor to 
detect seeding induced by agents potentially involved in Tau self-aggregation. To 
this aim, CST reporter cells were first exposed to synthetic Tau seeds added in 
culture medium. Synthetic seeds have been  prepared from 4R recombinant Tau 
fragment (297-391) (Kontsekova et al., 2014). As expected, after 48h treatment, 
CST was completely displaced from MTs and cytoplasmic inclusions appeared 
(Figure 3.6A). CST reporter cells were then exposed to protein extracts from AD 
human brains. Lysates from AD brain induced a significant relocalization of Tau 
forming intracellular Tau aggregates. Remarkably, the MT network was not 
grossly altered by Tau displacement as demonstrated by IF (Figure 3.6A). AD 
brain lysates contain many different components that might potentially act as 
seeds for Tau aggregation, including other misfolded proteins such as the Aβ 
peptide. In order to verify whether the seeding is specific for Tau, or whether 
other factors are also responsible for Tau aggregation, we treated CST reporter 
cells with preparations containing Aβ oligomers (AβOs). AβOs produced by the 
7PA2 fAD cell line (CHO cells overexpressing fAD human V717F APP mutant) 
and collected from the cellular supernatant have been used. The treatment of 
reporter cells with AβOs induced a significant relocalization of CST and the 
formation of fluorescent aggregates (Figure 3.6A). In order to confirm by a 
molecular approach that the observed CST-positive inclusions contain 
aggregated Tau proteins, the sarkosyl fractionation of the CST reporter cells 
treated with Tau seeds or with AβOs has been performed. Western blot analysis 
of the sarkosyl extracts with the anti-Tau DC25 antibody, showed a significant 
presence of full length CST into the sarkosyl-insoluble fraction in both treated 
samples, with a concomitant decrease of CST in the soluble fraction (Figure 
3.6B). Taken together, these results indicate that full length Tau undergoes 
aggregation in response to homotypic seeding, by Tau seeds, and also in 
response to heterotypic seeding, by cell supernatants containing AβOs. To 
further verify that the AβOs mediated aggregation is not due to the peculiar 
structure of CST, we repeated the experiments in cells expressing unlabeled Tau. 
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The immunofluorescence for Tau in AβOs- or Tau- treated cells confirmed that 
AβOs induces Tau relocalization and aggregation as effectively as Tau seeds 
(Figure 3.6C). The analysis of sarkosyl-insoluble and soluble fractions showed 
that full length Tau accumulates into insoluble fractions in both conditions, 
confirming the ability of AβOs to induce Tau aggregation (Figure 3.6D). This 
result further confirms that the fluorophores into the CST construct do not alter 
the conformational changes that Tau undergoes during neurodegeneration. In 
order to characterize the CST response when aggregation is induced, we 
performed FRET experiments in reporter cells treated with AD human brain 
extracts, Tau seeds or AβOs. We observed that all the treatments caused the 
formation of intracellular CST aggregates displaying positive FRET signals 
(Figure 3.6E). Moreover, since the CST interaction with tubulin was impaired, the 
FRET signal was lost on MTs. This evidences indicate that the CST is sensitive 
to pathological aggregation and provides an imaging output represented by the 
FRET-positive signal caused by the strong proximity between CST molecules. 
Taken together, these results indicate that Tau undergoes aggregation in cells, in 
response to synthetic Tau seeds as well as to complex lysates derived from 
brains of Alzheimer's disease patients. Heterotypic seeding by AβOs is also 
observed. Moreover, the CST is able to provide information about the molecular 
state of Tau discriminating between physiological, destabilizing and aggregation 
conditions. 
3.5 Development of a CST-based screening platform in vitro 
The CST has been demonstrated to be a multifunctional tool able to investigate 
Tau behaviour by several approaches. Due to its ability in discriminating different 
conditions of Tau molecular degeneration, we applied the sensor to develop a 
cell-based platform to test compounds able to alter Tau aggregation. With this 
purpose, we expressed the CST in two cell lines. First, we used HeLa cells, for 
the characterization and optimization of the system, then, we used differentiated 
SHSY5Y cells to test the compounds in a cellular background closer to the 
neuronal one. We performed two different protocols for Tau aggregation, to 
identify the one inducing the higher formation of CST inclusions and guaranteeing 
the higher reproducibility. For the first protocol the CSTWT was expressed in HeLa 
cells and aggregation was induced by the synthetic seeds (297-391) from TauWT 
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as previously described. For the second protocol we expressed CSTP301S and 
delivered recombinant heparin-assembled TauP301S fibrils to induce aggregation 
(see Materials and methods). We observed that aggregation occurred with both 
protocols but its extent and reproducibility was much higher by employing the 
CSTP301S.  Indeed, it has been reported also in recent papers that exploiting Tau 
seeds with the P301S mutation bursts the aggregation in cell cultures (Strang et 
al., 2018). For this reason, the development of the screening system has been 
performed in the second condition.  
 
Figure 3.7. CST forms FRET-positive amyloidogenic aggregates. A. FRET images of 
CST
P301S
 cells untreated or treated with heparin-Tau
P301S
 aggregates (t-student test, *** p<0.001). 
B. NFRET quantification of A. C. Integrated NFRET (iNFRET) analysis of controls and CST 
aggregates. D. iNFRET quantification of controls and CST aggregates (t-student test, *** 
p<0.001). E. K114 staining of control or CST-aggregated reporter cells and colocalization 
quantification. Box spans the standard error of the mean (black square) while whiskers indicates 
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. Tau is detected by the Tau13 antibody (red). G. 




. Left panel represents 
the Triton-X insoluble fraction (T-IF) while the right panel represents the Triton-X soluble fraction 
(T-SF). 
Quantitative sensitized emission FRET microscopy was employed for the 
detection of intracellular aggregates. After CSTP301S aggregation, we observed 
the detachment of the sensor from MTs and the formation of inclusions displaying 
a FRET-positive signal (Figure 3.7A). NFRET values on aggregates were 
significantly higher than those on MTs and this might be due to because the high 
amount of molecules contributing to the FRET signal (Figure 3.7B), consistent 
with the features of an aggregate. In order to take into account at the same time 
the close interaction between Tau molecules and the differences in the dimension 
of the aggregate, the integrated NFRET signal (iNFRET) has been considered. 
Lines crossing MTs or aggregates were selected and NFRET profile was 
obtained. The integral under the curve was designed to be iNFRET (Figure 3.7C). 
iNFRET values on aggregates were significantly higher than those on MTs as 
expected (Ctrl: 3.08±0.55SE; Fibrils: 26.65±2.23SE. Figure 3.7D). To 
characterize the amyloidogenic nature of CST-positive intracellular aggregates, 
we performed a K114 staining for β-sheet fibrils (Crystal et al., 2003). 
Remarkably, CST signal significantly colocalized with K114 signal in the 
aggregates (Costes et al., 2004), confirming that CST aggregates share 
structural characteristics with pathological Tau aggregates (Figure 3.7E). 
Additionally, to demonstrate that the presence of the fluorophores on the CST do 
not impact on aggregation, an immunofluorescence experiment employing anti-
Tau antibody was performed in cells expressing CSTP301S or TauP301S. Cells were 
treated with TauP301S fibrils and CST or Tau aggregates were detected by using a 
pan-Tau antibody. In both cases, aggregation was observed in treated cells while 
it was not detectable in untreated cells (Figure 3.7F). The result suggests that in 
the two conditions the aggregates have similar morphology indicating that the 
fluorophores do not interfere with the process of aggregation. Finally, detergent 
fractionation was performed to find out whether there were biochemical 
differences between CSTP301S and TauP301S aggregates. CST and Tau were 
increased in the Triton X-100 insoluble fraction upon treatment with preformed 
fibrils revealing a similar behaviour (Figure 3.7G). Altogether these results 
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suggest that the CST forms amyloidogenic aggregates similar to those formed by 
Tau and that it provides an output, the FRET signal, applicable in a cell-based 
platform. 
 
Figure 3.8. CST-based cellular platform is sensitive to compounds altering Tau 
phosphorylation. A. NFRET images of aggregated CST cells untreated or treated with 
staurosporine (STS) or okadaic acid (OA). B. iNFRET quantification of cells reported in A 
(ANOVA test, *** p<0.001). C. K114 staining of untreated or STS/OA treated cells and 
colocalization with the CST aggregates. D. Fluorescence quantification of K114 positive 
aggregates reported in C (ANOVA test, *** p<0.001). 
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The peculiar characteristics of the CST provide a reliable tool to quantify Tau 
aggregation in terms of structure and stability of the aggregate. After 
characterization of CST aggregation in HeLa cells, we chose differentiated 
SHSY5Y as the cellular system to develop the CST screening platform. This 
choice was established since Tau aggregation occurs prevalently in neurons and 
a cellular background close to the neuronal one is more reliable to test 
compounds against pathological Tau behaviour. Treatment of differentiated 
SHSY5Y expressing CSTP301S with TauP301S fibrils caused the delocalization of 
the sensor and its aggregation as already observed in HeLa cells. In order to 
optimize the cell-based platform, the effect of kinases on Tau aggregation has 
been evaluated since hyperphosphorylation is one of the main post-translational 
modifications involved in inducing and stabilizing Tau aggregate, as previously 
described. 
After the formation of CST inclusions, cells are treated with staurosporine (STS) 
or okadaic acid (OA). STS is a non-specific protein kinases inhibitor which 
prevents Tau phosphorylation and is used here as a negative control for 
aggregation. OA, the positive control for aggregation, is an inhibitor of protein 
phosphatase PP2A and it induces Tau hyperphosphorylation. As expected, the 
iNFRET was significantly reduced in STS-treated cells suggesting a weaker 
interaction between Tau molecules and a smaller dimension of the aggregates 
(Figure 3.8A-B). On the contrary, the iNFRET was significantly increased in OA-
treated cells compared to controls, indicating an increase in the aggregation and 
a stronger interaction between Tau proteins (Figure 3.8A-B). In order to verify 
that this finding was due to structural changes in the aggregates, K114 staining 
for β-sheet fibrils has been performed (Figure 3.8C). The intensity distribution of 
the pixels in the cells indicates that the K114 signal was significantly lower in 
STS-treated and it was significantly higher in OA-treated cells compared to 
controls (Figure 3.8D). These results support the fact that the CST cell-based 
platform is able to discriminate between different drugs affecting aggregation 
providing information about the stability and the dimension of aggregates. This 





Figure 3.9. Kinase inhibitors are not toxic for cells and reduce Tau phosphorylation. A. 
Survival curve of reporter cells treated with PD-901, D-JNKI-1, staurosporine (STS) and okadaic 
acid (OA). B. Western blot and relative quantification of phosphorylated Tau residues in reporter 
cells expressing aggregated CST and treated with staurosporine (STS) or okadaic acid (OA). C. 
Western blot and relative quantification of phosphorylated Tau residues in reporter cells 
expressing aggregated CST and treated with PD-901 or D-JNKI-1. 
In order to identify potential therapeutic molecules which could reduce Tau 
aggregation, we tested two kinase inhibitors in the CST cell-based system: PD-
901, an ERK pathway inhibitor, and D-JNKI-1, a JNK1 inhibitor (Henderson et al., 
2011; Hirt et al., 2004; Milano et al., 2007; Yap et al., 2011). The survival curve of 
cells treated with increasing concentration of compounds suggests that at the 
working range of concentrations, the drugs are not toxic for cells (Figure 3.9A). 
To verify the effect of the compounds on phosphorylation, reporter cells treated 
with TauP301S fibrils were exposed to PD-901 or D-JNKI-1 and to STS or OA as a 
control. Western blot experiments showed that PD-901 decreased 
phosphorylation at Thr231 and Ser356 residues, whose phosphorylation is 




Figure 3.10. PD-901 is able to reduce CST aggregation. A. NFRET images of aggregated CST 
cells untreated or treated with PD-901 or D-JNKI-1. B. iNFRET quantification of cells reported in A 
(ANOVA test, *** p<0.001, *p<0.05). C. K114 staining of untreated or PD-901/D-JNKI-1 treated 
cells and colocalization with the CST aggregates. D. Fluorescence quantification of K114 positive 
aggregates reported in C (ANOVA test, **** p<0.0001; ** p<0.01). 
To investigate the potential therapeutic effect of the drugs, upon aggregation 
induction, reporter cells were treated with PD-901 and D-JNKI-1 and quantitative 
sensitized emission FRET microscopy was employed to quantify aggregation. 
The iNFRET of the aggregates was significantly reduced in cells treated with PD-
901 or D-JNKI-1 than in controls (Figure 3.10A-B), suggesting that the inhibition 
of ERK or JNK pathways is able to impair Tau aggregation. Remarkably, the 
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effect of PD-901 in destabilizing Tau aggregates was stronger than D-JNKI-1, 
resulting in a more efficient candidate compound (PD-901: 13.26±1.31SE; D-
JNKI-1: 19.16±1.57SE). In order to verify this finding, K114 staining for β-sheet 
fibrils was performed. The intensity distribution of K114 signal was significantly 
lower in PD-901-treated cells than controls, while no significant difference could 
be detected between D-JNKI-1 and controls (Figure 3.10C-D). This effect might 
be caused by a weaker effect of D-JNKI-1 in altering aggregates. Altogether, 
these results point out that CST is a powerful tool to detect and quantify Tau 
aggregation. Moreover, the PD-901 could be a potential therapeutic agent to 




3.6 Development of an in vivo screening platform based on the CST 
 
Figure 3.11. Development of a transgenic zebrafish expressing the CST. A. Confocal imaging 
at 24hpf of donor and acceptor channels of a zebrafish embryo microinjected with the CST 
mRNA. B. Single-cell imaging of the zebrafish embryo represented in A. C. CST imaging of the F0 
transgenic line expressing the CST under the HuC promoter at 24hpf. D. Western blot of control 
and F1 transgenic line at 72hpf. E. IHC of F2 embryos at 72hpf and staining with Tau13 and 
phosphor-AT8 antibody. Experiments performed in collaboration with Miriam De Sarlo and 
Professor Michela Ori. 
The results obtained supported also a possible application in vivo. CST is 
genetically encoded and it can be stably expressed in animal models. In order to 
develop the CST-in vivo model, we employed D. rerio (zebrafish). We chose 
zebrafish since it is an ideal choice for the CST employment due to the 
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transparency of embryos allowing an easy imaging approach. Moreover, 
transgenesis in this animal is well-validated and efficient. Finally, previous 
experiments with zebrafish overexpressing human Tau revealed that, in this 
model, Tau hyperphosphorylation and aggregation is spontaneous and occurs in 
a short time span (Bai and Burton, 2011; Bai et al., 2007; Kim et al., 1996; 
Paquet et al., 2009, 2010; Saleem and Kannan, 2018) 
First, to demonstrate that CST is correctly expressed in zebrafish, the zygotes 
have been microinjected with CST mRNA and embryos have been analysed at 
24hpf (hours post fertilization) by confocal imaging. The injection of CST mRNA 
led to a transient whole embryo expression of the sensor. We observed that CST 
is correctly expressed in zebrafish embryos, in fact both CFP and YFP 
fluorophores can be detected (Figure 3.11A) and, at single cell level, CST 
displays a network typical of Tau protein bound to MTs, as expected (Figure 
3.11B). These results support the fact that CST can be used in this system and 
that it resembles Tau properties also in vivo. In order to develop a model based 
on CST, we cloned the CSTWT in a Tol2 plasmid, for the stable integration in 
zebrafish genome. We chose the HuC promoter which guarantees a durable 
expression of the sensor specifically in zebrafish neurons. Zebrafish zygotes 
were co-injected with Tol2-CST plasmid and the mRNA of the transposase, the 
enzyme which recognizes the Tol2 sequences and integrates the CST in the 
genome. The F0 line was selected for the positive fluorescent signal by confocal 
imaging 24hpf. As shown in figure 3.11C, the F0 is a chimera which expresses 
CST only in neuronal cells. Six founders were selected and inbreeded. A 
preliminary characterization on the F1 generation was performed. Fluorescence 
could be detected 24hpf in transgenic zebrafishes and western blot experiments 
of protein extracts from 72hpf embryos showed that the sensor was correctly 
expressed and did not undergo proteolytic cleavage (Figure 3.11D). Moreover, 
immunohistochemistry experiments performed at the same time point confirmed 
the expression of CST and demonstrated that it was phosphorylated at AT8 
epitope (Figure 3.11E). These preliminary analyses showed that CST is correctly 
expressed in zebrafish model and further characterizations, in particular the 
optimization of the FRET analyses in vivo, will be the basis for the development 
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of the in vivo platform which combines the properties of CST to those of zebrafish 
model. 
3.7 CST is detectable in cellular nuclei and does not display FRET signal 
 
The experimental procedures employed to characterize the CST showed 
additional evidences about the subcellular localization of Tau. The fractionation 
protocol, used to obtain the cytoplasmic fraction of cells expressing the Tau 
sensor also allowed the isolation of a soluble nuclear fraction (SNF) and a 
chromatin bound fraction (CBF). The analysis of these two fractions indicated the 
presence of the CST in the nuclear compartment (Figure 3.12A). Even if CST 
molecules were detectable in the HeLa and HT22 nuclei, the NFRET signal, that 
is independent from the total number of fluorescent molecules, was absent or 
extremely low (Figure 3.12B), suggesting that Tau conformation is different in this 
compartment compared to Tau in the cytosol or bound to MTs. This strong 
difference between nuclear and cytoplasmic Tau might be caused by the fact that 
nuclear Tau is soluble or interacts with proteins which modify its conformation. 
Figure 3.12. the CST is 
detectable in the nuclear 
compartment. A. 
Fractionation and WB of 
HT22 cells expressing CST. 
B. FRET images of HeLa and 
HT22 cells expressing the 
CST and relative FRET 
efficiency quantification in the 
cytosol and in the nucleus 
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3.8 Nuclear Tau modulates the VGluT1 expression 
 
Figure 3.13. Tau alters VGluT1 expression. A. Western blot of total extracts and subcellular 
fraction obtained from neuronal (HT22 and differentiated SHSY5Y) and non-neuronal (HeLa) cell 
lines. The 0N4R overexpressed Tau is compared with the corresponding endogenous isoform. B. 
Quantification of VGluT1 protein level in control and Tau-expressing cells. C. VGluT1 mRNA 
quantification by qPCR. (Mann–Whitney test; **** p<0.0001; *** p<0.001; ** p<0.01; * p<0.05). D. 
Quantification of VGluT1 protein and mRNA levels in control and CST-expressing cells. E. 
Western blot of subcellular fractions obtained from differentiated SHSY5Y cells treated with non-
targeting shRNA (Ctrl) or Tau targeting shRNAs (Tau KD). F. Quantification of Tau mRNA and 
protein levels in control and Tau KD cells. G. Quantification of VGluT1 mRNA and protein levels in 
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control and Tau KD cells. (Mann–Whitney test; * p<0.05). SNF: soluble nuclear fraction; CBF: 
chromatin-bound fraction. 
Since the CST was detected in the nucleus, we verified the presence of 
unlabelled Tau in this compartment. Tau was detected both in the SNF and CBF 
and this result led to the question about the function of Tau in that subcellular 
area. The possible roles of nuclear Tau have been described above but this field 
is still largely unexplored and it is not clear if nuclear Tau could have a role in 
modulating gene expression, a function that might be relevant for the 
pathophysiology of tauopathies. In order to identify its function we investigated 
the impact of nuclear Tau on the glutamate release pathway which is known to be 
altered in the early phases of tauopathies (Dickerson et al., 2005; Jadhav et al., 
2015; Khadrawyb YA, 2014; Maurin et al., 2014; Revett et al., 2013).  
To investigate the role of Tau in the modulation of gene expression, we 
expressed the CST or the Tau isoform 0N4R in cells expressing (HT22 and 
differentiated SHSY5Y) and not expressing (HeLa) endogenous Tau. By a 
subcellular fractionation protocol, we isolated the soluble nuclear (SNF) and 
chromatin bound (CBF) fractions. The CST and Tau were clearly detectable in 
the nuclear fraction, both in the soluble and in the chromatin bound one in all the 
cell lines (Figure 3.12A, 3.13A). Moreover, endogenous nuclear Tau was 
expressed and detected only in HT22 and SHSY5Y cells as expected 
(Figure3.13A). To investigate whether Tau can modulate gene expression, we 
checked the expression of disease-related genes. A growing body of evidence 
suggests that the glutamate release is altered during the progression of 
tauopathies, causing an early synaptic hyperexcitability in pre-symptomatic 
phases (Dickerson et al., 2005; Jadhav et al., 2015; Khadrawyb YA, 2014; Maurin 
et al., 2014; Revett et al., 2013). We focused on the presynaptic vesicular 
glutamate transporters (VGluT1) that package glutamate into vesicles for 
neurotransmitter exocytosis (Martineau et al., 2017; Siksou et al., 2013; Takamori 
et al., 2000). A significant increase of VGluT1 protein level was observed by 
western blot (HT22: 2.2±0.26SE Fold Change=FC; SHSY5Y: 2.24±0.44SE FC; 
HeLa: 2.19±0.49SE FC; Figure 3.13B) in neuronal and non-neuronal cell lines 
overexpressing Tau. Remarkably, VGluT1 mRNA levels also increased after Tau 
expression (HT22: 2.46 ± 0.21SE FC; SHSY5Y: 2.69±1.27SE FC; HeLa: 
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3.6±0.75SE FC; Figure 3.13C). A similar result has been observed in cells 
expressing the CST, suggesting that the presence of the fluorophores does not 
affect significantly the gene modulation mediated by Tau (Figure 3.13D). These 
results indicate that Tau modulates VGluT1 gene expression, in a cell type-
independent manner. To support this evidence, we performed a Tau knock-down 
(Tau KD) experiment by lentiviral delivery of shRNAs in differentiated SHSY5Y. A 
non-targeting shRNA was used as control. Cells were collected 72h after 
transduction and analysed to check the mRNA and protein expression of Tau and 
VGluT1. Tau knockdown in differentiated SHSY5Y cells was very efficient, 
causing a significant loss of Tau at both the protein and mRNA levels (mRNA: 
0.35±0.06SE FC; protein: 0.49±0.11SE FC; Figure 3.13E-F) with respect to 
control cells. In Tau KD cells a decrease of Tau protein could also be observed in 
the nuclear fractions (Figure 3.13E). Concomitantly, the expression of VGluT1 
was strongly reduced (mRNA: 0.76±0.06SE FC; protein: 0.5±0.08SE FC; Figure 
3.13E-G) demonstrating that, at least partly, it depends on Tau expression. 
 
Figure 3.14. Tau displacement from MTs increases Tau nuclear accumulation and VGluT1 
expression. A. Western blot of total extracts and subcellular fractions from HT22 untreated and 
treated cells. PTX (paclitaxel), Noc (nocodazole). B. Quantification of Tau protein levels in total 
extracts and nuclear fractions. C. Quantification of VGluT1 protein levels (Kruskal–Wallis ANOVA 
and Mann–Whitney test; ** p<0.01; * p<0.05). 
At the onset of pathology, Tau stability on microtubules is reduced. The increased 
availability of soluble Tau protein is currently believed to slowly favour the toxic 
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oligomerization (Braak et al., 1994). We reasoned that this event could shift the 
equilibrium between Tau pools in the cytoplasmic and nuclear compartments, 
thus increasing Tau nuclear localization after the displacement from MTs. The 
overexpression of Tau leads to an increase of the protein amount in all the 
cellular compartments, including the cytoskeletal fraction, thus providing a 
condition different from what happens during the pathology progression and 
which could alter VGluT1 expression for mechanisms partially independent from 
the nuclear accumulation of Tau. In order to avoid Tau overexpression and to 
study the effect of the destabilization on nuclear Tau functions, we worked on 
HT22 cells expressing endogenous Tau which has been destabilized and 
detached from MTs by treatment with paclitaxel (PTX) or nocodazole (Noc). 
These drugs increase soluble Tau with two opposite mechanisms: PTX stabilizes 
MTs and competes with Tau for the same binding pocket on the tubulin dimer, 
causing its displacement from MTs; nocodazole disassembles the MT network, 
leading to an increase in soluble Tau (Kar et al., 2003; Di Primio et al., 2017). WB 
experiments indicated that in HT22 treated cells, a significant increase of Tau 
levels in both the nuclear fractions could be observed (Figure 3.14A-B). On the 
contrary, there was a decrease of Tau in the cytoskeletal fraction, as expected 
(Figure 3.14A). By WB we observed that the increase in the soluble endogenous 
Tau, both in the cytoplasm and nucleus, determined a concomitant significant 
increase in VGluT1 expression in PTX- and Noc-treated cells (PTX: 2.0±0.23SE 
FC; Noc: 2.29±0.64SE FC; Figure 3.14C). These results demonstrate that the 
destabilization of the endogenous Tau from MTs has a double effect: it favours 
an increase in the cytoplasmic soluble pool and at the same time Tau is 
translocated to the nuclear compartment. The downstream effect of this 




Figure 3.15. VGluT1 increased expression is dependent on nuclear Tau. A. 
Immunofluorescence of HT22 cells expressing Tau-NLS or Tau-NES. Tau (red), DAPI (blue). B. 
Quantification of SNF and DBF compared to CF in HT22 cells expressing Tau, Tau-NLS or Tau-
NES. C. Western blot of HT22 cells expressing Tau-NLS or Tau-NES. D. Quantification of WB 
experiments (Kruskal–Wallis ANOVA and Mann–Whitney test; *** p<0.001, **** p<0.0001, n.s. 
p>0.05). E. VGluT1 mRNA quantification by qPCR in HT22 cells (Kruskal–Wallis ANOVA and 
Mann-Whitney test; *** p<0.001, n.s. p>0.05). 
To understand if the alteration in VGluT1 levels is mediated by Tau increase in 
the cytoplasmic or nuclear compartments, we forced the localization of Tau in the 
nucleus or its retention in the cytoplasm by including a nuclear localization 
sequence (Tau-NLS) or a nuclear export signal (Tau-NES), respectively. As 
expected, Tau-NLS prevalently accumulated in the nuclear fraction, while Tau-
NES was mainly detected in the cytoplasm (Figure 3.15A-B-C). Tau-NLS induced 
a significant increase in VGluT1 protein expression (2.0±0.36SE FC) comparable 
to that induced by untagged Tau. On the contrary, when the nuclear localization 
of Tau was prevented (Tau-NES), no increase in VGluT1 protein could be 
observed (Figure 3.15C-D). Likewise, cells expressing Tau-NES showed no 
increase in the level of VGluT1 mRNA, while cells expressing Tau-NLS showed 
an increase similar to that observed with untagged Tau (Tau-NLS: 2.04 ± 0.21SE 
FC; Tau-NES: 1.26 ± 0.12SE FC; Figure 3.15E). These results indicate that Tau 
proteins translocated into the nucleus regulate the expression of VGluT1. 
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Accordingly, shifting the equilibrium towards cytoplasmic Tau, by forcing its 
nuclear export, brings VGluT1 expression back to baseline. Altogether, these 
evidences demonstrate that nuclear Tau is able to alter the expression of VGluT1 
and reasonably of other proteins. 
 
Figure 3.16. Tau displacement from MTs increases VGluT1 expression altering the synaptic 
transmission. A. Representative confocal imaging of IF in primary neurons. Tau (red), VGluT1 
(green), DAPI (blue). B. Cumulative distributions of mEPSC frequency (i.e., interevent interval) 
and mEPSC amplitude following either PTX or Noc treatment, compared to untreated controls 
(Ctrl, n = 3002 events from 12 cells; PTX, n = 4911 events from 10 cells; Noc, n = 3576 events 
from 6 cells; Kolmogorov–Smirnov test, Ctrl versus PTX, p<0.001; Ctrl versus Noc, p<0.001; PTX 
versus Noc, p<0.001). C. Quantification of differentially expressed genes related to AMPA 
(GRIA2, MINK1) and NMDA (GRIN2C, GRIN2D) receptors. 
The effect of nuclear Tau on VGluT1 expression leads to the question if this 
alteration might have a real functional impact on neuronal excitability. In order to 
address this point, we analysed the effect of Tau in primary hippocampal 
neurons. To induce the destabilization of endogenous Tau, we treated cells with 
PTX or nocodazole. An increase in VGluT1 expression, detected by IF, was 
observed in treated primary neuronal cultures (Figure 3.16A). A patch-clamp 
recordings of spontaneous synaptic transmission (miniature Excitatory 
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Postsynaptic Currents, mEPSCs) on primary hippocampal neuronal cultures have 
been performed. Consistent with the increase in VGluT1 expression, a significant 
increase in mEPSC frequency after either PTX or Noc treatment was observed 
(Figure 3.16B). This indicates a prevalent presynaptic effect on glutamatergic 
transmission. In addition, both PTX and Noc also increased the mEPSC 
amplitude (Figure 3.16B), suggesting an additional post synaptic effect induced 
by modulating the nuclear Tau pool. In order to assess this possibility, the mRNA 
levels of AMPA and NMDA receptor subunits were measured in SHSY5Y cells 
overexpressing Tau by RNAseq experiments (described in details below). GO 
analysis individuated, among the altered categories, that, after Tau 
overexpression, the glutamate release pathway was significantly modulated. In 
particular, among post-synaptic genes, the mRNAs coding for NMDA receptor 
subunits GRIN2C and GRIN2D were upregulated, while the mRNAs of the AMPA 
receptor subunit GRIA2 and the AMPA trafficking protein MINK1 were unchanged 
(Figure 3.16C). Altogether, these results demonstrate that the modulation of the 
endogenous soluble Tau levels alters VGluT1 expression, as well as that of 
subunits of the NMDA receptors, thus altering the glutamatergic synaptic 
transmission. 




Figure 3.17. Tau pathological mutant P301L impairs Tau function of altering VGluT1 







B. Quantification of VGluT1 protein expression in HT22. C. VGluT1 mRNA quantification by qPCR 




. D. Western blot of total extracts of differentiated 




. E. Quantification of VGluT1 protein levels in 




. (Kruskal–Wallis ANOVA and Mann-Whitney test; **** 
p<0.0001; *** p<0.001, ** p<0.01; * p<0.05; n.s. p>0.05). 
The role of nuclear Tau in gene expression regulation was performed in 
conditions mimicking a pre-aggregation status of Tau protein, in particular those 
conditions in which the interaction with MTs is impaired and the amount of 
soluble Tau is increased. These evidences suggest that this nuclear function 
might be altered by pathological mechanisms, in particular mutations associated 
to tauopathies and aggregation. To investigate whether pathologically mutated 
Tau could have an impact on its role in the nuclear compartment, we expressed 
TauP301L in HT22 cells and we observed that this mutant is efficiently translocated 
into nucleus as well as wild type Tau (Figure 3.17A). TauP301L did not increase 
VGluT1 expression with respect to control cells. Indeed, both the protein 
(1.16±0.13SE FC) and mRNA levels (1.04±0.23SE FC) were not different from 
those in control cells (Figure 3.17B-C). Moreover, a similar result was observed in 
differentiated SHSY5Y, where mutated Tau did not induce a significant increase 
in VGluT1 expression (Figure 3.17D-E). Taken together, these results indicate 
that P301L mutation does not affect nuclear translocation but abolishes the ability 
of Tau to induce VGluT1 expression, thus causing a loss of its nuclear function. 
Remarkably, the employment of TauP301S in differentiated SHSY5Y, another well-
characterized Tau mutant related to the insurgency of tauopathies, is able to 
induce an increase in VGluT1 expression comparable to the one observed with 
TauWT (Figure 3.19), suggesting that two different missense mutations in the 
same residue can affect Tau nuclear function in different ways. 
 
Figure 3.18. Tau isoform 0N3R alters 
VGluT1 expression. A. Western blot of 
HT22 cells expressing Tau isoform 0N3R 
and relative quantification of VGluT1 protein 
levels. B. Western blot of SHSY5Y cells 
expressing Tau isoform 0N3R and relative 
quantification of VGluT1 protein levels. 
(Mann-Whitney test; * p<0.05). 
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Since these mutations are located on the second repeat of the MTBD, we 
investigated if the absence of this repeat could alter the role of Tau in the 
modulation of VGluT1 expression. Tau 3R isoforms, due the alternative splicing 
of the exon 10, are physiological variants which lack of the second repeat 
(Andreadis et al., 1992; Goedert and Jakes, 1990; Goedert et al., 1989a). In 
order to clarify if this sequence can influence Tau function, we expressed the Tau 
isoform 0N3R in HT22 and differentiated SHSY5Y and we analysed the 
expression of VGluT1 (Figure 3.18A-B). The absence of the second repeat in 
both cell lines did not affect the nuclear Tau function. As a matter of fact, a 
significant increase in VGluT1 protein levels was observed (Figure 3.18A-B). 
Indeed, the expression of Tau 0N3R isoform induces an alteration in VGluT1 
levels comparable to that observed in cells expressing the 0N4R isoform, sharing 
a similar function in gene modulation. These evidences suggest that Tau effect 
on gene expression is not dependent on the second repeat of the MTBD. 
Moreover, this result is associated to the effect of P301S and P301L mutations 
described above. In fact, even if the presence of the second repeat is not 
necessary for the modulation of VGluT1, P301L mutation, but not P301S, is able 
to impair nuclear Tau role, suggesting that this loss of function is mutation-
specific. 
 
Figure 3.19. Tau pathological aggregation 
impairs Tau modulation of VGluT1 expression. 
A. Western blot of HT22 cells expressing P301S 
and treated with Tau
P301S
 preformed fibrils (Fib). B. 
Quantification of VGluT1 levels in cells represented 
in A. (Mann-Whitney test; * p<0.05). 
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Finally, we performed preliminary experiments to study the effect of aggregation 
on nuclear Tau function in gene expression. Several studies indicated that during 
pre-clinical stages of AD, glutamate release is increased leading to excitotoxicity 
but, in later stages when Tau aggregation is consolidated in the brain, a reduction 
in the glutamate release is observed (Dickerson et al., 2005; Jadhav et al., 2015; 
Khadrawyb YA, 2014; Maurin et al., 2014; Revett et al., 2013). To clarify if the 
aggregation can impair Tau modulation of VGluT1, we induced TauP301S 
aggregation by preformed fibrils administration in differentiated SHSY5Y cells 
(Figure 3.19A). Figure 3.19 shows that cells expressing TauP301S have a higher 
expression of VGluT1 compared to controls but after Tau aggregation VGluT1 
amount returns to baseline levels (Figure 3.19B), suggesting that aggregation 
leads to a loss of Tau nuclear function in modulating gene expression.  
3.10 Tau nuclear function is mediated by chromatin remodelling 
 
Figure 3.20. Tau modulation of VGluT1 levels is not directed to the VGluT1 promoter. A. 
Confocal imaging of HT22 cells expressing Tau-mCherry, GFP under the VGluT1 promoter 
(VG::GFP) or both. GFP is represented in green, Tau in red. B. Western blot of HT22 cells 
expressing Tau, VG::GFP or both to detect Tau and GFP levels. C. Quantification of GFP levels 
in the western blot experiment reported in B. D. Confocal imaging of HeLa cells expressing Tau-
mCherry, GFP under the VGluT1 promoter (VG::GFP) or both. GFP is represented in green, Tau 
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in red. E. Western blot of HeLa cells expressing Tau, VG::GFP or both to detect Tau and GFP 
levels. F. Quantification of GFP levels in the western blot experiment reported in E (Mann-
Whitney test: n.s. p>0.05). 
We further investigated the molecular mechanism mediating the nuclear function 
of Tau. Since Tau interacts directly with genomic DNA (Benhelli-Mokrani et al., 
2018; Qi et al., 2015), we hypothesized that Tau could alter VGluT1 expression 
by interacting with the VGluT1 promoter. To address this point, we expressed the 
reporter gene GFP under the VGluT1 promoter (VG::GFP) in control or Tau-
overexpressing HeLa and HT22 cells. Imaging experiments showed that GFP 
signal was not altered by the increased expression of Tau in both cell types 
(Figure 3.20A-D). This result was confirmed by Western blot, in fact GFP 
expression was similar in Tau-overexpressing and control cells (Figure 3.20 B-C-
E-F). These results demonstrate that the modulation of VGluT1 expression 




Figure 3.21. Tau competes with HDAC1 for the interaction with TRIM28 altering gene 
expression. A. Immunofluorescence of control or Tau-expressing SHSY5Y cells. TRIM28 
staining (green) is detected mainly in the nuclear compartment as expected. Tau is represented in 
red, DAPI in blue. B. Western blot and qPCR quantification of total extracts in control and Tau-
expressing SHSY5Ycells and detection of TRIM28 and Tau levels. C. Western blot and relative 
quantification of chromatin-bound fraction (CBF) in control and Tau-expressing SHSY5Y cells and 
detection of TRIM28 and Tau levels. D. Western blot and qPCR quantification of total extracts in 
control and Tau-expressing SHSY5Y cells and detection of HDAC1 and Tau levels. E. Western 
blot and relative quantification of CBF in control and Tau-expressing SHSY5Y cells and detection 
of HDAC1 and Tau levels. F. Co-IP experiment in control and Tau-expressing SHSY5Y cells. 
Immunoprecipitation of Tau by Tau-13 antibody and detection of TRIM28 and HDAC1. G. 
Immunofluorescence of SHSY5Y cells expressing Tau or Tau-NES. HDAC1 staining (green) is 
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detected mainly in the nuclear compartment in control cells as expected. Tau is represented in 
red, DAPI in blue. H. Quantification of HDAC1 nuclear signal in control and Tau-expressing 
SHSY5Y cells. I. Western blot and relative quantification of SHSY5Y cells expressing Tau or 
treated with Tricostatin-A (TSA) and detection of VGluT1 levels. 
In order to elucidate the molecular mechanism exerted by nuclear Tau in the 
alteration of VGluT1 expression, we investigated the interaction of Tau with 
nuclear proteins which could influence gene expression. Recent studies identified 
the nuclear protein TRIM28 as a Tau interactor which mediates its translocation 
into the nucleus (Rousseaux et al., 2016). Remarkably, TRIM28 forms a big 
nuclear complex which alters the chromatin structure leading to formation of 
heterochromatin and, as a consequence, gene repression (Barde et al., 2013; 
Friedman et al., 2007). 
First, we investigated the association of Tau and TRIM28 in our SHSY5Y model. 
Immunofluorescence experiments showed that TRIM28 is detectable in the 
nuclear compartment as expected, and its expression is not altered by the 
increase of Tau mRNA and protein levels (Figure 3.21A). This result has been 
confirmed by Western blot analyses on total protein extracts and by qPCR 
(Figure 3.21B). Moreover, the CBF obtained by subcellular fractionation showed 
that TRIM28 nuclear localization did not change in Tau overexpressing cells 
(Figure 3.21C). These evidences demonstrate that Tau has no significant effect 
on TRIM28 expression and localization.  
Since TRIM28 has several nuclear partners which mediate the function of 
chromatin remodelling, we analysed the impact of Tau on TRIM28 interactors. 
HDAC1 is a well-known TRIM28 interactor belonging to histone deacetylases 
family whose function is to eliminate the acetyl group from histones favouring 
heterochromatin formation (Delcuve et al., 2013; Haberland et al., 2011). Due to 
its function and to the interaction with TRIM28 in the nucleus, HDAC1 has been 
investigated as a candidate for this study. Western blot in total extracts and 
qPCR showed that HDAC1 expression was not altered by Tau overexpression 
(Figure 3.21D), however, we observed a significant reduction in HDAC1 in CBF 
compared to control cells (Figure 3.21E). To understand if HDAC1 delocalization 
from the chromatin-bound fraction was due to a competitive effect with Tau, we 
performed a Co-IP experiment. We immune-precipitated Tau by anti-Tau 
antibodies and detected TRIM28 and HDAC1. Figure 3.21F shows that, while 
88 
 
TRIM28 is normally detected in the protein complex, HDAC1 is strongly reduced 
suggesting that there is a competitive effect between Tau and HDAC1 for the 
binding with TRIM28. This competition has been confirmed also by IF 
experiments. As a matter of fact, HDAC1 can be detected mainly in the nuclei of 
control cells as expected but, in Tau overexpressing cells, a significant reduction 
of HDAC1 signal in the nuclear compartment is observed with the concomintant 
relocalization into the cytoplasm confirming that Tau is involved in the subcellular 
localization of HDAC1 (Figure 3.21G-H). To discriminate if the competition 
between Tau and HDAC1 occurs in the cytosol or in the nucleus, we exploited 
the Tau-NES constructs. The retainment of Tau in the cytoplasm, by expressing 
Tau-NES in HT22 cells, showed that cytoplasmic Tau did not influence the 
nuclear localization of HDAC1 (Figure 3.21G) that is detected in the nuclear 
compartment as in control cells. This suggests that HDAC1 delocalization is 
mainly due to nuclear Tau molecules. However, the competitive mechanism 
between nuclear Tau and HDAC1 cannot still explain the increase in VGluT1 
levels.  
Our hypothesis is that the delocalization of HDAC1 from the nuclear compartment 
might impair its function as a chromatin remodeller. Thus, this might lead to an 
altered gene expression and in particular to an increase in VGluT1 expression. 
To address this point, we treated control cells with Tricostatin-A, a compound 
able to block the activity of HDAC family proteins, among these HDAC1. Western 
blot experiments in cells treated with TSA showed a significant increase in 
VGluT1 expression that was comparable to the increase observed in Tau-
expressing cells (Figure 3.21I), supporting our hypotheses. In conclusion these 
results suggest that Tau could modulate gene expression by altering the 




3.11 Tau protein causes a global alteration of gene expression and 
modulates pathways related to L-MCI 
 
Figure 3.22. Tau overexpression alters globally gene expression and reproduces a L-MCI 
condition. A. PCA analysis of control and Tau-expressing differentiated SHSY5Y cells. B. DEGs 
clustering analysis based on KEGG database. The table reports the most significant categories 
identified by gene ontology of DEGs between control and Tau-expressing cells. C. Venn diagram 
of DEGs identified in our transcriptome, DEGs identified in hippocampi of L-MCI patients and their 
intersection. D. Comparison between common DEGs of Tau-expressing SHSY5Y and L-MCI 
hippocampi. R
2
 reported in the graph is the Pearson correlation and different colours indicate 
different gene categories. E. Graphs reporting common DEGs between Tau-expressing SHSY5Y 
and E-MCI or AD hippocampi. R
2
 reported in the graph is the Pearson correlation. 
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The discovery that nuclear Tau modulates VGluT1 gene expression suggests 
that this function might also have an impact on the expression of other genes. In 
order to identify the genes whose expression is altered by Tau protein, we 
performed a RNAseq experiment in differentiated SHSY5Y. We compared the 
transcriptome profile of three controls and three Tau-expressing samples. First, 
the analyses of the principal components (PCA) showed that Tau expressing and 
control samples group separately (Figure 3.22A). The sequencing analysis 
revealed that 3902 genes were differentially expressed (DEGs) after Tau 
expression. Moreover, gene ontology of these genes by using the KEGG 
database identified clusters of gene functions which were strongly regulated by 
the higher amount of Tau protein. Remarkably, among the most regulated 
pathways, several are related to the glutamate release pathway, mRNA 
processing, protein homeostasis and signalling pathways (Figure 3.22B). These 
observations indicate that the increase of Tau is able to globally alter the 
transcriptome, thus potentially influencing several fundamental mechanisms for 
cellular homeostasis.  
In order to clarify if our cellular model overexpressing Tau can mimic molecular 
aspects characterizing AD patients, we compared the DEGs of Tau-
overexpressing SHSY5Y cells with DEGs of database GSE84422. In detail, 
GSE84422 database contains microarray data of hippocampi from AD patients 
collected at different stages of disease. Three groups are available: E-MCI, L-
MCI and AD. The comparison of our RNAseq data with this database indicated 
that there was a strong positive correlation between Tau-expressing differentiated 
SHSY5Y cells with hippocampi at L-MCI stage (Figure 3.22C-D). A lower 
correlation was observed for E-MCI and AD samples (Figure 3.22E), suggesting 
that the increase in soluble Tau mimics the pathological condition characterized 
by Tau destabilization in neuronal cells. Common DEGs between RNAseq data 
and L-MCI samples and gene ontology analysis showed that the cellular 
functions altered by Tau were also altered in L-MCI (Figure 3.22C-D), supporting 
this cellular system as a simple and reliable model to study the pathological 
effects of Tau in a pre-clinical condition. In conclusion, Tau protein alters VGluT1 
expression but several genes are also modulated, mimicking conditions related to 
L-MCI. Further analyses and experiments will clarify which are the genes 
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exclusively modulated by nuclear Tau and the role that this new function might 




Chapter 4  
Discussion 
4.1 Development of a Tau conformational sensor and application in vitro 
and in vivo 
Tau is an unfolded neuronal protein deeply studied because of its central role in 
neurodegenerative diseases. In tauopathies, Tau assumes a β-sheet structure 
and forms amyloidogenic aggregates that can be currently studied by high 
resolution techniques (Alonso et al., 2001; von Bergen et al., 2000; Fitzpatrick et 
al., 2017; Wang and Mandelkow, 2016). However, a few conclusions have been 
achieved for the structure of monomers since Tau is an intrinsically disordered 
protein (Cleveland et al., 1977; Hirokawa et al., 1988; Mukrasch et al., 2009). 
Current techniques do not allow to determine Tau atomic structure in 
physiological conditions or at the early onset of pathology, before aggregation. 
However, at a minor resolution, it is possible to investigate in a cellular system 
the physiological conformation of Tau and the conformational changes it 
undergoes in pathological conditions. 
We developed and characterized the Conformational Sensitive Tau Sensor (CST) 
which allows to investigate Tau conformation in living cells and in different cellular 
contexts (Di Primio et al., 2017). The main difference of this tool with already 
available Tau biosensors (Kfoury et al., 2012; Tak et al., 2013) is the tagging of 
Tau with a FRET couple enabling to monitor, in real time, Tau conformational 
dynamics from the binding to MTs to displacement and aggregation. By 
expressing the CST in different cellular systems we confirmed that the presence 
of the two fluorophores does not affect the interaction of Tau with MTs (Figure 
3.1-3.2) supporting the fact that Tau main physiological function is preserved in 
the CST as expected (Avila et al., 2004; Breuzard et al., 2013; Samsonov et al., 
2004). The CST has been applied in order to study Tau behaviour in 
physiological conditions. The CST on MTs displays a positive FRET signal and a 
comparison with cells co-expressing monolabelled CFP-Tau and Tau-YFP 
demonstrates that the FRET signal is mainly due to an intramolecular interaction 
between the N- and C-terminal ends. This result shows, for the first time, that Tau 
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bound to MTs assumes a loop conformation in which the ends of the protein are 
close each other. On the contrary, a more relaxed conformation is detectable for 
Tau soluble molecules in the cytoplasm. As a matter of fact, by destabilizing the 
cytoskeleton or the interaction between Tau and tubulin, a strong reduction of 
FRET signal is observed and it is associated to a significant increase in the 
cytoplasmic fraction of Tau (figure 3.3). The employment of the CST in living cells 
confirmed previous in vitro studies indicating that in absence of MTs the soluble 
Tau assumes a paperclip conformation (Bibow et al., 2011; Jeganathan et al., 
2006; Mukrasch et al., 2009). Our approach clarified that this paperclip 
conformation is distinctive of Tau bound to MTs while the soluble cytoplasmic 
Tau assumes a completely different conformation that was undetectable in vitro. 
Certainly, in vitro experiments performed in test tubes do not resemble the 
cellular complexity and in this case the loss of the loop conformation for soluble 
monomers might be due to cellular interactors or post-translational modifications.  
The possibility to discriminate between physiological and destabilized state led to 
the application of the CST to determine the conformational changes of Tau 
mutants associated to tauopathies (Bugiani et al., 1999; Hutton et al., 1998; 
Rizzu et al., 1999; Spillantini et al., 1998a). The P301L and ΔK280 mutations 
have been considered. These two mutations are strongly linked to FTDP and 
Pick’s disease and molecular studies demonstrated that they have reduced 
affinity to tubulin, resulting in a destabilization of MTs, and are more prone to 
post-translational modifications and aggregation (Goedert et al., 1999). The 
employment of CSTP301L and CSTΔK280 shows similar results for P301L and 
ΔK280 mutations. FRET analysis reveals that both mutants display a positive 
FRET signal on MTs but significantly lower than CSTWT, suggesting that the 
presence of mutations causes a conformational change leading to a more relaxed 
conformation of Tau bound to tubulin. The fraction of mutated Tau soluble in the 
cytosol is higher than wild-type Tau indicating a lower affinity to tubulin. 
Moreover, the analysis of the mutated CST network on MTs indicates a reduced 
number of branching points and of the total filament length. The alteration of Tau 
network further supports a destabilization and a lower complexity of the 
cytoskeleton that, associated to the increase in the soluble fraction of the protein, 
indicates a general impairment of Tau function. This result confirmed previous 
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studies indicating that these mutants reduce the MTs stability and are more 
subjected to post-translational modifications and aggregation (Hasegawa et al., 
1998b; Spillantini et al., 1998b, 1998a). The CST adds a new evidence on these 
pathological mutations. As a matter of fact, the destabilization caused by P301L 
and ΔK280 corresponds to a conformational change of Tau protein on MTs. 
Mutated CST is significantly more relaxed that the wild-type, thus suggesting that 
the destabilization of Tau protein and its structure are closely related. This 
association is confirmed by employing a CST mutant more stable on MTs. By 
impeding the phosphorylation of the AT8 epitope by site-directed mutagenesis 
(CSTAT8mut), a significant increase in the fraction of Tau bound to cytoskeleton is 
observed (Figure 3.4). Moreover, the MT network analysis shows an increase in 
branching points and total filament length compared to the CSTWT, suggesting a 
higher network complexity. The FRET analysis of the AT8 phospho-mutant 
indicates that the FRET of the sensor bound to MTs is higher than the wild-type, 
indicating a conformation significantly closer than the CSTWT. Altogether these 
results show that there is an association between the conformation of Tau and its 
binding to tubulin, resulting in an alteration of the cytoskeleton network. 
These evidences stimulated further investigation of mutations still not completely 
characterized but related to a particular tauopathy. Intriguingly, in recent years a 
novel Tau mutation associated to Pick’s disease, Q336H, was discovered. In vitro 
experiments revealed that TauQ336H is able to increase the tubulin polymerization, 
a peculiar effect generally opposite to other Tau mutations (Tacik et al., 2015). 
We generated the CSTQ336H and we studied its effect on MT network and Tau 
conformation. The CSTQ336H network analysis shows a significant increase in 
branching points and filament length compared to CSTWT, in a way similar to the 
AT8 phospho-mutant. The FRET signal of the CSTQ336H is higher than wild-type, 
revealing a closer conformation of molecules bound to MTs than the CSTWT. 
These first results suggest a stabilizing function of Q336H mutation increasing 
the complexity of MTs. Remarkably, this mutation is associated to aggregation 
and development of Pick’s disease even if its impact on Tau structure seems in 
contrast to other tauopathy-related mutations. A possible explanation might be 
that Tau conformational alteration has a double effect: the cytoskeleton 
stabilization and, at the same time, a higher sensitivity to post-translational 
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modifications and/or oligomerization leading to aggregation. Another explanation 
might be that the mutation alters the 3R/4R isoforms ratio which seems related to 
specific tauopathies (Arai et al., 2001; Buée-Scherrer et al., 1996; Delacourte et 
al., 1996; Sergeant et al., 1997; Togo et al., 2002). Further studies will provide 
new insights on the effect of Q336H on Tau functions and will clarify how it is 
linked to pathology.  
Tau pathology development goes through different steps, from a physiological 
condition to Tau destabilization and oligomerization, concluding with intracellular 
amyloidogenic inclusions (Avila et al., 2004; Wang and Mandelkow, 2016). The 
employment of the CST to investigate the molecular dynamics of Tau pathology 
showed that it provides an imaging readout discriminating Tau conformations in 
different cellular conditions. To characterize how the sensor responds to 
pathological aggregation, CST reporter cells have been treated with different 
amyloidogenic aggregates. The administration of brain lysates from AD patients 
causes a delocalization of the CST from MTs to the cytoplasm and subsequent 
formation of FRET-positive aggregates, demonstrating that CST is also sensitive 
to pathological aggregation. The AD brain lysate represents a mixture of proteins 
in the final pathological stage of the disease. This means that it contains the two 
major inclusions detectable in AD, Tau tangles and Aβ aggregates (Lane et al., 
2018). The homotypic treatment of reporter cells by Tau fibrils induces the 
delocalization and aggregation of the CST, resulting in a FRET positive signal 
and its isolation in the sarkosyl-insoluble fraction. Remarkably, a similar effect is 
observed with the heterotypic treatment with AβOs; the CST forms insoluble 
intracellular inclusions which display a FRET signal. Same results have been 
obtained also in cells expressing the unlabelled Tau, demonstrating that the 
presence of the fluorophores is negligible in this mechanism. The treatment with 
Tau fibrils leads to the sensor aggregation as expected and allows to add a new 
feature of the CST, in fact it provides a FRET positive output in aggregation 
conditions. The employment of AD brain lysates and, more clearly, of AβOs 
further supports the sensitivity of CST in response to a pathological state, 
indicating that heterotypic aggregates are able to alter Tau pathological 
dynamics. Tau aggregates forming in response to administration of AβOs 
suggest that these pathological proteins in AD can interact enhancing the Tau 
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aggregation process. The cross-reaction between Tau and Aβ has been already 
observed both in vitro and in vivo experiments indicating that it favours post-
translational modifications of Tau (Guo et al., 2006). However, the mechanisms 
behind this response are still unclear and further studies are necessary to clarify 
how Tau and Aβ impact each other during the progression of AD. 
The sensitivity of the CST to pathological conditions, led to the development of in 
vitro and in vivo systems to identify molecules or conditions able to reduce or 
prevent Tau pathological behaviour. Many attempts to block or revert tauopathies 
progression failed in providing an efficient treatment for these pathologies, even if 
Tau-based clinical trials are currently ongoing and are evaluating the safety and 
the efficacy of the Tau-directed therapy on AD patients (Novak et al., 2010, 
2018c, 2018b, 2018a; West et al., 2017). However, the lack of a cure for Tau 
pathology is due to several factors, in particular the insufficient knowledge of its 
functions and mechanisms related to the pathology and the poor development of 
screening techniques to easily and efficiently identify therapeutic compounds.  
About the last point, a number of Tau biosensors are currently available and 
sensitive to aggregation (Kfoury et al., 2012; Tak et al., 2013). However, they are 
still not employed for high throughput screening assays. We developed a cellular 
platform based on CST to identify potential therapeutic compounds against Tau 
pathology. 
First of all, for the assay optimization, the CSTP301S has been expressed in HeLa 
cells and aggregation has been induced by administration of heparin-TauP301S 
fibrils to favour a higher amount of aggregation. The characterization of 
aggregates shows that CSTP301S inclusions are insoluble and positive to K114 
staining as well as amyloidogenic aggregates (Crystal et al., 2003). Moreover, the 
imaging analysis clearly indicates that the FRET signal of CST included in 
aggregates is much higher than the signal displayed by the sensor bound to MTs. 
These results demonstrates that, by means of different FRET values, the CST 
provides three different outcomes relative to three states of Tau: bound on MTs, 
soluble in the cytosol and aggregated. However, while the FRET signal in 
physiological and destabilizing conditions provides information also about the 
conformation of Tau, upon aggregation the FRET signal does not  mean a 
structure or the directionality of interacting Tau molecules. In order to improve the 
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signal of the aggregated CST, taking into account the different dimensions of 
aggregates and to increase the sensitivity to different treatments, the integrated 
NFRET signal has been considered (iNFRET). The iNFRET value describes two 
aspects of the aggregate: the proximity of CST molecules and the dimension of 
the aggregate. By comparing iNFRET values of CST bound to MTs and 
aggregated we found that the iNFRET of aggregates is significantly higher. The 
analysis suggests that this system can be suitable for a screening application. 
After this preliminary characterization, the CSTP301S has been expressed in a 
disease relevant cell line: differentiated SHSY5Y cells. Upon aggregation, the 
FRET and iNFRET signals were comparable to those in HeLa cells indicating that 
this CST-based cellular system could be exploited as a platform to test potential 
therapeutic compounds impairing Tau aggregation.  
Several candidates are available which might block specific mechanisms of Tau 
aggregation and we focused on kinase inhibitors since phosphorylation is the 
most characterized post-translational modification related to Tau pathology 
(Pevalova et al., 2006; Wang and Mandelkow, 2016). Initially, reporter cells  have 
been treated with known kinase or phosphatase inhibitors, staurosporine (STS) 
and okadaic acid (OA) respectively, to evaluate the response of the system to 
these treatments and to set up optimal experimental conditions. STS is a pan-
kinase inhibitor and induces a strong reduction of CST aggregation, thus it has 
been considered the positive control for the screening. On the contrary OA is a 
phosphatases inhibitor and induces hyperphosphorylation facilitating Tau 
aggregation (Arendt et al., 2016; Guo et al., 2017; Karaman et al., 2008). For its 
effect, OA is the negative control of the system. The FRET analysis of 
aggregates shows that STS induces a significant decrease of iNFRET values 
compared to untreated cells, leading to smaller aggregates where CST molecules 
are less packed. OA treatment, instead, causes a huge increase of iNFRET, with 
bigger and more stable aggregates. Moreover, the detection of phosphorylation 
levels at Tau specific residues related to pathology confirms that STS induces 
Tau phosphorylation inhibition, in particular on AT8, T231 and S356 epitopes, 
while OA significantly increases the Tau phosphorylation. These results indicate 
that the CST-based cellular platform is sensitive to the phosphorylation changes 
upon aggregation and it can be used to identify novel anti-aggregation 
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compounds. To identify potential therapeutic molecules, the platform has been 
challenged with two kinase inhibitors, PD-901 and D-JNKI-1, which are employed 
in clinical trials against thyroid carcinoma, acute hearing loss and ischemia 
(Henderson et al., 2011; Hirt et al., 2004; Milano et al., 2007; Yap et al., 2011). 
PD-901 blocks the ERK pathway, involved in the first stages of pathological Tau 
phosphorylation (Hanger et al., 2009). D-JNKI-1 is an inhibitor of JNK which 
phosphorylates Tau in later stages of aggregation (Hanger et al., 2009). The 
treatment of reporter cells with PD-901 or D-JNKI-1 shows that both molecules 
induce a significant decrease in iNFRET values of CSTP301S aggregates, resulting 
in a lower dimension of aggregates and a weaker interaction between CST 
proteins. Remarkably, the effect of PD-901 is much stronger than D-JNKI-1. This 
evidence suggests that the inhibition of the ERK pathway impairs Tau 
aggregation more efficiently than the inhibition of JNK and this is confirmed also 
by the K114 staining which is significantly lower in PD-901 treated cells. 
Altogether these results indicate PD-901 as a potential therapeutic compound to 
reduce Tau aggregation. The different effect between PD-901 and D-JNKI-1 has 
been investigated by analysing the phosphorylation of Tau specific epitopes. Both 
ERK and JNK phosphorylate several Tau residues, however, ERK is considered 
more involved in phosphorylation events occurring at early stages of the 
pathology to prime aggregation. On the contrary, JNK seems to be involved in 
later phases, when Tau aggregation is already consolidated. Western blot 
experiments show that upon aggregation the phospho-AT8 epitope is not altered 
by treatments with PD-901 or D-JNKI-1. Remarkably, phosphorylation at T231 
and S356 residues is significantly reduced in cells treated with PD-901 while no 
effect is observed with D-JNKI-1 treatment. The phosphorylation of these 
epitopes is considered an early event in destabilization and hyperphosphorylation 
of Tau (Johnson, 2004), thus our results suggest that Tau aggregation is 
impaired when early phospho-epitopes are blocked. It is conceivable that the loss 
of early pathological phosphorylation signature destabilizes the protein of the 
forming aggregate; on the other end, this might prevent further accumulation of 
Tau to the inclusions. Given the promising results obtained by the CST-based 
platform, PD-901 will be tested in animal models for Tau pathology in order to 
confirm its efficacy in a more complex system. 
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The development of the CST-based platform and the identification of molecules 
preventing Tau aggregation support that the CST is a reliable tool for this kind of 
applications. The employment of the sensor in a cellular context leads to the 
possibility of an in vivo use in order to test drugs in a more complex system. The 
aim of the subsequent project was to obtain a CST-transgenic model for high-
throughput screenings of compounds against Tau pathology. Several animal 
models are available to study Tau pathological behaviour and to generate our 
transgenic line, the D. rerio (zebrafish) has been chosen. The zebrafish model is 
a perfect candidate for screenings since embryos are transparent for days, the 
treatments are easy to be administrated and transgenesis is simple and efficient. 
Moreover, previous experiments with zebrafish overexpressing human Tau 
revealed that in this model Tau pathological behaviour is spontaneous and 
occurs  after a few days post fertilization (Bai and Burton, 2011; Bai et al., 2007; 
Paquet et al., 2009, 2010). Preliminary experiments with transient expression of 
CST by mRNA injection show that the sensor can be expressed in this model 
and, at cellular level, it displays a fluorescent network on microtubules as 
expected, confirming that the CST maintains its basic characteristics in zebrafish. 
To develop the transgenic animal, the CSTWT has been integrated in the 
zebrafish genome under the HuC promoter which guarantees the expression only 
in neuronal cells (Kim et al., 1996). The analysis of the F0 line at 24hpf clearly 
shows the transgene expressed in neurons as expected. The inbreeding of the F0 
provided the F1 generation which stably expresses CST in all neurons. Currently 
the F1 zebrafishes are under characterization. A preliminary imaging analysis 
showed the CST signal in the nervous system and the western blot analyses 
indicated that the sensor is correctly expressed and does not undergo any 
cleavage in vivo. Moreover, an immunohistochemistry experiment performed at 
72hpf showed that the CST is highly phosphorylated at AT8 epitope in that stage 
while the signal is undetectable in control animals. This result confirms previous 
observations reporting that  human Tau overexpressed in zebrafish is 
progressively hyperphosphorylated with aging and induces neurodegeneration 
(Paquet et al., 2009). Further experiments are necessary to characterize this 
model, in particular the FRET measurements in vivo. The final goal of this 
transgenic model is to combine the peculiar characteristics of CST and zebrafish 
to obtain a reliable model to screen therapeutic molecules impairing Tau 
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aggregation and neurodegeneration. Due to the preliminary results obtained in 
vitro, PD-901 will be the first test compound analysed in this model. 
This research has the aim to study different aspects of Tau protein by molecular 
and cellular approaches to solve some biological problems about Tau which were 
still unclear. The development of a biosensor able to monitor in real time Tau 
conformation provides a new tool whose employment could help the investigation 
of the factors which modify the conformation of Tau in the first stages of the 
pathology, finding potential targets to prevent this important but neglected aspect 
of tauopathies. Moreover, the sensitivity of the CST to pathological aggregation 
can also be applied to clarify late pathological mechanisms and to screen 
candidate compounds to impair or revert the formation of Tau toxic inclusions. 
Even if the CST has been used mainly in a cellular context, a transgenic 
zebrafish is currently under development, with the aim to combine a complex 
biological system with a simple molecular output able to determine Tau 
conformational dynamics in pathological conditions. This will be the base for an in 
vivo screening model of potential therapeutic compounds preventing Tau 
pathologic behaviour. In addition, the CST could also be employed in tauopathy 
mouse models for example to study the alteration of Tau conformation in different 
brain areas and at different stages of tauopathy progression, an aspect still 
unclear and which could add new information about    Tau pathological dynamics 
in vivo. Finally, the first in vitro application of the CST to discover molecules 
potentially able to alter Tau pathological progression resulted in the identification 
of PD-901 and D-JNKI-1 as compounds which can reduce Tau aggregation, in 
particular PD-901 demonstrated to have a stronger effect than D-JNKI-1, 
suggesting that the inhibition of the EKR pathway is more efficient in preventing 
Tau aggregation that the JNK pathway. The effect of PD-901 on Tau pathology 
needs to be evaluated in mouse models, not only to confirm its efficacy in vivo 
but also to clarify its way of action in a complex system and the administration. 
Remarkably, if these data would be confirmed in vivo, the exploitation of PD-901 
in humans might be very fast and easy, since it is already used in clinical trials 
alone or in combination with other therapeutic molecules (ClinicalTrials.gov 
Identifier: NCT02022982; NCT02039336; NCT03905148) and working 
concentrations and side effects are already known.  
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4.2 The role of Tau in gene expression 
Tau recent-discovered functions in the dendritic and nuclear compartments are 
still an open field and further investigations are necessary to understand their 
impact on pathology. During the characterization of the CST, the subcellular 
fractionation of HeLa and SHSY5Y cells allowed the isolation of the cytoplasmic 
fraction (CF) and of soluble nuclear (SNF) and chromatin-bound fractions (CBF). 
The western blot analyses of these fractions reveal that CST localizes not only in 
the cytosol as expected, but also in the nuclear compartment. The nuclear 
localization of Tau was described for the first time in neuroblastoma cells and 
then confirmed in neurons, suggesting that Tau may have other roles not strictly 
related to MTs (Loomis et al., 1990; Rady et al., 1995). In order to study the 
function of nuclear Tau and to avoid any interference due to the presence of the 
two fluorophores in the CST construct, the unlabelled Tau 0N4R has been 
employed for the subsequent experiments.  
Tau has been transfected in HeLa, HT22 and differentiated SHSY5Y cells. The 
presence of Tau in the nuclear fraction is supported by previous in vitro 
experiments which demonstrated the interaction of Tau with DNA and by a 
genome-wide study which investigated the DNA regions bound by Tau (Benhelli-
Mokrani et al., 2018; Hua and He, 2003; Padmaraju et al., 2010; Qi et al., 2015; 
Sjöberg et al., 2006). In our experiments we found that Tau is detectable in 
nuclei, confirming that the ability of Tau to translocate into the nucleus is retained 
also in non-neuronal cell lines. Several evidences suggest a role for nuclear Tau 
in nucleolar organization and DNA protection in stress conditions (Maina et al., 
2018; Sjöberg et al., 2006; Sultan et al., 2011; Violet et al., 2014). Moreover, Tau 
has been seen to accumulate in heterochromatin during aging and to alter 
transposons activation suggesting a role in gene expression modulation, still 
debated (Gil et al., 2017; Guo et al., 2018; Sun et al., 2018). In order to clarify the 
nuclear role of Tau in relation to a possible alteration of gene expression, we first 
analysed the accumulation of Tau in the chromatin bound fraction and we found 
that in neuronal cell lines employed there is a detectable amount of endogenous 
Tau that can be significantly increased by Tau overexpression. 
102 
 
Then, we focused on the effect of Tau on genes involved in glutamatergic 
synaptic transmission. A common event occurring during the progression of Tau 
pathology is a strong change in synaptic transmission. In particular, in early 
pathologic stages, glutamate release is increased and correlates with toxic 
hyperexcitability; in late stages a glutamate release impairment can be observed 
(Avila et al., 2017; Crescenzi et al., 2017; Dickerson et al., 2005; Hall et al., 2015; 
Hunsberger et al., 2015; Jadhav et al., 2015; Khadrawyb YA, 2014; Maurin et al., 
2014; Revett et al., 2013). Synaptic glutamate release is dependent by several 
proteins, and the VGluT family has a relevant role by mediating glutamate loading 
into synaptic vesicles (Martineau et al., 2017; Siksou et al., 2013). In tauopathy 
mouse models, glutamate release and VGluT1 levels are increased in the pre-
symptomatic phase of the disease, when Tau is destabilized or oligomeric, while 
a glutamate reduction is observed in late stages, when Tau aggregation is 
established, a behaviour similar to that observed in human brains (Crescenzi et 
al., 2017; Dickerson et al., 2005; Hunsberger et al., 2015; Khadrawyb YA, 2014). 
This suggests that alterations of VGluT1 expression are associated to both the 
stage of the disease and the state of Tau protein, soluble in the cytoplasm or 
aggregated. It is conceivable that the nuclear role of Tau in these two stages 
might be distinct. The increased expression of Tau in HeLa, HT22 and SHSY5Y 
cells induces a significant increase of VGluT1 mRNA and protein that is not 
detectable for VGluT2 and VGluT3, meaning that this modulation is selective and 
specific.  
The over-expression of Tau should mimic the pre-clinical stages of Tau pathology 
when it is unstable on MTs and its levels as soluble monomers are higher in the 
cytoplasm. Moreover, we found that the total increase of Tau favours also a 
significant increase in the nuclear compartment. To provide further supporting 
evidence, cells have been treated with PTX and Noc, chemicals that increase the 
Tau soluble pool by different mechanisms: Tau displacement from MTs or 
cytoskeletal disruption respectively (Kar et al., 2003; Di Primio et al., 2017). Both 
treatments increase Tau in the nucleus, highlighting an equilibrium between 
cytoplasmic and nuclear Tau. Concomitantly, the expression of VGluT1 protein is 
increased. This demonstrates that Tau detachment from MTs not only affects 
MTs stability but also favours its nuclear translocation, thus ultimately affecting 
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VGluT1 expression. A relevant point is that these experiments are performed on 
not-transfected cells, demonstrating that the VGluT1 modulation does not depend 
on Tau overexpression but on endogenous Tau delocalization. Remarkably, 
nuclear Tau and VGluT1 expression have a functional effect on neurons since an 
increased spontaneous synaptic transmission can be observed by patch-clamp 
experiments. In particular, the higher mEPSC frequency indicates a presynaptic 
effect that can be directly linked to higher VGluT1 levels. This 
electrophysiological observation correlates with the neuronal hyperexcitability 
detected in the early-stage tauopathy. The relationship between Tau and VGluT1 
expression has been confirmed also by depletion experiments. As a matter of 
fact, Tau knock-down reduces VGluT1 levels, accounting for a bidirectional 
correlation between the levels of Tau and the expression of VGluT1. 
In the experiments described above, the effect of Tau on VGluT1 has been 
analysed when Tau amount was increased both in the cytosol and in the nucleus. 
In order to discriminate if the effect on gene expression is due to cytoplasmic or 
nuclear Tau, we exploited Tau tagged with NLS or NES. The expression of these 
two constructs shows a disequilibrium of Tau subcellular localization, with Tau-
NLS accumulated in the nucleus while Tau-NES mostly present in the cytosol as 
expected. Remarkably, forcing the nuclear localization of Tau increases VGluT1 
expression at the same level attained by overexpression of untagged Tau. On the 
contrary, by forcing the export of Tau from the nucleus the expression of VGluT1 
returns to control level. This is the first evidence clearly demonstrating that the 
modulation of VGluT1 expression is mainly depend on Tau in the nuclear 
compartment. The fact that the VGluT1 alteration is comparable between 
untagged Tau and Tau-NLS expressing cells might indicate that the amount of 
untagged Tau reaching the nucleus is already saturating. A suggestion about this 
point can be observed in PTX and Noc treated cells, where the increase in 
VGluT1 expression is similar to the one observed in transfected cells but Tau in 
the nucleus is about two fold higher than in untreated cells, indicating that a small 
increase of nuclear Tau is sufficient to significantly alter VGluT1 levels. Altogether 
these results demonstrate that the modulation of VGluT1 expression can be 
triggered by Tau molecules and this effect is exerted in the nuclear compartment.  
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The discovery of this nuclear role of Tau leads to the question if pathological 
mutations or aggregation could affect its function. The expression of the 
tauopathy related P301S or P301L mutations shows two different and 
unexpected effects. Subcellular fractionation indicates that both mutations lead to 
an increase of Tau in the nucleus that is comparable to TauWT. However, when 
we look at the nuclear function, TauP301S is able to induce a significant increase in 
VGluT1 that is not detectable in cells expressing TauP301L. This result indicates 
that P301L mutation causes a loss of function of Tau in the nuclear compartment 
while P301S does not affect nuclear Tau. Intriguingly, previous characterizations 
of these two mutations indicated that they similarly destabilize Tau on MTs and 
induce aggregation leading to pathology. On the contrary, the study of their 
nuclear behaviour demonstrates a significant difference in modulating VGluT1 
expression even if the mechanism is still unclear and under investigation. A 
possibility is that they undergo different post-translational modifications which 
differentially influence nuclear Tau function. Another cause might be the nature of 
the substituted aminoacids since the leucine is apolar and might have a stronger 
impact on Tau properties than the polar serine. The Pro301 residue is located in 
the second repeat of the MTBD that is absent in 3R Tau isoforms so we 
expressed the Tau 0N3R in order to clarify if the absence of R2 could impair the 
modulation of VGluT1 levels. The expression of Tau 0N3R induces an increase 
of VGluT1 comparable to the one observed by Tau 0N4R suggesting that the R2 
is not necessary for Tau nuclear function even if in vitro studies showed that it is 
important for the interaction with DNA (Hua and He, 2003; Qi et al., 2015). 
Moreover, this result suggests that the loss of function caused by the P301L 
mutation is specific and independent from the repeats in the MTBD. Although the 
molecular mechanisms involved are still unclear, a more extensive study on gene 
expression might be performed to elucidate the role of wild-type and mutated Tau 
on the modulation of genes involved in glutamatergic synaptic transmission. It 
would be interesting to investigate whether other pathological mutations impair 
Tau modulation of gene expression.  
This novel function might have a relevant role in the onset of the pathology as it 
has been widely demonstrated that the glutamate release is increased and 
causes hippocampal hyperexcitability in the pre-symptomatic phase of 
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tauopathies. To study the nuclear effect in later stages, Tau aggregation has 
been induced. However, VGluT1 expression is comparable to control cells, 
demonstrating that pathological inclusions impair Tau nuclear function. 
Remarkably, Tau aggregation is an hallmark of late stages of neurodegeneration 
which corresponds to a reduction in the excitability and glutamate release (Braak 
et al., 2006; Dickerson et al., 2005). It’s still unsolved how aggregation affects 
Tau nuclear function, it may aggregate also in the nucleus blocking its function or 
it may alter cytoplasmic mechanisms related to nuclear Tau. A possible 
mechanism has been suggested in a recent study by Benhelli-Mokrani et al. They 
demonstrated that Tau oligomers in neuronal nuclei induce a repression of gene 
expression on specific targets bound directly by Tau (Benhelli-Mokrani et al., 
2018). However further experiments will be performed to better characterize the 
role of Tau aggregation in the nuclear compartment. 
To investigate whether other genes are modulated by Tau a high-throughput 
approach has been employed by RNAseq technique. The overexpression of Tau 
0N4R in differentiated SHSY5Y induces a global transcriptome alteration. Indeed, 
~4000 genes are differentially expressed (DEGs) and GO analysis for cellular 
functions identifies several clusters that are significantly altered and mostly 
related to neurodegeneration. Remarkably the glutamate release pathway cluster 
is represented, suggesting that Tau influences not only VGluT1 expression but 
several genes involved in this function. Moreover, a further analysis reveals that 
Tau alters post-synaptic genes specific for the NMDA receptors, for example 
NMDA subunits GRIN2C and GRIN2D, but not AMPA receptors, demonstrating 
that its function is selective. Remarkably, the post-synaptic modulation has a 
functional counterpart observed by patch-clamp in primary hippocampal neurons. 
As a matter of fact, we observe a significant increase of mEPSC amplitude in 
treated cells which is usually attributed to a post-synaptic effect, supporting the 
transcriptome analysis. Other clusters are deregulated in Tau expressing cells, 
such as those regarding protein synthesis and genome stability, which are also 
altered in AD models and patients (Garcia-Esparcia et al., 2017; Hernández-
Ortega et al., 2016; Sultan et al., 2011). Our transcriptome has been compared to 
a database of hippocampi from patients at different stages of AD in order to 
understand if the genes and clusters identified in our cellular model are also 
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represented in the human pathological context. Indeed, the DEGs observed in 
our model strongly correlate with DEGs individuated in L-MCI patients, while the 
correlation is lower with both E-MCI and AD patients. These evidences suggest 
that Tau overexpression mimics a L-MCI pathological context which generally 
corresponds at cellular level to Tau destabilization and the first step of 
aggregation (Braak et al., 2006; Lowe et al., 2018). These data support our 
cellular model as a reliable and easy system for preliminary studies of Tau 
pathological behaviour in destabilizing conditions, in particular for studies of gene 
modulation and functional alteration. These preliminary results open to further 
experiments in order to clarify how the deregulation of gene expression observed 
in tauopathies is directly caused by Tau protein, in particular by its nuclear pool, 
leading to a new relevant pathological Tau function which can be targeted to 
prevent neurodegeneration. 
It’s a key point to further investigate this function to identify possible targets for 
therapeutic intervention. Since Tau has been seen to bind directly the DNA in the 
nucleus (Benhelli-Mokrani et al., 2018), we evaluated if Tau modulates VGluT1 
levels by acting on its promoter. However, we demonstrated that Tau effect on 
VGluT1 is not directed to the promoter. This result does not exclude that Tau can 
influence VGluT1 expression by interacting directly or indirectly to other 
regulatory genetic regions, such as enhancers or silencers, and this hypothesis 
will be investigated in future experiments. A possible mechanism which could 
explain nuclear Tau alteration of gene expression is that by interacting with other 
proteins, it may influence the expression of genes as a transcription factor or it 
may induce a chromatin modification. Indeed, recent studies suggest that nuclear 
Tau is associated to heterochromatin regions. Analysis of human brains showed 
that Tau phosphorylated at AT100 epitope increases during aging and 
colocalizes with heterochromatin. Moreover, the loss of Tau causes the activation 
of transposons which are usually silenced in heterochromatic regions (Gil et al., 
2017; Guo et al., 2018; Sun et al., 2018). The mechanisms by which Tau 
localizes to the nucleus are still unknown, although it has been shown that the 
interaction of Tau with TRIM28 stabilizes and promotes Tau nuclear 
accumulation. In addition, both nuclear Tau and nuclear TRIM28 are increased in 
AD brains (Rousseaux et al., 2016). Remarkably, TRIM28 is a key nuclear 
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protein whose function is to form a big complex with several interactors, leading 
to chromatin condensation (Barde et al., 2013; Friedman et al., 2007). The 
interaction between Tau and TRIM28 and the association of Tau and 
heterochromatin lead to the hypothesis that nuclear Tau may alter gene 
expression by chromatin remodelling. Our experiments indicate that TRIM28 
expression and subcellular localization is not altered by the increase in Tau 
nuclear levels. Remarkably, by checking the expression of HDAC1, a TRIM28 
well-characterized interactor, a significant reduction can be seen in the 
chromatin-bound fraction confirmed also by immunofluorescence experiments. 
These results suggest that the increase in Tau levels is able to induce a 
delocalization of HDAC1 with no effect on HDAC1 and TRIM28 expression. A 
preliminary co-IP experiment shows that Tau might have a competitive effect on 
HDAC1 for the interaction with TRIM28 which could explain the HDAC1 
delocalization from the chromatin fraction. However, the properties of this 
putative complex have to be further confirmed and investigated and other 
TRIM28 interactors will be considered. The open question is if HDAC1 
delocalization is due to cytoplasmic or nuclear Tau. A preliminary result with Tau-
NES suggests that cytoplasmic Tau does not influence HDAC1 nuclear 
localization, indicating that the competition for the interaction with TRIM28 is 
probably due to the nuclear fraction of Tau. In addition, we evaluated if the 
delocalization of HDAC1 from the chromatin is sufficient to explain the alteration 
of VGluT1 expression observed when Tau levels are increased. To clarify this 
point cells were treated with TSA, an inhibitor of HDACs family members, among 
these HDAC1 (Delcuve et al., 2013). Western blot analysis shows that VGluT1 
levels in TSA-treated cells are higher than control cells and comparable to the 
increase observed in Tau expressing cells, suggesting that the delocalization and 
the impairment of HDAC1 function might induce an increase in VGluT1 
expression. Further investigation is needed as knock-down experiments of 
TRIM28 and HDAC1, Tau effect on other TRIM28 interactors and studies in 
animal models for tauopathies. However, these preliminary results indicate a 
mechanism associated to a Tau-dependent chromatin remodelling which has 
also been observed in a Drosophila model for tauopathies (Frost et al., 2014). 
Remarkably a global chromatin relaxation was also seen in AD human brains, 
with altered levels of HDAC class I and histone acetylation influencing gene 
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expression (Frost et al., 2014; Sun et al., 2018). Another possible mechanism 
explaining the gene expression modulation mediated by nuclear Tau and the 
interaction with TRIM28 can be related to an alteration in the acetylation profile of 
Tau. Indeed, TRIM28 cofactors, in particular proteins of the HDAC family, may 
modify the acetylation of Tau, currently associated to destabilization and 
pathological aggregation, thus altering its nuclear amount or function 
(Carlomagno et al., 2017; Ulrich et al., 2018). Moreover, Tau has been seen to 
interact with HDAC6 in the cytosol reducing its deacetylation activity and 
increasing the acetylation of HDAC6 targets as a consequence (Ding et al., 2008; 
Perez et al., 2009; Selenica et al., 2014). This evidence suggests that other 
mechanisms involving Tau and HDACs have been identified and similar 
processes could also take place in the nuclear compartment with members of the 
same family. However, further studies are necessary such as the identification of 
acetylated residues of Tau in the nucleus and the acetylation level of TRIM28 and 
HDACs targets in presence or absence of Tau. 
Altogether these results indicate that Tau has a role in gene expression 
modulation which can be altered if the protein is destabilized and its soluble 
amount is increased as a consequence. Remarkably, the evidence that nuclear 
Tau affects exclusively VGluT1 expression influencing neuronal excitability, 
suggests that the progressive pathological functional alterations that neurons 
undergo in tauopathies might be dependent more on the unbalancing of soluble 
Tau which becomes more available to be translocated into the nucleus than on 
modifications of cytoplasmic Tau functions. This is also supported by the fact that 
the increase in Tau amount induces not only an increase in VGluT1 levels but 
also a global gene alteration, mimicking specifically a L-MCI condition in patients. 
However, in order to determine which neuronal functions are dependent 
exclusively on nuclear Tau alteration, further studies are needed in particular 
transcriptomic analyses on cells expressing Tau-NLS or Tau-NES will 
discriminate the gene sets modulated by Tau in the nucleus or in the cytosol and 
this experiment will be coupled to functional validations in neuronal cells to 
evaluate that the gene altered by nuclear Tau have a real impact in the cellular 
context. Moreover, to clarify if nuclear Tau could be a new therapeutic target to 
treat tauopathies progression, its role needs to be confirmed in mouse models for 
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tauopathies, focusing on different phases of Tau pathology progression or 
developing a new model in which Tau subcellular localization is unbalanced 
towards the nuclear compartment. Another important point is to understand the 
effect of Tau aggregation on nuclear Tau both in vitro and in vivo, above all in 
relation to the late stages of tauopathies. The discovery of Tau as a gene 
modulator in the nucleus, if its centrality will be confirmed with further 
investigations, could lead to a different way to approach Tau pathologies, not only 
focusing on the aggregate and its spreading but considering a new subcellular 
compartment where Tau is localized. Therapeutic strategies could target different 
aspects of nuclear Tau to prevent its pathological effect for example the 
regulation of its transport into the nucleus or its mechanism in gene modulation or 
cofactors which mediate its nuclear function. 
In conclusion, with this research we investigated Tau alternative functions, a field 
that was underestimated in past decades but that is currently growing due to 
strong evidences which support the importance of these functions both in 
physiology and pathology. In particular, we focused on the nuclear localization of 
Tau which is important in physiology to maintain genome stability but this 
protective action is impaired during tauopathies leading to neuronal damage. We 
discovered an additional Tau function in the nucleus as a matter of fact Tau is 
able to modulate gene expression altering the neuronal excitability in conditions 
mimicking early pathological stages of tauopathies. In addition, this function 
seems related to an effect of Tau on chromatin remodelling suggesting that 
nuclear Tau can be more important than previously hypothesized since a 
chromatin structural reorganization is associated to a global gene alteration, an 
hallmark typical of tauopathies. However further studies are needed to clarify the 
behaviour of nuclear Tau in late pathological stages when Tau is aggregated but 
also a complete picture of the nuclear mechanisms in order to identify a potential 
target to impede the damages caused by Tau functional alteration in the nuclear 
compartment, opening to new therapeutic approaches to challenge the 









Abraha, A., Ghoshal, N., Gamblin, T.C., Cryns, V., Berry, R.W., Kuret, J., and 
Binder, L.I. (2000). C-terminal inhibition of tau assembly in vitro and in 
Alzheimer’s disease. J. Cell Sci. 113 Pt 21, 3737–3745. 
Ahmed, T., Van der Jeugd, A., Blum, D., Galas, M.-C., D’Hooge, R., Buee, L., 
and Balschun, D. (2014). Cognition and hippocampal synaptic plasticity in mice 
with a homozygous tau deletion. Neurobiol. Aging 35, 2474–2478. 
Ali, Y.O., Ruan, K., and Zhai, R.G. (2012). NMNAT suppresses tau-induced 
neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers 
in a Drosophila model of tauopathy. Hum. Mol. Genet. 21, 237–250. 
Allen, B., Ingram, E., Takao, M., Smith, M.J., Jakes, R., Virdee, K., Yoshida, H., 
Holzer, M., Craxton, M., Emson, P.C., et al. (2002). Abundant tau filaments and 
nonapoptotic neurodegeneration in transgenic mice expressing human P301S 
tau protein. J. Neurosci. 22, 9340–9351. 
Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2001). 
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical 
filaments/straight filaments. Proc. Natl. Acad. Sci. U. S. A. 98, 6923–6928. 
Alonso, A. del C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. 
(2004). Promotion of hyperphosphorylation by frontotemporal dementia tau 
mutations. J. Biol. Chem. 279, 34873–34881. 
Alonso, A.D., Grundke-Iqbal, I., Barra, H.S., and Iqbal, K. (1997). Abnormal 
phosphorylation of tau and the mechanism of Alzheimer neurofibrillary 
degeneration: sequestration of microtubule-associated proteins 1 and 2 and the 
disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U. S. A. 
94, 298–303. 
Alonso, A.D., Di Clerico, J., Li, B., Corbo, C.P., Alaniz, M.E., Grundke-Iqbal, I., 
and Iqbal, K. (2010). Phosphorylation of tau at Thr212, Thr231, and Ser262 
combined causes neurodegeneration. J. Biol. Chem. 285, 30851–30860. 




Anders, S., and Huber, W. (2010). Differential expression analysis for sequence 
count data. Genome Biol. 11, R106. 
Andorfer, C.A., and Davies, P. (2000). PKA Phosphorylations on Tau: 
Developmental Studies in the Mouse. Dev. Neurosci. 22, 303–309. 
Andreadis, A., Brown, W.M., and Kosik, K.S. (1992). Structure and novel exons 
of the human tau gene. Biochemistry 31, 10626–10633. 
Arai, T., Ikeda, K., Akiyama, H., Shikamoto, Y., Tsuchiya, K., Yagishita, S., 
Beach, T., Rogers, J., Schwab, C., and McGeer, P.L. (2001). Distinct isoforms of 
tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, 
corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 
101, 167–173. 
Arai, T., Miklossy, J., Klegeris, A., Guo, J.-P., and McGeer, P.L. (2006). Thrombin 
and prothrombin are expressed by neurons and glial cells and accumulate in 
neurofibrillary tangles in Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 
65, 19–25. 
Arendt, T., Stieler, J.T., and Holzer, M. (2016). Tau and tauopathies. Brain Res. 
Bull. 126, 238–292. 
Arriagada, P. V, Growdon, J.H., Hedley-Whyte, E.T., and Hyman, B.T. (1992). 
Neurofibrillary tangles but not senile plaques parallel duration and severity of 
Alzheimer’s disease. Neurology 42, 631–639. 
Avila, J., Lucas, J.J., Perez, M., and Hernandez, F. (2004). Role of tau protein in 
both physiological and pathological conditions. Physiol. Rev. 84, 361–384. 
Avila, J., Llorens-Martín, M., Pallas-Bazarra, N., Bolós, M., Perea, J.R., 
Rodríguez-Matellán, A., and Hernández, F. (2017). Cognitive decline in neuronal 
aging and Alzheimer’s disease: Role of NMDA receptors and associated proteins. 
Front. Neurosci. 11, 1–9. 
Azoury, J., Lee, K.W., Georget, V., Rassinier, P., Leader, B., Curie, M., Bat, C., 
Bernard, Q. Saint, Bat, B., and Bernard, Q. Saint (2008). Report Spindle 
113 
 
Positioning in Mouse Oocytes Relies on a Dynamic Meshwork of Actin Filaments. 
1514–1519. 
Bai, Q., and Burton, E.A. (2011). Zebrafish models of Tauopathy. Biochim. 
Biophys. Acta - Mol. Basis Dis. 1812, 353–363. 
Bai, Q., Garver, J.A., Hukriede, N.A., and Burton, E.A. (2007). Generation of a 
transgenic zebrafish model of Tauopathy using a novel promoter element derived 
from the zebrafish eno2 gene. Nucleic Acids Res. 35, 6501–6516. 
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, 
J., Lynch, T., Bigio, E., and Hutton, M. (1999). Association of an extended 
haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 
8, 711–715. 
Barde, I., Rauwel, B., Marin-Florez, R.M., Corsinotti, A., Laurenti, E., Verp, S., 
Offner, S., Marquis, J., Kapopoulou, A., Vanicek, J., et al. (2013). A KRAB/KAP1-
miRNA Cascade Regulates Erythropoiesis Through Stage-Specific Control of 
Mitophagy. Science (80-. ). 340, 350–353. 
Barghorn, S., and Mandelkow, E. (2002). Toward a unified scheme for the 
aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41, 
14885–14896. 
Beevers, J.E., Lai, M.C., Collins, E., Booth, H.D.E., Zambon, F., Parkkinen, L., 
Vowles, J., Cowley, S.A., Wade-Martins, R., and Caffrey, T.M. (2017). MAPT 
Genetic Variation and Neuronal Maturity Alter Isoform Expression Affecting 
Axonal Transport in iPSC-Derived Dopamine Neurons. Stem Cell Reports 9, 
587–599. 
Benhelli-Mokrani, H., Mansuroglu, Z., Chauderlier, A., Albaud, B., Gentien, D., 
Sommer, S., Schirmer, C., Laqueuvre, L., Josse, T., Buée, L., et al. (2018). 
Genome-wide identification of genic and intergenic neuronal DNA regions bound 
by Tau protein under physiological and stress conditions. Nucleic Acids Res. 1, 
1–18. 
Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., Smith, G.P., Milton, J., 
Brown, C.G., Hall, K.P., Evers, D.J., Barnes, C.L., Bignell, H.R., et al. (2008). 
114 
 
Accurate whole human genome sequencing using reversible terminator 
chemistry. Nature 456, 53–59. 
von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E.M., and 
Mandelkow, E. (2000). Assembly of tau protein into Alzheimer paired helical 
filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta 
structure. Proc. Natl. Acad. Sci. U. S. A. 97, 5129–5134. 
Bertrand, J., Plouffe, V., Sénéchal, P., and Leclerc, N. (2010). The pattern of 
human tau phosphorylation is the result of priming and feedback events in 
primary hippocampal neurons. Neuroscience 168, 323–334. 
Bibow, S., Ozenne, V., Biernat, J., Blackledge, M., Mandelkow, E., and 
Zweckstetter, M. (2011). Structural Impact of Proline-Directed 
Pseudophosphorylation at AT8, AT100, and PHF1 Epitopes on 441-Residue Tau. 
J. Am. Chem. Soc. 133, 15842–15845. 
Bier, E. (2005). Drosophila, the golden bug, emerges as a tool for human 
genetics. Nat. Rev. Genet. 6, 9–23. 
Bilen, J., and Bonini, N.M. (2005). Drosophila as a Model for Human 
Neurodegenerative Disease. Annu. Rev. Genet. 39, 153–171. 
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., 
Fridman, W.-H., Pagès, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a 
Cytoscape plug-in to decipher functionally grouped gene ontology and pathway 
annotation networks. Bioinformatics 25, 1091–1093. 
Binder, L.I., Frankfurter, A., and Rebhun, L.I. (1985). The distribution of tau in the 
mammalian central nervous system. J. Cell Biol. 101, 1371–1378. 
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane 
Database Syst. Rev. CD005593. 
Boekhoorn, K., Terwel, D., Biemans, B., Borghgraef, P., Wiegert, O., Ramakers, 
G.J.A., de Vos, K., Krugers, H., Tomiyama, T., Mori, H., et al. (2006). Improved 
long-term potentiation and memory in young tau-P301L transgenic mice before 
onset of hyperphosphorylation and tauopathy. J. Neurosci. 26, 3514–3523. 
115 
 
Bondulich, M.K., Guo, T., Meehan, C., Manion, J., Rodriguez Martin, T., Mitchell, 
J.C., Hortobagyi, T., Yankova, N., Stygelbout, V., Brion, J.-P., et al. (2016). 
Tauopathy induced by low level expression of a human brain-derived tau 
fragment in mice is rescued by phenylbutyrate. Brain 139, 2290–2306. 
Bonneau, C., Gurard-Levin, Z.A., Andre, F., Pusztai, L., and Rouzier, R. (2015). 
Predictive and prognostic value of the Tau protein in breast cancer. Anticancer 
Res. 35, 5179–5184. 
Braak, H., Braak, E., and Strothjohann, M. (1994). Abnormally phosphorylated 
tau protein related to the formation of neurofibrillary tangles and neuropil threads 
in the cerebral cortex of sheep and goat. Neurosci. Lett. 171, 1–4. 
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., and Del Tredici, K. (2006). 
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin 
sections and immunocytochemistry. Acta Neuropathol. 112, 389–404. 
Bretteville, A., Marcouiller, F., Julien, C., El Khoury, N.B., Petry, F.R., Poitras, I., 
Mouginot, D., Lévesque, G., Hébert, S.S., and Planel, E. (2012). Hypothermia-
induced hyperphosphorylation: a new model to study tau kinase inhibitors. Sci. 
Rep. 2, 480. 
Breuzard, G., Hubert, P., Nouar, R., De Bessa, T., Devred, F., Barbier, P., 
Sturgis, J.N., and Peyrot, V. (2013). Molecular mechanisms of Tau binding to 
microtubules and its role in microtubule dynamics in live cells. J. Cell Sci. 126, 
2810–2819. 
Buée-Scherrer, V., Hof, P.R., Buée, L., Leveugle, B., Vermersch, P., Perl, D.P., 
Olanow, C.W., and Delacourte, A. (1996). Hyperphosphorylated tau proteins 
differentiate corticobasal degeneration and Pick’s disease. Acta Neuropathol. 91, 
351–359. 
Bugiani, O., Murrell, J.R., Giaccone, G., Hasegawa, M., Ghigo, G., Tabaton, M., 
Morbin, M., Primavera, A., Carella, F., Solaro, C., et al. (1999). Frontotemporal 
dementia and corticobasal degeneration in a family with a P301S mutation in tau. 
J. Neuropathol. Exp. Neurol. 58, 667–677. 
Caffrey, T.M., Joachim, C., Paracchini, S., Esiri, M.M., and Wade-Martins, R. 
116 
 
(2006). Haplotype-specific expression of exon 10 at the human MAPT locus. 
Hum. Mol. Genet. 15, 3529–3537. 
Carlomagno, Y., Chung, D.C., Yue, M., Castanedes-Casey, M., Madden, B.J., 
Dunmore, J., Tong, J., DeTure, M., Dickson, D.W., Petrucelli, L., et al. (2017). An 
acetylation–phosphorylation switch that regulates tau aggregation propensity and 
function. J. Biol. Chem. 292, 15277–15286. 
Carlyle, B.C., Nairn, A.C., Wang, M., Yang, Y., Jin, L.E., Simen, A.A., Ramos, 
B.P., Bordner, K.A., Craft, G.E., Davies, P., et al. (2014). cAMP-PKA 
phosphorylation of tau confers risk for degeneration in aging association cortex. 
Proc. Natl. Acad. Sci. 111, 5036–5041. 
Cataldo, A.M., Barnett, J.L., Pieroni, C., and Nixon, R.A. (1997). Increased 
neuronal endocytosis and protease delivery to early endosomes in sporadic 
Alzheimer’s disease: neuropathologic evidence for a mechanism of increased 
beta-amyloidogenesis. J. Neurosci. 17, 6142–6151. 
Chauderlier, A., Gilles, M., Spolcova, A., Caillierez, R., Chwastyniak, M., Kress, 
M., Drobecq, H., Bonnefoy, E., Pinet, F., Weil, D., et al. (2018). Tau/DDX6 
interaction increases microRNA activity. Biochim. Biophys. Acta. Gene Regul. 
Mech. 1861, 762–772. 
Chen, J., Kanai, Y., Cowan, N.J., and Hirokawa, N. (1992). Projection domains of 
MAP2 and tau determine spacings between microtubules in dendrites and axons. 
Nature 360, 674–677. 
Cho, J.-H., and Johnson, G.V.W. (2003). Glycogen synthase kinase 3beta 
phosphorylates tau at both primed and unprimed sites. Differential impact on 
microtubule binding. J. Biol. Chem. 278, 187–193. 
Cho, J.-H., and Johnson, G.V.W. (2004). Glycogen synthase kinase 3 beta 
induces caspase-cleaved tau aggregation in situ. J. Biol. Chem. 279, 54716–
54723. 
Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., Probst, 
A., Fraser, G., Stalder, A.K., Beibel, M., Staufenbiel, M., et al. (2009). 
Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell 
117 
 
Biol. 11, 909–913. 
Cleveland, D.W., Hwo, S.Y., and Kirschner, M.W. (1977). Purification of tau, a 
microtubule-associated protein that induces assembly of microtubules from 
purified tubulin. J. Mol. Biol. 116, 207–225. 
Cohen, T.J., Guo, J.L., Hurtado, D.E., Kwong, L.K., Mills, I.P., Trojanowski, J.Q., 
and Lee, V.M.Y. (2011). The acetylation of tau inhibits its function and promotes 
pathological tau aggregation. Nat. Commun. 2, 252. 
Colodner, K.J., and Feany, M.B. (2010). Glial fibrillary tangles and JAK/STAT-
mediated glial and neuronal cell death in a Drosophila model of glial tauopathy. J. 
Neurosci. 30, 16102–16113. 
Le Corre, S., Klafki, H.W., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, 
H., Monse, B., Seneci, P., Lewis, J., Eriksen, J., et al. (2006). An inhibitor of tau 
hyperphosphorylation prevents severe motor impairments in tau transgenic mice. 
Proc. Natl. Acad. Sci. U. S. A. 103, 9673–9678. 
Costes, S. V., Daelemans, D., Cho, E.H., Dobbin, Z., Pavlakis, G., and Lockett, 
S. (2004). Automatic and quantitative measurement of protein-protein 
colocalization in live cells. Biophys. J. 86, 3993–4003. 
Crescenzi, R., DeBrosse, C., Nanga, R.P.R., Byrne, M.D., Krishnamoorthy, G., 
D’Aquilla, K., Nath, H., Morales, K.H., Iba, M., Hariharan, H., et al. (2017). 
Longitudinal imaging reveals sub-hippocampal dynamics in glutamate levels 
associated with histopathologic events in a mouse model of tauopathy and 
healthy mice. Hippocampus 27, 285–302. 
Cruz, J.C., Tseng, H.-C., Goldman, J.A., Shih, H., and Tsai, L.-H. (2003). 
Aberrant Cdk5 activation by p25 triggers pathological events leading to 
neurodegeneration and neurofibrillary tangles. Neuron 40, 471–483. 
Crystal, A.S., Giasson, B.I., Crowe, A., Kung, M.P., Zhuang, Z.P., Trojanowski, 
J.Q., and Lee, V.M.Y. (2003). A comparison of amyloid fibrillogenesis using the 
novel fluorescent compound K114. J. Neurochem. 86, 1359–1368. 
Daebel, V., Chinnathambi, S., Biernat, J., Schwalbe, M., Habenstein, B., Loquet, 
118 
 
A., Akoury, E., Tepper, K., Müller, H., Baldus, M., et al. (2012). β-Sheet core of 
tau paired helical filaments revealed by solid-state NMR. J. Am. Chem. Soc. 134, 
13982–13989. 
Daly, N.L., Hoffmann, R., Otvos, L., and Craik, D.J. (2000). Role of 
phosphorylation in the conformation of tau peptides implicated in Alzheimer’s 
disease. Biochemistry 39, 9039–9046. 
Dayanandan, R., Van Slegtenhorst, M., Mack, T.G.A., Ko, L., Yen, S.-H., Leroy, 
K., Brion, J.-P., Anderton, B.H., Hutton, M., and Lovestone, S. (1999). Mutations 
in tau reduce its microtubule binding properties in intact cells and affect its 
phosphorylation. FEBS Lett. 446, 228–232. 
Delacourte, A., Robitaille, Y., Sergeant, N., Buée, L., Hof, P.R., Wattez, A., 
Laroche-Cholette, A., Mathieu, J., Chagnon, P., and Gauvreau, D. (1996). 
Specific pathological Tau protein variants characterize Pick’s disease. J. 
Neuropathol. Exp. Neurol. 55, 159–168. 
Delcuve, G., Khan, D., and Davie, J. (2013). Roles of Histone Deacetylases in 
Epigenetic Regulation. Epigenetics Pathol. 143–172. 
Devos, S.L., Miller, R.L., Schoch, K.M., Holmes, B.B., Kebodeaux, C.S., 
Wegener, A.J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017). Tau 
reduction prevents neuronal loss and reverses pathological tau deposition and 
seeding in mice with tauopathy. 0481. 
DeVos, S.L., Goncharoff, D.K., Chen, G., Kebodeaux, C.S., Yamada, K., Stewart, 
F.R., Schuler, D.R., Maloney, S.E., Wozniak, D.F., Rigo, F., et al. (2013). 
Antisense Reduction of Tau in Adult Mice Protects against Seizures. J. Neurosci. 
33, 12887–12897. 
DeVos, S.L., Corjuc, B.T., Commins, C., Dujardin, S., Bannon, R.N., Corjuc, D., 
Moore, B.D., Bennett, R.E., Jorfi, M., Gonzales, J.A., et al. (2018). Tau reduction 
in the presence of amyloid-β prevents tau pathology and neuronal death in vivo. 
Brain 141, 2194–2212. 
Dickerson, B.C., Salat, D.H., Greve, D.N., Chua, E.F., Rand-Giovannetti, E., 
Rentz, D.M., Bertram, L., Mullin, K., Tanzi, R.E., Blacker, D., et al. (2005). 
119 
 
Increased hippocampal activation in mild cognitive impairment compared to 
normal aging and AD. Neurology 65, 404–411. 
Ding, H., Dolan, P.J., and Johnson, G.V.W. (2008). Histone deacetylase 6 
interacts with the microtubule-associated protein tau. J. Neurochem. 106, 2119–
2130. 
Dixit, R., Ross, J.L., Goldman, Y.E., and Holzbaur, E.L.F. (2008). Differential 
regulation of dynein and kinesin motor proteins by tau. Science 319, 1086–1089. 
Dotti, C.G., Banker, G.A., and Binder, L.I. (1987). The expression and distribution 
of the microtubule-associated proteins tau and microtubule-associated protein 2 
in hippocampal neurons in the rat in situ and in cell culture. Neuroscience 23, 
121–130. 
Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and 
Mandelkow, E. (1998). Overexpression of tau protein inhibits kinesin-dependent 
trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for 
Alzheimer’s disease. J. Cell Biol. 143, 777–794. 
Eckermann, K., Mocanu, M.-M., Khlistunova, I., Biernat, J., Nissen, A., Hofmann, 
A., Schönig, K., Bujard, H., Haemisch, A., Mandelkow, E., et al. (2007). The beta-
propensity of Tau determines aggregation and synaptic loss in inducible mouse 
models of tauopathy. J. Biol. Chem. 282, 31755–31765. 
Feige, J.N., Sage, D., Wahli, W., Desvergne, B., and Gelman, L. (2005). 
PixFRET, an ImageJ plug-in for FRET calculation that can accommodate 
variations in spectral bleed-throughs. Microsc. Res. Tech. 68, 51–58. 
Filipcik, P., Zilka, N., Bugos, O., Kucerak, J., Koson, P., Novak, P., and Novak, 
M. (2012). First transgenic rat model developing progressive cortical 
neurofibrillary tangles. Neurobiol. Aging 33, 1448–1456. 
Fitzpatrick, A.W.P., Falcon, B., He, S., Murzin, A.G., Murshudov, G., Garringer, 
H.J., Crowther, R.A., Ghetti, B., Goedert, M., and Scheres, S.H.W. (2017). Cryo-
EM structures of tau filaments from Alzheimer’s disease. Nature 547, 185–190. 
Förster, T. (1948). Zwischenmolekulare Energiewanderung und Fluoreszenz. 
120 
 
Ann. Phys. 437, 55–75. 
Frandemiche, M.L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., Lante, 
F., and Buisson, A. (2014). Activity-Dependent Tau Protein Translocation to 
Excitatory Synapse Is Disrupted by Exposure to Amyloid-Beta Oligomers. J. 
Neurosci. 34, 6084–6097. 
Friedman, J.R., Neilson, E.G., Speicher, D.W., Rauscher, F.J., Fredericks, W.J., 
Jensen, D.E., and Huang, X.P. (2007). KAP-1, a novel corepressor for the highly 
conserved KRAB repression domain. Genes Dev. 10, 2067–2078. 
Frost, B., Jacks, R.L., and Diamond, M.I. (2009). Propagation of tau misfolding 
from the outside to the inside of a cell. J. Biol. Chem. 284, 12845–12852. 
Frost, B., Hemberg, M., Lewis, J., and Feany, M.B. (2014). Tau promotes 
neurodegeneration through global chromatin relaxation. Nat. Neurosci. 17, 357–
366. 
Futerman, A.H., and Banker, G.A. (1996). The economics of neurite outgrowth--
the addition of new membrane to growing axons. Trends Neurosci. 19, 144–149. 
Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., 
Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003). Caspase cleavage of 
tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc. Natl. 
Acad. Sci. U. S. A. 100, 10032–10037. 
Garcia-Esparcia, P., Sideris-Lampretsas, G., Hernandez-Ortega, K., Grau-Rivera, 
O., Sklaviadis, T., Gelpi, E., and Ferrer, I. (2017). Altered mechanisms of protein 
synthesis in frontal cortex in Alzheimer disease and a mouse model. Am. J. 
Neurodegener. Dis. 6, 15–25. 
Gil, L., Federico, C., Pinedo, F., Bruno, F., Rebolledo, A.B., Montoya, J.J., 
Olazabal, I.M., Ferrer, I., and Saccone, S. (2017). Aging dependent effect of 
nuclear tau. Brain Res. 1677, 129–137. 
Gistelinck, M., Lambert, J.-C., Callaerts, P., Dermaut, B., and Dourlen, P. (2012). 
Drosophila Models of Tauopathies: What Have We Learned? Int. J. Alzheimers. 
Dis. 2012, 1–14. 
121 
 
Goedert, M., and Jakes, R. (1990). Expression of sepearate isoforms of human 
tau protein. Embo 9, 4225–4230. 
Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., and Crowther, R.A. 
(1989a). Multiple isoforms of human microtubule-associated protein tau: 
sequences and localization in neurofibrillary tangles of Alzheimer’s disease. 
Neuron 3, 519–526. 
Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J., and Crowther, R.A. 
(1989b). Cloning and sequencing of the cDNA encoding an isoform of 
microtubule-associated protein tau containing four tandem repeats: differential 
expression of tau protein mRNAs in human brain. EMBO J. 8, 393–399. 
Goedert, M., Spillantini, M.G., and Crowther, R.A. (1992). Cloning of a big tau 
microtubule-associated protein characteristic of the peripheral nervous system. 
Proc. Natl. Acad. Sci. 89, 1983–1987. 
Goedert, M., Jakes, R., and Crowther, R.A. (1999). Effects of frontotemporal 
dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. 
FEBS Lett. 450, 306–311. 
Gómez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., 
Parisi, J.E., and Hyman, B.T. (1997). Neuronal loss correlates with but exceeds 
neurofibrillary tangles in Alzheimer’s disease. Ann. Neurol. 41, 17–24. 
Gómez de Barreda, E., Dawson, H.N., Vitek, M.P., and Avila, J. (2010). Tau 
deficiency leads to the upregulation of BAF-57, a protein involved in neuron-
specific gene repression. FEBS Lett. 584, 2265–2270. 
Gong, C.-X., Liu, F., Grundke-Iqbal, I., and Iqbal, K. (2005). Post-translational 
modifications of tau protein in Alzheimer’s disease. J. Neural Transm. 112, 813–
838. 
Gong, C.X., Singh, T.J., Grundke-Iqbal, I., and Iqbal, K. (1993). Phosphoprotein 
phosphatase activities in Alzheimer disease brain. J. Neurochem. 61, 921–927. 
Gu, Y., Oyama, F., and Ihara, Y. (1996). Tau is widely expressed in rat tissues. J. 
Neurochem. 67, 1235–1244. 
122 
 
Guillozet-Bongaarts, A.L., Garcia-Sierra, F., Reynolds, M.R., Horowitz, P.M., Fu, 
Y., Wang, T., Cahill, M.E., Bigio, E.H., Berry, R.W., and Binder, L.I. (2005). Tau 
truncation during neurofibrillary tangle evolution in Alzheimer’s disease. 
Neurobiol. Aging 26, 1015–1022. 
Guillozet-Bongaarts, A.L., Cahill, M.E., Cryns, V.L., Reynolds, M.R., Berry, R.W., 
and Binder, L.I. (2006). Pseudophosphorylation of tau at serine 422 inhibits 
caspase cleavage: in vitro evidence and implications for tangle formation in vivo. 
J. Neurochem. 97, 1005–1014. 
Guo, C., Jeong, H.H., Hsieh, Y.C., Klein, H.U., Bennett, D.A., De Jager, P.L., Liu, 
Z., and Shulman, J.M. (2018). Tau Activates Transposable Elements in 
Alzheimer’s Disease. Cell Rep. 23, 2874–2880. 
Guo, J.-P., Arai, T., Miklossy, J., and McGeer, P.L. (2006). Abeta and tau form 
soluble complexes that may promote self aggregation of both into the insoluble 
forms observed in Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 103, 
1953–1958. 
Guo, T., Noble, W., and Hanger, D.P. (2017). Roles of tau protein in health and 
disease. Acta Neuropathol. 133, 665–704. 
Haase, C., Stieler, J.T., Arendt, T., and Holzer, M. (2004). 
Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. 
Neurochem. 88, 1509–1520. 
Haberland, M., Montgomery, R.L., and Olson, E.N. (2011). Physiology : 
Implications for Disease and Therapy. Nat. Rev. Genet. 10, 32–42. 
Hall, A.M., Throesch, B.T., Buckingham, S.C., Markwardt, S.J., Peng, Y., Wang, 
Q., Hoffman, D.A., and Roberson, E.D. (2015). Tau-Dependent Kv4.2 Depletion 
and Dendritic Hyperexcitability in a Mouse Model of Alzheimer’s Disease. J. 
Neurosci. 35, 6221–6230. 
Hanger, D.P., Anderton, B.H., and Noble, W. (2009). Tau phosphorylation: the 




Hardcastle, T.J., and Kelly, K.A. (2010). baySeq: Empirical Bayesian methods for 
identifying differential expression in sequence count data. BMC Bioinformatics 
11, 422. 
Hasegawa, M., Smith, M.J., and Goedert, M. (1998a). Tau proteins with FTDP-17 
mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 
437, 207–210. 
Hasegawa, M., Smith, M.J., and Goedert, M. (1998b). Tau proteins with FTDP-17 
mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 
437, 207–210. 
Henderson, Y.C., Chen, Y., Frederick, M.J., Lai, S.Y., and Gary, L. (2011). MEK 
Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid 
Carcinoma Cells In vitro and In vivo. Mol. Cancer Ther. 9, 1968–1976. 
Hernández-Ortega, K., Garcia-Esparcia, P., Gil, L., Lucas, J.J., and Ferrer, I. 
(2016). Altered Machinery of Protein Synthesis in Alzheimer’s: From the 
Nucleolus to the Ribosome. Brain Pathol. 26, 593–605. 
Hernández, F., García-García, E., and Avila, J. (2013). Microtubule 
Depolymerization and Tau Phosphorylation. J. Alzheimer’s Dis. 37, 507–513. 
Himmel, M., Ritter, A., Rothemund, S., Pauling, V., Rottner, K., Gingras, A.R., 
and Ziegler, W.H. (2009). Control of High Affinity Interactions in the Talin C 
Terminus. 284, 13832–13842. 
Hirokawa, N., Shiomura, Y., and Okabe, S. (1988). Tau proteins: the molecular 
structure and mode of binding on microtubules. J. Cell Biol. 107, 1449–1459. 
Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., 
and Bogousslavsky, J. (2004). D-JNKI1, a cell-penetrating c-Jun-N-terminal 
kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 
35, 1738–1743. 
Holmes, B.B., Furman, J.L., Mahan, T.E., Yamasaki, T.R., Mirbaha, H., Eades, 
W.C., Belaygorod, L., Cairns, N.J., Holtzman, D.M., and Diamond, M.I. (2014). 




Holth, J.K., Bomben, V.C., Reed, J.G., Inoue, T., Younkin, L., Younkin, S.G., 
Pautler, R.G., Botas, J., and Noebels, J.L. (2013). Tau loss attenuates neuronal 
network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. 
Neurosci. 33, 1651–1659. 
Hua, Q., and He, R.Q. (2003). Tau could protect DNA double helix structure. 
Biochim. Biophys. Acta - Proteins Proteomics 1645, 205–211. 
Hunsberger, H.C., Rudy, C.C., Batten, S.R., Gerhardt, G.A., and Reed, N. 
(2015). P301L Tau Expression Affects Glutamate Release and Clearance in the 
Hippocampal Trisynaptic Pathway. J Neurochem. 132, 169–182. 
Hutton, M. (2006). Molecular Genetics of Chromosome 17 Tauopathies. Ann. N. 
Y. Acad. Sci. 920, 63–73. 
Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H.H., 
Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998). 
Association of missense and 5’-splice-site mutations in tau with the inherited 
dementia FTDP-17. Nature 393, 702–704. 
Hwang, S.C., Jhon, D.-Y., Bae, Y.S., Kim, J.H., and Rhee, S.G. (1996). Activation 
of Phospholipase C-γ by the Concerted Action of Tau Proteins and Arachidonic 
Acid. J. Biol. Chem. 271, 18342–18349. 
Ingelson, M., Vanmechelen, E., and Lannfelt, L. (1996). Microtubule-associated 
protein tau in human fibroblasts with the Swedish Alzheimer mutation. Neurosci. 
Lett. 220, 9–12. 
Irwin, D.J., Cohen, T.J., Grossman, M., Arnold, S.E., Xie, S.X., Lee, V.M.-Y., and 
Trojanowski, J.Q. (2012). Acetylated tau, a novel pathological signature in 
Alzheimer’s disease and other tauopathies. Brain 135, 807–818. 
Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, 
H., Chieng, B.C., Christie, M.J., Napier, I.A., et al. (2010). Dendritic function of 




Iyengar, S., and Farnham, P.J. (2011). KAP1 protein: an enigmatic master 
regulator of the genome. J. Biol. Chem. 286, 26267–26276. 
Jadhav, S., Cubinkova, V., Zimova, I., Brezovakova, V., Madari, A., Cigankova, 
V., and Zilka, N. (2015). Tau-mediated synaptic damage in Alzheimer’s disease. 
Transl. Neurosci. 6, 214–226. 
Jeganathan, S., Bergen, M. Von, and Brutlach, H. (2006). Global Hairpin Folding 
of Tau in Solution †. 2283–2293. 
Van der Jeugd, A., Ahmed, T., Burnouf, S., Belarbi, K., Hamdame, M., Grosjean, 
M.-E., Humez, S., Balschun, D., Blum, D., Buée, L., et al. (2011). Hippocampal 
tauopathy in tau transgenic mice coincides with impaired hippocampus-
dependent learning and memory, and attenuated late-phase long-term 
depression of synaptic transmission. Neurobiol. Learn. Mem. 95, 296–304. 
Johnson, G.V.W. (2004). Tau phosphorylation in neuronal cell function and 
dysfunction. J. Cell Sci. 117, 5721–5729. 
Kaláb, P., and Soderholm, J. (2010). The design of Förster (fluorescence) 
resonance energy transfer (FRET)-based molecular sensors for Ran GTPase. 
Methods 51, 220–232. 
Kar, S., Fan, J., Smith, M.J., Goedert, M., and Amos, L.A. (2003). Repeat motifs 
of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 22, 
70–77. 
Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., 
Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., et al. (2008). A 
quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132. 
Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M., and Diamond, M.I. (2012). 
Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. J. Biol. Chem. 
287, 19440–19451. 
Khadrawyb YA, E.H. (2014). Glutamate Excitotoxicity and Neurodegeneration. J. 
Mol. Genet. Med. 08, 8–11. 
KIDD, M. (1963). Paired helical filaments in electron microscopy of Alzheimer’s 
126 
 
disease. Nature 197, 192–193. 
Kim, C.H., Ueshima, E., Muraoka, O., Tanaka, H., Yeo, S.Y., Huh, T.L., and Miki, 
N. (1996). Zebrafish elav/HuC homologue as a very early neuronal marker. 
Neurosci. Lett. 216, 109–112. 
Kim, W., Lee, S., Jung, C., Ahmed, A., Lee, G., and Hall, G.F. (2010). 
Interneuronal transfer of human tau between Lamprey central neurons in situ. J. 
Alzheimers. Dis. 19, 647–664. 
Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C.M., Irizarry, M.C., and Hyman, 
B.T. (2003). Demonstration by FRET of BACE interaction with the amyloid 
precursor protein at the cell surface and in early endosomes. J. Cell Sci. 116, 
3339–3346. 
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., and Ripova, D. (2012). 
Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers. 
Dis. 2012, 731526. 
Kontsekova, E., Zilka, N., Kovacech, B., Novak, P., and Novak, M. (2014). First-
in-man tau vaccine targeting structural determinants essential for pathological 
tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in 
an Alzheimer’s disease model. Alzheimer’s Res. Ther. 6, 1–12. 
Kosmidis, S., Grammenoudi, S., Papanikolopoulou, K., and Skoulakis, E.M.C. 
(2010). Differential effects of Tau on the integrity and function of neurons 
essential for learning in Drosophila. J. Neurosci. 30, 464–477. 
Kremer, A., Maurin, H., Demedts, D., Devijver, H., Borghgraef, P., and Van 
Leuven, F. (2011). Early improved and late defective cognition is reflected by 
dendritic spines in Tau.P301L mice. J. Neurosci. 31, 18036–18047. 
KrishnaKumar, V.G., and Gupta, S. (2017). Simplified method to obtain enhanced 
expression of tau protein from E. coli and one-step purification by direct boiling. 
Prep. Biochem. Biotechnol. 47, 530–538. 
Kwok, J.B.J., Teber, E.T., Loy, C., Hallupp, M., Nicholson, G., Mellick, G.D., 
Buchanan, D.D., Silburn, P.A., and Schofield, P.R. (2004). Tau haplotypes 
127 
 
regulate transcription and are associated with Parkinson’s disease. Ann. Neurol. 
55, 329–334. 
Lane, C.A., Hardy, J., and Schott, J.M. (2018). Alzheimer’s disease. Eur. J. 
Neurol. 25, 59–70. 
Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and 
memory-efficient alignment of short DNA sequences to the human genome. 
Genome Biol. 10, R25. 
Lau, D.H.W., Hogseth, M., Phillips, E.C., O’Neill, M.J., Pooler, A.M., Noble, W., 
and Hanger, D.P. (2016). Critical residues involved in tau binding to fyn: 
implications for tau phosphorylation in Alzheimer’s disease. Acta Neuropathol. 
Commun. 4, 49. 
Lee, M., Kwon, Y.T., Li, M., Peng, J., Friedlander, R.M., and Tsai, L.-H. (2000). 
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360–364. 
Lee, V.M.-Y., Goedert, M., and Trojanowski, J.Q. (2001). Neurodegenerative 
Tauopathies. Annu. Rev. Neurosci. 24, 1121–1159. 
Leugers, C.J., and Lee, G. (2010). Tau potentiates nerve growth factor-induced 
mitogen-activated protein kinase signaling and neurite initiation without a 
requirement for microtubule binding. J. Biol. Chem. 285, 19125–19134. 
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van 
Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., et al. 
(2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in 
mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402–405. 
Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, 
S.H., Sahara, N., Skipper, L., Yager, D., et al. (2001). Enhanced neurofibrillary 
degeneration in transgenic mice expressing mutant tau and APP. Science 293, 
1487–1491. 
Liu, C., and Götz, J. (2013). Profiling Murine Tau with 0N, 1N and 2N Isoform-
Specific Antibodies in Brain and Peripheral Organs Reveals Distinct Subcellular 




Liu, F., and Gong, C.-X. (2008). Tau exon 10 alternative splicing and tauopathies. 
Mol. Neurodegener. 3, 8. 
Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C.-X. (2005). Contributions of 
protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau 
phosphorylation. Eur. J. Neurosci. 22, 1942–1950. 
Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., and 
Gong, C.-X. (2009). Reduced O-GlcNAcylation links lower brain glucose 
metabolism and tau pathology in Alzheimer’s disease. Brain 132, 1820–1832. 
Loomis, P. a, Howard, T.H., Castleberry, R.P., and Binder, L.I. (1990). 
Identification of nuclear tau isoforms in human neuroblastoma cells. Proc Natl 
Acad Sci U S A 87, 8422–8426. 
Lowe, V.J., Wiste, H.J., Senjem, M.L., Weigand, S.D., Therneau, T.M., Boeve, 
B.F., Josephs, K.A., Fang, P., Pandey, M.K., Murray, M.E., et al. (2018). 
Widespread brain tau and its association with ageing, Braak stage and 
Alzheimer’s dementia. Brain 141, 271–287. 
Lu, M., and Kosik, K.S. (2001). Competition for microtubule-binding with dual 
expression of tau missense and splice isoforms. Mol. Biol. Cell 12, 171–184. 
Luna-Munoz, J., R., C., M., C., Flores-Rodriguez, P., Avila, J., R., S., la Cruz, F. 
De, Mena, R., A., M., and Floran-Garduno, B. (2013). Phosphorylation of Tau 
Protein Associated as a Protective Mechanism in the Presence of Toxic, C-
Terminally Truncated Tau in Alzheimer’s Disease. In Understanding Alzheimer’s 
Disease, (InTech), p. 
Luna-Muñoz, J., Peralta-Ramirez, J., Chávez-Macías, L., Harrington, C.R., 
Wischik, C.M., and Mena, R. (2008). Thiazin red as a neuropathological tool for 
the rapid diagnosis of Alzheimer’s disease in tissue imprints. Acta Neuropathol. 
116, 507–515. 
Maccioni, R.B., Otth, C., Concha, I.I., and Muñoz, J.P. (2001). The protein kinase 
Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer’s 
129 
 
pathology. Eur. J. Biochem. 268, 1518–1527. 
Magnani, E., Fan, J., Gasparini, L., Golding, M., Williams, M., Schiavo, G., 
Goedert, M., Amos, L.A., and Spillantini, M.G. (2007). Interaction of tau protein 
with the dynactin complex. EMBO J. 26, 4546–4554. 
Maina, M.B., Bailey, L.J., Wagih, S., Biasetti, L., Pollack, S.J., Quinn, J.P., 
Thorpe, J.R., Doherty, A.J., and Serpell, L.C. (2018). The involvement of tau in 
nucleolar transcription and the stress response. Acta Neuropathol. Commun. 6, 
70. 
Mainardi, M., Spinelli, M., Scala, F., Mattera, A., Fusco, S., D’Ascenzo, M., and 
Grassi, C. (2017). Loss of Leptin-Induced Modulation of Hippocampal Synaptic 
Trasmission and Signal Transduction in High-Fat Diet-Fed Mice. Front. Cell. 
Neurosci. 11, 1–11. 
Makin, S. (2018). The amyloid hypothesis on trial. Nature 559, S4–S7. 
Makrides, V., Massie, M.R., Feinstein, S.C., and Lew, J. (2004). Evidence for two 
distinct binding sites for tau on microtubules. 1–6. 
Mandell, J.W., and Banker, G.A. (1996). A spatial gradient of tau protein 
phosphorylation in nascent axons. J. Neurosci. 16, 5727–5740. 
Di Maria, E., Tabaton, M., Vigo, T., Abbruzzese, G., Bellone, E., Donati, C., 
Frasson, E., Marchese, R., Montagna, P., Munoz, D.G., et al. (2000). 
Corticobasal degeneration shares a common genetic background with 
progressive supranuclear palsy. Ann. Neurol. 47, 374–377. 
Martineau, M., Guzman, R.E., Fahlke, C., and Klingauf, J. (2017). VGLUT1 
functions as a glutamate/proton exchanger with chloride channel activity in 
hippocampal glutamatergic synapses. Nat. Commun. 8. 
Maurin, H., Chong, S.A., Kraev, I., Davies, H., Kremer, A., Seymour, C.M., 
Lechat, B., Jaworski, T., Borghgraef, P., Devijver, H., et al. (2014). Early 
structural and functional defects in synapses and myelinated axons in stratum 
lacunosum moleculare in two preclinical models for tauopathy. PLoS One 9. 
McEwan, W.A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A.L., Ghetti, B., 
130 
 
Goedert, M., and James, L.C. (2017). Cytosolic Fc receptor TRIM21 inhibits 
seeded tau aggregation. Proc. Natl. Acad. Sci. U. S. A. 114, 574–579. 
Medina, M., and Avila, J. (2014). The role of extracellular Tau in the spreading of 
neurofibrillary pathology. Front. Cell. Neurosci. 8, 113. 
Mershin, A. (2004). Learning and Memory Deficits Upon TAU Accumulation in 
Drosophila Mushroom Body Neurons. Learn. Mem. 11, 277–287. 
Milano, G., Morel, S., Bonny, C., Samaja, M., von Segesser, L.K., Nicod, P., and 
Vassalli, G. (2007). A peptide inhibitor of c-Jun NH2-terminal kinase reduces 
myocardial ischemia-reperfusion injury and infarct size in vivo. Am. J. Physiol. 
Heart Circ. Physiol. 292, H1828-35. 
Mirbaha, H., Holmes, B.B., Sanders, D.W., Bieschke, J., and Diamond, M.I. 
(2015). Tau Trimers Are the Minimal Propagation Unit Spontaneously 
Internalized to Seed Intracellular Aggregation. J. Biol. Chem. 290, 14893–14903. 
Mirbaha, H., Chen, D., Morazova, O.A., Ruff, K.M., Sharma, A.M., Liu, X., 
Goodarzi, M., Pappu, R. V, Colby, D.W., Mirzaei, H., et al. (2018). Inert and seed-
competent tau monomers suggest structural origins of aggregation. Elife 7. 
Momeni, P., Pittman, A., Lashley, T., Vandrovcova, J., Malzer, E., Luk, C., 
Hulette, C., Lees, A., Revesz, T., Hardy, J., et al. (2009). Clinical and pathological 
features of an Alzheimer’s disease patient with the MAPT ΔK280 mutation. 
Neurobiol. Aging 30, 388–393. 
Mondragón-Rodríguez, S., Trillaud-Doppia, E., Dudilot, A., Bourgeois, C., 
Lauzon, M., Leclerc, N., and Boehm, J. (2012). Interaction of endogenous tau 
protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-
dependent tau phosphorylation. J. Biol. Chem. 287, 32040–32053. 
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008). 
Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 
5, 621–628. 
Mukrasch, M.D., Bibow, S., Korukottu, J., Jeganathan, S., Biernat, J., Griesinger, 
C., Mandelkow, E., and Zweckstetter, M. (2009). Structural polymorphism of 441-
131 
 
residue tau at single residue resolution. PLoS Biol. 7, e34. 
Münch, G., Deuther-Conrad, W., and Gasic-Milenkovic, J. (2002). Glycoxidative 
stress creates a vicious cycle of neurodegeneration in Alzheimer’s disease--a 
target for neuroprotective treatment strategies? J. Neural Transm. Suppl. 303–
307. 
Myers, A.J., Kaleem, M., Marlowe, L., Pittman, A.M., Lees, A.J., Fung, H.C., 
Duckworth, J., Leung, D., Gibson, A., Morris, C.M., et al. (2005). The H1c 
haplotype at the MAPT locus is associated with Alzheimer’s disease. Hum. Mol. 
Genet. 14, 2399–2404. 
Nakanishi, H., Amano, T., Sastradipura, D.F., Yoshimine, Y., Tsukuba, T., 
Tanabe, K., Hirotsu, I., Ohono, T., and Yamamoto, K. (1997). Increased 
expression of cathepsins E and D in neurons of the aged rat brain and their 
colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer 
amyloid precursor protein. J. Neurochem. 68, 739–749. 
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., 
Wang, L., LaFrancois, J., Feinstein, B., et al. (2005). Inhibition of glycogen 
synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration 
in vivo. Proc. Natl. Acad. Sci. U. S. A. 102, 6990–6995. 
Nouar, R., Devred, F., Breuzard, G., and Peyrot, V. (2013). FRET and FRAP 
imaging: approaches to characterise tau and stathmin interactions with 
microtubules in cells. Biol. Cell 105, 149–161. 
Novak, M., Kabat, J., and Wischik, C.M. (1993). Molecular characterization of the 
minimal protease resistant tau unit of the Alzheimer’s disease paired helical 
filament. EMBO J. 12, 365–370. 
Novak, P., Schmidt, R., Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., 
and Vince-kazmerova, Z. (2010). Safety and immunogenicity of the tau vaccine 
AADvac1 in patients with Alzheimer ’ s disease : a randomised , double-blind , 
placebo-controlled , phase 1 trial. Lancet Neurol. 16, 123–134. 
Novak, P., Kontsekova, E., Zilka, N., and Novak, M. (2018a). Ten Years of Tau-
Targeted Immunotherapy : The Path Walked and the Roads Ahead. 12, 1–14. 
132 
 
Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., 
Fialova, L., Prcina, M., Parrak, V., Dal-bianco, P., et al. (2018b). FUNDAMANT : 
an interventional 72-week phase 1 follow-up study of AADvac1 , an active 
immunotherapy against tau protein pathology in Alzheimer ’ s disease. 1, 1–16. 
Novak, P., Zilka, N., Zilkova, M., Kovacech, B., Skrabana, R., Ondrus, M., 
Fialova, L., Kontsekova, E., Otto, M., and Novak, M. (2018c). AADvac1, an Active 
Immunotherapy for Alzheimer’s Disease and Non Alzheimer Tauopathies: An 
Overview of Preclinical and Clinical Development. 1–7. 
Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., 
Metherate, R., Mattson, M.P., Akbari, Y., and LaFerla, F.M. (2003). Triple-
transgenic model of Alzheimer’s disease with plaques and tangles: intracellular 
Abeta and synaptic dysfunction. Neuron 39, 409–421. 
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., and Kudo, Y. 
(2018). The development and validation of tau PET tracers: current status and 
future directions. Clin. Transl. Imaging 6, 305–316. 
Oyama, F., Kotliarova, S., Harada, A., Ito, M., Miyazaki, H., Ueyama, Y., 
Hirokawa, N., Nukina, N., and Ihara, Y. (2004). Gem GTPase and tau: 
morphological changes induced by gem GTPase in cho cells are antagonized by 
tau. J. Biol. Chem. 279, 27272–27277. 
P. Vasudevaraju, E.G., Hegde, M.L., Collen, T.B., Britton, G.B., and Rao, K.S. 
(2012). New evidence on α-synuclein and Tau binding to conformation and 
sequence specific GC* rich DNA: Relevance to neurological disorders. J. Pharm. 
Bioallied Sci. 4, 112–117. 
Padmaraju, V., Indi, S.S., and Rao, K.S.J. (2010). New evidences on Tau-DNA 
interactions and relevance to neurodegeneration. Neurochem. Int. 57, 51–57. 
Paquet, D., Bhat, R., Sydow, A., Mandelkow, E.-M., Berg, S., Hellberg, S., 
Fälting, J., Distel, M., Köster, R.W., Schmid, B., et al. (2009). A zebrafish model 
of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J. 
Clin. Invest. 119, 1382–1395. 
Paquet, D., Schmid, B., and Haass, C. (2010). Transgenic zebrafish as a novel 
133 
 
animal model to study tauopathies and other neurodegenerative disorders in vivo. 
Neurodegener. Dis. 7, 99–102. 
Pei, J.J., Tanaka, T., Tung, Y.C., Braak, E., Iqbal, K., and Grundke-Iqbal, I. 
(1997). Distribution, levels, and activity of glycogen synthase kinase-3 in the 
Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70–78. 
Perez, M., Santa-Maria, I., Gomez de Barreda, E., Zhu, X., Cuadros, R., Cabrero, 
J.R., Sanchez-Madrid, F., Dawson, H.N., Vitek, M.P., Perry, G., et al. (2009). 
Tau--an inhibitor of deacetylase HDAC6 function. J. Neurochem. 109, 1756–
1766. 
Perry, G., Roder, H., Nunomura, A., Takeda, A., Friedlich, A.L., Zhu, X., Raina, 
A.K., Holbrook, N., Siedlak, S.L., Harris, P.L., et al. (1999). Activation of neuronal 
extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to 
abnormal phosphorylation. Neuroreport 10, 2411–2415. 
Pevalova, M., Filipcik, P., Novak, M., Avila, J., and Iqbal, K. (2006). Post-
translational modifications of tau protein. Bratisl. Lek. Listy 107, 346–353. 
Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res. 29, 45e – 45. 
Piacentini, R., Li Puma, D.D., Mainardi, M., Lazzarino, G., Tavazzi, B., Arancio, 
O., and Grassi, C. (2017). Reduced gliotransmitter release from astrocytes 
mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. Glia 
65, 1302–1316. 
Piedrahita, D., Hernández, I., López-Tobón, A., Fedorov, D., Obara, B., 
Manjunath, B.S., Boudreau, R.L., Davidson, B., Laferla, F., Gallego-Gómez, J.C., 
et al. (2010). Silencing of CDK5 reduces neurofibrillary tangles in transgenic 
alzheimer’s mice. J. Neurosci. 30, 13966–13976. 
Planel, E., Miyasaka, T., Launey, T., Chui, D.-H., Tanemura, K., Sato, S., 
Murayama, O., Ishiguro, K., Tatebayashi, Y., and Takashima, A. (2004). 
Alterations in glucose metabolism induce hypothermia leading to tau 
hyperphosphorylation through differential inhibition of kinase and phosphatase 
activities: implications for Alzheimer’s disease. J. Neurosci. 24, 2401–2411. 
134 
 
Plouffe, V., Mohamed, N.-V., Rivest-McGraw, J., Bertrand, J., Lauzon, M., and 
Leclerc, N. (2012). Hyperphosphorylation and cleavage at D421 enhance tau 
secretion. PLoS One 7, e36873. 
Di Primio, C., Quercioli, V., Siano, G., Rovere, M., Kovacech, B., Novak, M., and 
Cattaneo, A. (2017). The Distance between N and C Termini of Tau and of 
FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells. Front. 
Mol. Neurosci. 10, 1–13. 
Prince, M., Wimo, A., M, G., GC, A., YT, W., and M, P. (2015). World Alzheimer 
Report 2015 The Global Impact of Dementia An analysis of prevalence, 
incidence, cost and trends. Alzheimer’s Dis. Int. 
Qi, H., Cantrelle, F.-X., Benhelli-Mokrani, H., Smet-Nocca, C., Buée, L., Lippens, 
G., Bonnefoy, E., Galas, M.-C., and Landrieu, I. (2015). Nuclear Magnetic 
Resonance Spectroscopy Characterization of Interaction of Tau with DNA and Its 
Regulation by Phosphorylation. Biochemistry 54, 1525–1533. 
Rady, R.M., Zinkowski, R.P., and Binder, L.I. (1995). Presence of tau in isolated 
nuclei from human brain. Neurobiol. Aging 16, 479–486. 
Rao, M. V, Mohan, P.S., Peterhoff, C.M., Yang, D.-S., Schmidt, S.D., Stavrides, 
P.H., Campbell, J., Chen, Y., Jiang, Y., Paskevich, P.A., et al. (2008). Marked 
calpastatin (CAST) depletion in Alzheimer’s disease accelerates cytoskeleton 
disruption and neurodegeneration: neuroprotection by CAST overexpression. J. 
Neurosci. 28, 12241–12254. 
Revett, T.J., Baker, G.B., Jhamandas, J., and Kar, S. (2013). Glutamate system, 
amyloid β peptides and tau protein: Functional interrelationships and relevance to 
Alzheimer disease pathology. J. Psychiatry Neurosci. 38, 6–23. 
Rissman, R.A., Poon, W.W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M.P., 
LaFerla, F.M., Rohn, T.T., and Cotman, C.W. (2004). Caspase-cleavage of tau is 
an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121–
130. 
Rizzu, P., Van Swieten, J.C., Joosse, M., Hasegawa, M., Stevens, M., Tibben, A., 
Niermeijer, M.F., Hillebrand, M., Ravid, R., Oostra, B.A., et al. (1999). High 
135 
 
prevalence of mutations in the microtubule-associated protein tau in a population 
study of frontotemporal dementia in the Netherlands. Am. J. Hum. Genet. 64, 
414–421. 
Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor 
package for differential expression analysis of digital gene expression data. 
Bioinformatics 26, 139–140. 
Rossi, G., Dalprà, L., Crosti, F., Lissoni, S., Sciacca, F.L., Catania, M., Di Fede, 
G., Mangieri, M., Giaccone, G., Croci, D., et al. (2008). A new function of 
microtubule-associated protein tau: Involvement in chromosome stability. Cell 
Cycle 7, 1788–1794. 
Rossi, G., Conconi, D., Panzeri, E., Redaelli, S., Piccoli, E., Paoletta, L., Dalprà, 
L., and Tagliavini, F. (2013). Mutations in MAPT gene cause chromosome 
instability and introduce copy number variations widely in the genome. J. 
Alzheimer’s Dis. 33, 969–982. 
Rossi, G., Conconi, D., Panzeri, E., Paoletta, L., Piccoli, E., Ferretti, M.G., 
Mangieri, M., Ruggerone, M., Dalprà, L., and Tagliavini, F. (2014). Mutations in 
MAPT give rise to aneuploidy in animal models of tauopathy. Neurogenetics 15, 
31–40. 
Rossi, G., Redaelli, V., Contiero, P., Fabiano, S., Tagliabue, G., Perego, P., 
Benussi, L., Bruni, A.C., Filippini, G., Farinotti, M., et al. (2018). Tau mutations 
serve as a novel risk factor for cancer. Cancer Res. canres.3175.2017. 
Rousseaux, M.W.C., de Haro, M., Lasagna-Reeves, C.A., de Maio, A., Park, J., 
Jafar-Nejad, P., Al-Ramahi, I., Sharma, A., See, L., Lu, N., et al. (2016). TRIM28 
regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. 
Elife 5, 1–24. 
Sabbagh, J.J., and Dickey, C.A. (2016). The Metamorphic Nature of the Tau 
Protein: Dynamic Flexibility Comes at a Cost. Front. Neurosci. 10, 1–5. 
Sadot, E., Heicklen-Klein, A., Barg, J., Lazarovici, P., and Ginzburg, I. (1996). 
Identification of a tau promoter region mediating tissue-specific-regulated 
expression in PC12 cells. J. Mol. Biol. 256, 805–812. 
136 
 
Saint-Aubert, L., Lemoine, L., Chiotis, K., Leuzy, A., Rodriguez-Vieitez, E., and 
Nordberg, A. (2017). Tau PET imaging: present and future directions. Mol. 
Neurodegener. 12, 19. 
Saito, K., Elce, J.S., Hamos, J.E., and Nixon, R.A. (1993). Widespread activation 
of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer 
disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. 
Sci. U. S. A. 90, 2628–2632. 
Saleem, S., and Kannan, R.R. (2018). Zebrafish: an emerging real-time model 
system to study Alzheimer’s disease and neurospecific drug discovery. Cell 
Death Discov. 4. 
Samsonov, A., Yu, J.-Z., Rasenick, M., and Popov, S. V (2004). Tau interaction 
with microtubules in vivo. J. Cell Sci. 117, 6129–6141. 
Santa-María, I., Pérez, M., Hernández, F., Avila, J., and Moreno, F.J. (2006). 
Characteristics of the binding of thioflavin S to tau paired helical filaments. J. 
Alzheimer’s Dis. 9, 279–285. 
Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J.-P., Hamdane, M., 
and Buée, L. (2006). Alzheimer’s disease-like tau neuropathology leads to 
memory deficits and loss of functional synapses in a novel mutated tau 
transgenic mouse without any motor deficits. Am. J. Pathol. 169, 599–616. 
Selenica, M.-L., Benner, L., Housley, S.B., Manchec, B., Lee, D.C., Nash, K.R., 
Kalin, J., Bergman, J.A., Kozikowski, A., Gordon, M.N., et al. (2014). Histone 
deacetylase 6 inhibition improves memory and reduces total tau levels in a 
mouse model of tau deposition. Alzheimers. Res. Ther. 6, 12. 
Sengupta, A., Kabat, J., Novak, M., Wu, Q., Grundke-Iqbal, I., and Iqbal, K. 
(1998). Phosphorylation of tau at both Thr 231 and Ser 262 is required for 
maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 
299–309. 
Sergeant, N., David, J.P., Lefranc, D., Vermersch, P., Wattez, A., and 
Delacourte, A. (1997). Different distribution of phosphorylated tau protein 
isoforms in Alzheimer’s and Pick’s diseases. FEBS Lett. 412, 578–582. 
137 
 
Sergeant, N., Delacourte, A., and Buée, L. (2005). Tau protein as a differential 
biomarker of tauopathies. Biochim. Biophys. Acta - Mol. Basis Dis. 1739, 179–
197. 
Shahpasand, K., Uemura, I., Saito, T., Asano, T., Hata, K., Shibata, K., 
Toyoshima, Y., Hasegawa, M., and Hisanaga, S.-I. (2012). Regulation of 
mitochondrial transport and inter-microtubule spacing by tau phosphorylation at 
the sites hyperphosphorylated in Alzheimer’s disease. J. Neurosci. 32, 2430–
2441. 
Sharma, A.M., Thomas, T.L., Woodard, D.R., Kashmer, O.M., and Diamond, M.I. 
(2018). Tau monomer encodes strains. Elife 7. 
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S.H., and Livesey, F.J. (2012). 
A human stem cell model of early Alzheimer’s disease pathology in Down 
syndrome. Sci. Transl. Med. 4, 124ra29. 
Shipton, O.A., Leitz, J.R., Dworzak, J., Acton, C.E.J., Tunbridge, E.M., Denk, F., 
Dawson, H.N., Vitek, M.P., Wade-Martins, R., Paulsen, O., et al. (2011). Tau 
protein is required for amyloid {beta}-induced impairment of hippocampal long-
term potentiation. J. Neurosci. 31, 1688–1692. 
Shrestha, D., Jenei, A., Nagy, P., Vereb, G., and Szöllősi, J. (2015). 
Understanding FRET as a research tool for cellular studies. Int. J. Mol. Sci. 16, 
6718–6756. 
Siksou, L., Silm, K., Biesemann, C., Nehring, R.B., Wojcik, S.M., Triller, A., El 
Mestikawy, S., Marty, S., and Herzog, E. (2013). A role for vesicular glutamate 
transporter 1 in synaptic vesicle clustering and mobility. Eur. J. Neurosci. 37, 
1631–1642. 
Singh, T.J., Wang, J.Z., Novak, M., Kontzekova, E., Grundke-Iqbal, I., and Iqbal, 
K. (1996). Calcium/calmodulin-dependent protein kinase II phosphorylates tau at 
Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett. 387, 
145–148. 
Sjöberg, M.K., Shestakova, E., Mansuroglu, Z., Maccioni, R.B., and Bonnefoy, E. 
(2006). Tau protein binds to pericentromeric DNA: a putative role for nuclear tau 
138 
 
in nucleolar organization. J. Cell Sci. 119, 2025–2034. 
Spillantini, M.G., Murrell, J.R., Goedert, M., Farlow, M.R., Klug, A., and Ghetti, B. 
(1998a). Mutation in the tau gene in familial multiple system tauopathy with 
presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 95, 7737–7741. 
Spillantini, M.G., Bird, T.D., and Ghetti, B. (1998b). Frontotemporal dementia and 
Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain 
Pathol. 8, 387–402. 
Stefansson, H., Helgason, A., Thorleifsson, G., Steinthorsdottir, V., Masson, G., 
Barnard, J., Baker, A., Jonasdottir, A., Ingason, A., Gudnadottir, V.G., et al. 
(2005). A common inversion under selection in Europeans. Nat. Genet. 37, 129–
137. 
Steiner, B., Mandelkow, E.M., Biernat, J., Gustke, N., Meyer, H.E., Schmidt, B., 
Mieskes, G., Söling, H.D., Drechsel, D., Kirschner, M.W., et al. (1990). 
Phosphorylation of microtubule-associated protein tau: identification of the site for 
Ca2(+)-calmodulin dependent kinase and relationship with tau phosphorylation in 
Alzheimer tangles. EMBO J. 9, 3539–3544. 
Strang, K.H., Croft, C.L., Sorrentino, Z.A., Chakrabarty, P., Golde, T.E., and 
Giasson, B.I. (2018). Distinct differences in prion-like seeding and aggregation 
between Tau protein variants provide mechanistic insights into tauopathies. J. 
Biol. Chem. 293, 2408–2421. 
Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., 
Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S., et al. (2011). Nuclear Tau, 
a key player in neuronal DNA protection. J. Biol. Chem. 286, 4566–4575. 
Sun, W., Samimi, H., Gamez, M., Zare, H., and Frost, B. (2018). Pathogenic tau-
induced piRNA depletion promotes neuronal death through transposable element 
dysregulation in neurodegenerative tauopathies. Nat. Neurosci. 21, 1038–1048. 
Tacik, P., DeTure, M., Hinkle, K.M., Lin, W.-L., Sanchez-Contreras, M., 
Carlomagno, Y., Pedraza, O., Rademakers, R., Ross, O.A., Wszolek, Z.K., et al. 
(2015). A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick 
Disease. J. Neuropathol. Exp. Neurol. 74, 1042–1052. 
139 
 
Tak, H., Haque, M.M., Kim, M.J., Lee, J.H., Baik, J.-H., Kim, Y., Kim, D.J., 
Grailhe, R., and Kim, Y.K. (2013). Bimolecular fluorescence complementation; 
lighting-up tau-tau interaction in living cells. PLoS One 8, e81682. 
Takahashi, T., and Mihara, H. (2012). FRET detection of amyloid β-peptide 
oligomerization using a fluorescent protein probe presenting a pseudo-amyloid 
structure. Chem. Commun. (Camb). 48, 1568–1570. 
Takamori, S., Rhec, J.S., Rosenmund, C., and Jahn, R. (2000). Identification of a 
vesicular glutamate transporter that defines a glutamatergic phenotype in 
neurons. Nature 407, 189–194. 
Talmat-Amar, Y., Arribat, Y., Redt-Clouet, C., Feuillette, S., Bougé, A.-L., 
Lecourtois, M., and Parmentier, M.-L. (2011). Important neuronal toxicity of 
microtubule-bound Tau in vivo in Drosophila. Hum. Mol. Genet. 20, 3738–3745. 
Tang, Z., Ioja, E., Bereczki, E., Hultenby, K., Li, C., Guan, Z., Winblad, B., and 
Pei, J.-J. (2015). mTor mediates tau localization and secretion: Implication for 
Alzheimer’s disease. Biochim. Biophys. Acta - Mol. Cell Res. 1853, 1646–1657. 
Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., 
Borghgraef, P., and Van Leuven, F. (2005). Changed conformation of mutant 
Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal 
axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 280, 3963–3973. 
Togo, T., Sahara, N., Yen, S.-H., Cookson, N., Ishizawa, T., Hutton, M., de Silva, 
R., Lees, A., and Dickson, D.W. (2002). Argyrophilic grain disease is a sporadic 
4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 61, 547–556. 
Tomasiewicz, H.G., Flaherty, D.B., Soria, J.P., and Wood, J.G. (2002). 
Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 70, 734–
745. 
Tournissac, M., Bourassa, P., Martinez-Cano, R.D., Vu, T.-M., Hébert, S.S., 
Planel, E., and Calon, F. (2019). Repeated cold exposures protect a mouse 
model of Alzheimer’s disease against cold-induced tau phosphorylation. Mol. 
Metab. 22, 110–120. 
140 
 
Trinczek, B., Ebneth, A., Mandelkow, E.M., and Mandelkow, E. (1999). Tau 
regulates the attachment/detachment but not the speed of motors in microtubule-
dependent transport of single vesicles and organelles. J. Cell Sci. 112 ( Pt 1, 
2355–2367. 
Trojanowski, J.Q., and Lee, V.M. (1995). Phosphorylation of paired helical 
filament tau in Alzheimer’s disease neurofibrillary lesions: focusing on 
phosphatases. FASEB J. 9, 1570–1576. 
Tsai, L.-H., Lee, M.-S., and Cruz, J. (2004). Cdk5, a therapeutic target for 
Alzheimer’s disease? Biochim. Biophys. Acta 1697, 137–142. 
Ulrich, G., Salvadè, A., Boersema, P., Calì, T., Foglieni, C., Sola, M., Picotti, P., 
Papin, S., and Paganetti, P. (2018). Phosphorylation of nuclear Tau is modulated 
by distinct cellular pathways. Sci. Rep. 8, 17702. 
Vandal, M., White, P.J., Tournissac, M., Tremblay, C., St-Amour, I., Drouin-
Ouellet, J., Bousquet, M., Traversy, M.-T., Planel, E., Marette, A., et al. (2016). 
Impaired thermoregulation and beneficial effects of thermoneutrality in the 3×Tg-
AD model of Alzheimer’s disease. Neurobiol. Aging 43, 47–57. 
Vanier, M.T., Neuville, P., Michalik, L., and Launay, J.F. (1998). Expression of 
specific tau exons in normal and tumoral pancreatic acinar cells. J. Cell Sci. 111 ( 
Pt 1, 1419–1432. 
Violet, M., Delattre, L., Tardivel, M., Sultan, A., Chauderlier, A., Caillierez, R., 
Talahari, S., Nesslany, F., Lefebvre, B., Bonnefoy, E., et al. (2014). A major role 
for Tau in neuronal DNA and RNA protection in vivo under physiological and 
hyperthermic conditions. Front. Cell. Neurosci. 8, 1–11. 
Wang, R., and Reddy, P.H. (2017). Role of Glutamate and NMDA Receptors in 
Alzheimer’s Disease. J. Alzheimer’s Dis. 57, 1041–1048. 
Wang, Y., and Mandelkow, E. (2016). Tau in physiology and pathology. Nat. Rev. 
Neurosci. 17, 5–21. 
Wang, J.-Z., Grundke-Iqbal, I., and Iqbal, K. (1996). Glycosylation of 
microtubule–associated protein tau: An abnormal posttranslational modification in 
141 
 
Alzheimer’s disease. Nat. Med. 2, 871–875. 
Wang, Y., Xue, D., Li, Y., Pan, X., Zhang, X., Kuang, B., Zhou, M., Li, X., Xiong, 
W., Li, G., et al. (2016). The Long Noncoding RNA MALAT-1 is A Novel 
Biomarker in Various Cancers: A Meta-analysis Based on the GEO Database 
and Literature. J. Cancer 7, 991–1001. 
Wei, Y., Qu, M.H., Wang, X.S., Chen, L., Wang, D.L., Liu, Y., Hua, Q., and He, 
R.Q. (2008). Binding to the minor groove of the double-strand, Tau protein 
prevents DNA damage by peroxidation. PLoS One 3. 
Weingarten, M.D., Lockwood, A.H., Hwo, S.-Y., and Kirschner, M.W. (1975). A 
Protein Factor Essential for Microtubule Assembly (tau factor/tubulin/electron 
microscopy/phosphocellulose). Proc.Nat.Acad.Sci  72, 1858–1862. 
West, T., Hu, Y., Verghese, P.B., Bateman, R.J., Braunstein, J.B., Fogelman, I., 
Budur, K., Florian, H., Mendonca, N., and Holtzman, D.M. (2017). Preclinical and 
Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for 
Treatment of Alzheimer’s Disease and Other Tauopathies. 4, 236–241. 
Whittington, R.A., Bretteville, A., Dickler, M.F., and Planel, E. (2013). Anesthesia 
and tau pathology. Prog. Neuro-Psychopharmacology Biol. Psychiatry 47, 147–
155. 
Wischik, C.M., Harrington, C.R., and Storey, J.M.D. (2014). Tau-aggregation 
inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 88, 529–539. 
Xia, Z., and Liu, Y. (2001). Reliable and global measurement of fluorescence 
resonance energy transfer using fluorescence microscopes. Biophys. J. 81, 
2395–2402. 
Yagishita, S., Itoh, Y., Nan, W., and Amano, N. (1981). Reappraisal of the fine 
structure of Alzheimer’s neurofibrillary tangles. Acta Neuropathol. 54, 239–246. 
Yan, S.D., Yan, S.F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M.A., 
Perry, G., Godman, G.C., and Nawroth, P. (1995). Non-enzymatically glycated 
tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine 
gene expression and release of amyloid beta-peptide. Nat. Med. 1, 693–699. 
142 
 
Yap, J.L., Worlikar, S., MacKerell, A.D., Shapiro, P., and Fletcher, S. (2011). 
Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel 
Anticancer Therapeutics. ChemMedChem 6, 38–48. 
Yeh, P.-A., Chien, J.-Y., Chou, C.-C., Huang, Y.-F., Tang, C.-Y., Wang, H.-Y., 
and Su, M.-T. (2010). Drosophila notal bristle as a novel assessment tool for 
pathogenic study of Tau toxicity and screening of therapeutic compounds. 
Biochem. Biophys. Res. Commun. 391, 510–516. 
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T.C., 
Maeda, J., Suhara, T., Trojanowski, J.Q., and Lee, V.M.-Y. (2007). Synapse loss 
and microglial activation precede tangles in a P301S tauopathy mouse model. 
Neuron 53, 337–351. 
Yu, J.-Z., and Rasenick, M.M. (2006). Tau associates with actin in differentiating 
PC12 cells. FASEB J. 20, 1452–1461. 
Zheng-Fischhöfer, Q., Biernat, J., Mandelkow, E.M., Illenberger, S., Godemann, 
R., and Mandelkow, E. (1998). Sequential phosphorylation of Tau by glycogen 
synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the 
Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-
filament-like conformation. Eur. J. Biochem. 252, 542–552. 
Zhu, X., Raina, A.K., Rottkamp, C.A., Aliev, G., Perry, G., Boux, H., and Smith, 
M.A. (2001). Activation and redistribution of c-jun N-terminal kinase/stress 
activated protein kinase in degenerating neurons in Alzheimer’s disease. J. 
Neurochem. 76, 435–441. 
 
